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Program Schedule
Thursday, 2 November 2000
1:00± 5:00 p.m. Registration, Set Up Posters Ð  Hotel Lobby
6:00± 7:00 p.m. Welcome Reception Ð  Meerman Room
Friday, 3 November 2000
7:00 a.m. Registration, breakfast for meeting attendees Ð  Foyer Okura
8:00 a.m. Welcome, Opening Announcements Ð  Heian Room
8:15 a.m. CASE DISCUSSION: `Treatment of Gynecological Sarcomas’
Moderators & discussants: Vivien Bramwell (London, Ont.) & Nicholas Reed (Glasgow)
9:00 a.m. NINA AXELRAD KEYNOTE LECTURE:
Supported by Nina Axelrad Sarcoma Fund
Introduction/moderator: Brian O’Sullivan (Toronto)
Murray Brennan (Memorial Sloan-Kettering Cancer Center, New York): `Soft Tissue Sar-
coma: 25 Years of Achievements, Failures and Challenges’.
9.45 a.m. Coffee Break, Poster Viewing Ð  Foyer Okura, Foyer Amstel & Otter, Esperance
Room
10:15 a.m. PROFFERED PAPERS: `Surgical Treatment of Sarcomas’ Ð  Heian Room
Moderators: Antonie Tamineau (Leiden) & Frits van Coevorden (Amsterdam)
10:15 a.m. Chondrosarcoma of bone: analysis of factors related to prognosis in 108
cases with a minimum of two years follow-up Ð  Michelle Ghert
10:25 a.m. The effect of re-resection in extremity soft tissue sarcoma Ð  Jonathan
Lewis
10:35 a.m. Classification of positive margins after resection of extremity soft tissue
sarcoma predicts the risk of local recurrence Ð  Craig Gerrand
10:45 a.m. Combined modality management of retroperitoneal sarcomas: phase 1
trial of pre-operative doxorubicin-based concurrrent chemoradiation sur-
gical  resections,  and  intraoperative  electron-beam  radiation  therapy
(IORT) Ð  Peter Pisters
10:55 a.m. Peritoneal sarcomatosis treated by cytoreductive surgery and intraperito-
neal hyperthermic perfusion Ð  Marcello Deraco
11:05 a.m. Frits van Coevorden: `Review of session related posters’
11.15 a.m. Antonie Tamineau: `Review of session (state of the art)’
11:30 a.m. MINI SYMPOSIUM: `Local Recurrence of Soft Tissue Sarcomas’
Moderators: Jonathan Lewis (New York) & Martin Robinson (Sheffield)
11:30 a.m.  Surgery Ð  Murray Brennan
11:38 a.m.   Radiation Oncology Ð  Martin Robinson
11:46 a.m.  Medical Oncology Ð  Robert Benjamin
11:54 a.m. `General discussion’
12:15 p.m. Lunch, Poster Viewing Ð  Foyer Okura, Foyer Amstel & Otter, Esperance Room
1:15 p.m. PROFFERED PAPERS: `Radiation Oncology’ Ð  Heian Room
Moderators: Charles Catton (Toronto) & Thor Alvegaard (Lund)
1:15 p.m. Complete resection and intra-operative radiation therapy improve out-
come of retroperitoneal sarcomas Ð  Jean-Pierre Pierie
1:25 p.m. Radiation morbidity two years post treatment: results from a randomized
trial of pre- versus post-operative radiotherapy Ð  Aileen Davis38 CTOS  abstracts
1:35 p.m. Real-time radiotherapy review of a randomized trial of pre-and post-oper-
ative  radiotherapy for localized soft-tissue sarcoma of the extremity Ð
Charles Catton
1:45 p.m. Thor Alvegaard: `Review of session related posters’
1.55 p.m. Charles Catton: `Review of session (state of the art)’
2:10 p.m. PROFFERED PAPERS: `Basic Science/Biology’
Moderators: Claude S. Turc-Carel (Nice) & Jay S. Wunder (Toronto)
2:10 p.m. Differential expression of EZRIN in a high and low metastatic osteosar-
coma model Ð  Chand Khanna
2:20 p.m. Molecular cloning of putative oncogene and antioncogen involved in the
development of osteosarcoma Ð  Junya Toguchida
2:30 p.m. Clinico-pathological and biological analyses of the  chop-related fusion
genes in myxoid liposarcomas Ð  Taisuki Hosaka
2:40 p.m. Cytokine levels in serum of the patients with soft tissue sarcomas and their
relationship to alterations of routine blood tests Ð  Piotr Rutkowski
2:50 p.m. Wild-Type  P53  sensitizes  soft  tissue  sarcoma  cells  to  doxorubicin by
downregulation of MDR1 expression Ð  Raphael Pollock
3:00 p.m. Jay Wonder: `Review of session related posters’
3:10 p.m. Claude Turc-Carel: `Review of session (state of the art)’
3:25 p.m. Coffee Break, Poster Viewing Ð  Foyer Okura, Foyer Amstel & Otter, Esperance
Room
3:55 p.m. CTOS YOUNG INVESTIGATOR AWARD PRESENTATIONS Ð  Heian Room
Moderator: Nicola Baldini (Bologna) 
3:55 p.m. Nicola Baldini: `Short introduction’
4:00 p.m.  Award Presentation 1: Regulation of osteosarcoma (OS) metastasis by
IGF-I receptor signaling: a novel therapeutic target Ð  Kristy Weber
4:20 p.m. Award Presentation 2: Results of two consecutive phase II studies and
interim analysis of a phase III intergroup study of neoadjuvant treatment
including regional hyperthermia (RHT) in high risk soft tissue sarcoma
(HR-STS) Ð  Clemens Wendtner
4:40 p.m. PROFFERED PAPERS: `Medical Oncology’
Moderators: Robert Benjamin (Houston) & Ian Judson (London)
4:40 p.m. Expression of the trail receptor dr4 in human soft tissue sarcomas Ð  Rudy
Komdeur
4:50 p.m. Dominant negative IkBa Potentiates in anti-tumor activity of doxorubicin
in a rat hind limb isolated perfusion model Ð  Robert Davidson
5:00 p.m. A pilot study of short course intensive multiagent chemotherapy for poor
risk osteosarcoma Ð  Jim Janinis
5:10 p.m. A phase 1 trial of intraperitoneal hyperthermic chemotherapy for the treat-
ment of sarcomatosis Ð  Malcolm Bilimoria 
5:20 p.m. Ian Judson: `Review of session related posters’
5:30 p.m. Robert Benjamin: `Review of session (state of the art)’
5:45 p.m. Adjourn
6:15 p.m. Reception and Boat Tour
7:15 p.m. Dinner Banquet Ð  Ballroom I & II
Saturday, 4 November 2000
7:00 a.m. Registration, breakfast for meeting attendees Ð  Foyer OkuraCTOS  abstracts 39
8:00 a.m. WORKSHOP: `Management of osteosarcomas’
Moderators: Piero Picci (Bologna) & Robert Grimer (Birmingham)
Suggested topics: 
8:00 a.m. Histopathological problems Ð  Pancras Hogendoorn
8:20 a.m. Surgical aspects. New developments Ð  Robert Grimer
8:40 a.m. Role of high dose Methotrexate Ð  Kirsten Sundby Hall
8:55 a.m. Treatment of high risk patients Ð  Piero Picci
9:15 a.m. Late effects of the treatment of bone tumors Ð  Juliet Hale
9:30 a.m. Long-term problems after surgery Ð  Per-Ulf Tunn
9:45 a.m. `General discussion’
10:00 a.m. Coffee Break, Poster Viewing Ð  Foyer Okura, Foyer Amstel & Otter, Esperance
Room
10:30 a.m. COOPERATIVE GROUP SESSION: `How do we improve Intergroup collabora-
tion?’ Ð  Heian Room
Moderators: Peter Pisters (Houston) & Peter R. Hohenberger (Berlin)
10:30 a.m. How to moderate intergroup studies Ð  M. van Glabbeke
10:45 a.m. Panel  discussion:  `How  to  improve  International  Collaboration  and
Research?’
Panel members: 
Peter Pisters: `ACOSOG’ & `RTOG’
Lee Helman: `Pediatric Coop. Group’
John Edmonson: `ECOG’
Ian Judson: `EORTC’
Bihn N Bui: `French SG’
Piero Picci: `Italian SG’
Vivien Bramwell: `NCIC-CTG/CSG’
Thor Alvegaard: `SSG’
11:45 a.m. Peter Pisters & Peter R. Hohenberger: `Summary of discussion and con-
clusions (how to proceed?)’
12:00 noon Lunch, Poster Viewing Ð  Foyer Okura, Foyer Amstel & Otter, Esperance Room
1:00 p.m. PROFFERED PAPERS: `Pediatric Oncology’ Ð  Heian Room
Moderators: Lee Helman (Bethesda) & Axel Le Cesne (Paris)
1:00 p.m. CD99 engagement: an effective therapeutic strategy for Ewing tumors Ð
Katia Scotlandi
1:10 p.m. Induction of chemoresistence to doxorubicin in cells carrying a P53 germ-
line mutation detected in a Li± Fraumeni family Ð  Luca Sangiorgi
1:20 p.m. Study of age as major prognostic factor in localised Ewing’s sarcoma Ð
Nicole Delepine
1:30 p.m. Lee Helman: `Review of session and session related posters’
1:50 p.m. PROFFERED PAPERS: `Diagnostic Imaging/Pathology’
Moderators: Pancras Hogendoorn (Leiden) & Laurence Baker (Ann Arbor)
1:50 p.m. Monitoring the effect of isolated limb perfusion in soft tissue sarcoma with
dynamic contrast-enhanced MR imaging Ð  C.S.P. van Rijswijk
2:00 p.m. Upregulation of PTHrP and BCL-2 expression characterizes early malig-
nant transformation of osteochondroma towards peripheral chondrosar-
coma and is a late event in central chondrosarcoma Ð  JVMG Bovee40 CTOS  abstracts
2:10 p.m. Does the histologic subtype of high-grade central osteosarcoma influence
the response to treatment with chemotherapy and does it affect overall sur-
vival Ð  E. Hauben
2:20 p.m. Round-cell and myxoid liposarcoma of the extremities. A clinicopatho-
logic study of 102 cases Ð  Andrea Pellacani
2:30 p.m. Laurence Baker: `Review of session related posters’
2:40 p.m. P. Hoogendoorn: `Review of session (state of the art)’
3:05 p.m. Coffee break Ð  Foyer Okura, Foyer Amstel & Otter, Esperance Room
3:35 p.m. MINI SYMPOSIUM: `New Drugs in Sarcomas’ Ð  Heian Room 
Moderators: George Demetri (Boston) & Jaap Verweij (Rotterdam)
3:35 p.m. Troglitazone and newer PPAR-gamma receptor ligands in liposarcomas
Ð  George Demetri
3:50 p.m. ET-743 in soft tissue sarcomasÐ  Jaap Verweij
4:05 p.m. New emerging concepts Ð  Ian Judson
4:20 p.m. `General discussion’
4.30 p.m. Closing. Summary of Scientific Meeting. Next Meeting. 
Reviewer/presenter: Karen Antman (New York)
4:45 p.m. Member’s Business Meeting
6:00 p.m. AdjournmentCTOS  abstracts 41
Proffered Papers Ð  Surgical Treatment of Sarcomas
Chondrosarcoma of Bone: Analysis of Factors Related to 
Prognosis in 108 Cases With a Minimum of Two Years 
Follow-up
Rizzo M, Ghert MA, Harrelson JM, Scully SP
Duke University Medical Center, Durham, NC 27710, USA
Introduction: Chondrosarcoma is unresponsive to existing adju-
vant therapies and is primarily a surgical disease. There is an estab-
lished relationship between the histologic grade of these tumors
and prognosis. The purpose of this study was to review our institu-
tion’s experience with chondrosarcoma and assess factors related
to prognosis and outcome.
Methods: The medical  records of 108  patients  were retrospec-
tively reviewed. Data was evaluated with respect to patient demo-
graphics,  tumor  location,  histologic  grade, tumor  size,  surgical
margins, metastases and recurrence. The tumors were sub-classi-
fied based on histologic grade with grade 1 lesions defined as low-
grade,  and  grade  2  and  3  lesions  (as  well  as  dedifferentiated
lesions)  defined as high-grade. All  patients  were  followed for a
minimum of 2 years. Statistical analysis was performed using uni-
variate, multivariate, and Kaplan± Meier survival analysis.
Results: There were 68 males and 40 females with a mean age at
presentation of 53 years (range, 26± 70 years). Clinical follow-up
averaged 97 months (range, 3± 314). The most  common tumor
locations included the femur (46), pelvis (22) and humerus (10).
There were 31  low-grade  and 77  high-grade chondrosarcomas.
One hundred and one patients underwent surgical resection. Wide
margins  were  achieved  in  78  patients,  11  underwent  marginal
resection and 12 tumor resections had positive margins (intrale-
sional). Seventy-two patients  remained alive at the  time  of this
study with no evidence of disease, 23 have died of disease, six died
without disease and seven remain alive with recurrent disease. The
high-grade tumors had a significantly increased rate of death due
to disease (p < 0.01), development of metastases (p < 0.01), and
local recurrence (p < 0.01). There was a significant relationship
between  local  recurrence and positive  margins  (p < 0.03), and
between metastases and positive margins (p < 0.03). Patient demo-
graphics, tumor location and size did not correlate significantly
with outcome.
Conclusions: This  study  supports  previous  findings  that  tumor
grade  in  chondrosarcoma  has  prognostic  significance,  and  that
adequate surgical margins are essential to maximize survival. As
chondrosarcoma does not respond to standard chemotherapy or
radiation protocols, our findings emphasize the need for molecular
markers and novel biologic adjuvant therapies.
The Effect of Re-resection in Extremity Soft Tissue 
Sarcoma
Lewis JJ, Leung D, Espat J, Woodruff JM, Brennan MF
Memorial Sloan-Kettering Cancer Center, New York, NY 10021, 
USA
Introduction: This study was undertaken to determine if re-resec-
tion impacts on disease-specific  survival in patients  with inade-
quately  resected,  primary  extremity  soft  tissue  sarcoma.  We
analyzed two groups of patients:  those who underwent a single
definitive radical resection at a specialist cancer center versus those
who underwent an incomplete excisional resection in the commu-
nity, followed by a second definitive radical re-resection at a spe-
cialist cancer center.
Methods: Patients who underwent treatment for primary tumors
(from July 1982 to June 1999) at a single institution were the subject
of study. Two groups of patients were analyzed: those who under-
went one definitive radical resection (one operation) and those who
were previously resected and then referred for subsequent radical
re-resection  (two  operations). Survival  was  determined  with  the
Kaplan± Meier actuarial method. Statistical significance was evalu-
ated using log-rank testing and Cox model stepwise regression.
Results: During this time, we resected 1092 patients with primary
extremity soft tissue sarcoma. Of these, 685 underwent definitive
radical resection and 407 underwent re-resection after undergoing
excisional  resection  elsewhere.  The  median  follow-up  was  4.8
years. The 5-year disease-specific survival of the definitive resec-
tion (one operation) group was 68% and that of the re-resection
(two operations) group was 84% (p = 0.0001). On multivariate
analysis, re-resection was adjusted and controlled for age, grade,
depth, size, histology and margins. Re-resection (two operations)
remained a significant predictor of improved disease-specific sur-
vival (p = 0.003), even after these adjustments. In order to further
determine whether this difference was stage or referral biased, we
divided the patient population by AJCC stage. In all stages there
was a trend to improved outcome, and this was most marked and
statistically significant (p = 0.005) for those with AJCC Stage III
disease (> 5 cm, high-grade and deep).
Conclusions: These data suggest that patients with extremity soft
tissue sarcoma who undergo re-resection with two `primary’ oper-
ations  have  an  improved  survival  compared  with  those  who
undergo one operation. The most plausible explanation, referral
and selection bias is questionable given the significance of re-resec-
tion as a variable, even after adjusting for stage and other high-risk
factors. This suggests that where possible, re-resection (two oper-
ations) should be liberally applied in patients with primary extrem-
ity soft tissue sarcoma.
(Ann Surg, in press). Paper will be presented by Murray F. Bren-
nan, and we would like consideration for Jonathan J. Lewis (non-
member) to present.
Classification of Positive Margins After Resection of 
Extremity Soft Tissue Sarcoma Predicts The Risk of Local 
Recurrence
Gerrand CH, Wunder JS, Griffin A, Kandel RA, O’Sullivan B, 
Catton CN, Bell RS, Davis AM
Mount Sinai Hospital, Toronto, Ont., Canada M5G 1X5, and 
Princess Margaret Hospital, Toronto, Ont., Canada M5G 2C1
Introduction: Local failure after combined treatment of soft tissue
sarcoma by surgery and radiotherapy is highly associated with a
positive resection margin. We a priori hypothesized that patients
who have a positive margin can be classified on the basis of their
clinical features into groups that are at low or high risk of local
recurrence. Four groups were defined.
Group 1, low grade liposarcomas (low risk). The positive margin
followed an intentionally marginal excision of a low-grade liposar-
coma.
Group 2, planned positive margin against a critical structure (low
risk). In order to preserve a functional extremity, a positive margin
was accepted against a critical structure (nerve, vessel or bone).
Group 3, prior unplanned excision  (high risk). An intralesional
unplanned excision  was  performed  prior  to  referral.  A  positive
margin was found after resection of the residual tumour in our cen-
tre.
Group 4, unplanned positive margin (high risk). A positive margin
was unexpectedly found during primary resection of tumour, usu-
ally following surgical error.
Methods: To test this  hypothesis,  we used a prospectively  col-
lected database, containing 537 patients who underwent surgical
excision of an extremity soft tissue sarcoma in our hospital and had
the potential for 3 years of follow-up. There were positive margins
in 112  cases:  87  of these  had undergone a standard treatment
regime of surgery and adjuvant radiotherapy. Twenty-five patients
were excluded because they did not receive radiotherapy (13), they
received chemotherapy (7), or the procedure was not intended to
be curative (5). Mean follow-up was 4.0 years (0.2± 9.3). Patients42 CTOS  abstracts
were assigned to groups by one investigator who reviewed the clin-
ical records and was blinded to outcome.
Results: Group 1 tumours were low grade by definition. Groups
2, 3 and 4 did not differ from each other significantly by histologi-
cal grade, length of follow-up, patient age, gender, or anatomical
location.
The rate of local recurrence in group 2 was significantly less than
group 3 (p = 0.01) and group 4 (p = 0.01). There was no significant
difference between groups 3 and 4. Twenty-two patients died or
were lost to follow-up before 2 years. When these patients were
excluded  from  the  analysis,  the  differences  in  local  recurrence
between the groups remained significant.
Conclusion: Planned positive  margins  against critical  structures
by experienced surgical oncologists represent a low risk for tumour
recurrence. Classifying patients with positive margins into groups
according to clinical setting provides a useful indication of the risk
of local recurrence following local treatment of soft tissue sarcoma. 
Combined Modality Management Of Retroperitoneal 
Sarcomas: Phase I Trial Of Pre-operative Doxorubicin-
based Concurrent Chemoradiation, Surgical Resection, 
And Intraoperative Electron-beam Radiation Therapy 
(Iort). 
Pisters PWT, Patel SR, Crane C, Feig BW, Hunt KK, Burgess 
MA, Papadopoulos NE, Plager C, Benjamin RS, Pollock RE, 
Janjan NE
University of Texas M.D. Anderson Cancer Center, Houston, TX 
77030, USA 
Background: Patterns of failure for patients with retroperitoneal
sarcomas (RPS) demonstrate that the majority of patients develop
local recurrence. Strategies to enhance to efficacy/intensity of local
therapies are needed. One approach involves the use of pre-opera-
tive chemoradiotherapy (chemoXRT). This protocol explores the
use of pre-operative doxorubicin given by protracted venous infu-
sion (PVI) with concurrent external beam radiotherapy (EBRT).
This  approach takes  advantage of  the  benefits  of  pre-operative
radiotherapy, the activity of doxorubicin in STS, and the radiosen-
sitizing properties of doxorubicin. When chemo XRT is combined
with surgical resection and intraoperative electron-beam radiation
therapy  (IORT), local  therapy  is  maximized.  Objectives  of this
phase I trial included: (1) define the toxicities of pre-operative PVI
doxorubicin and concurrent EBRT followed by surgical resection
with IORT; and (2) establish the maximum tolerated dose (MTD)
of EBRT when combined with PVI doxorubicin. 
Methods: Patients with localized, resectable, grade II or III pri-
mary or recurrent RPS are eligible. Pre-operative continuous infu-
sion doxorubicin is administered (4 mg/m2 over 24 hours x 4 days/
week for 4 weeks) with concomitant escalating doses of EBRT (1.8
Gy/fraction). The dose escalation scheme (and number of patients
treated) for successive cohorts of patients has been: 18 Gy (three
patients), 30.6 Gy (three patients), 36 Gy (three patients), 41.4 Gy
(three patients), 46.8 Gy (12 patients), and 50.4 Gy (two patients). 
Results: Twenty-six  patients  have  been  treated.  The  median
tumor size was 12 cm (range, 6± 31 cm). Histologies included leio-
myosarcoma (n = 8), liposarcoma (n = 5), malignant fibrous histi-
ocytoma (n = 5), unclassified soft tissue sarcoma (n = 5), and other
RPS (n = 3). The MTD has not yet been defined. Only one patient
experienced grade IV neutropenia at 18 Gy and there were no epi-
sodes of febrile neutropenia. Grade III gastrointestinal toxicities
have included diarrhea (one patient each at 18, 30.6, and 50.4 Gy)
and nausea (one patient each at 46.8 and 50.4 Gy); no patients
have experienced grade IV gastrointestinal toxicities. Twenty-one
patients  have undergone surgical  resection. IORT (15 Gy) was
provided to 15 patients with no identifiable toxicities. No major
wound complications have been observed. 
Conclusions: (1) Doxorubicin-based concurrent chemoradiation
can be given to a dose of 46.8 Gy with minimal grade III/IV toxic-
ities; (2) MTD has not yet been defined; and (3) no identifiable
toxicities  are  attributed  to  IORT.  This  combined  modality
approach appears to have an acceptable overall toxicity profile and
capitalizes on all of the advantages of pre-operative/intraoperative
treatment to enhance the therapeutic ratio of surgery and radio-
therapy in the management of RP STS. 
Peritoneal Sarcomatosis Treated By Cytoreductive Surgery 
And Intraperitoneal Hyperthermic Perfusion
Deraco M, Gronchi A, Pennacchioli E, Baratti D, Bertulli R, 
Casali PG, Rasponi A, Dileo P, Pilotti S, Vaglini M, Azzarelli A
Istituto Nazionale Tumori, Milan, Italy
Intervention: Peritoneal  sarcomatosis  (PS)  is  a  very  aggressive
condition with a poor prognosis. We propose to investigate  the
effect of an aggressive surgery followed by intra peritoneal drugs
delivery and local hyperthermia.
Patients  and  methods: In  a  phase  II  clinical  study,  21  patients
(eight men and 13 women) with PS were treated by cytoreductive
surgery  (CRS)  and  intraperitoneal  hyperthermic  perfusion
(IPHP). The median age was 52.3 years (range, 29± 74 years). The
mean follow-up was 15.6 months (range, 2± 44 months). Twelve
patients  (57%)  presented  retroperitoneal  sarcomas  and  nine
(43%) patients had visceral ones. Nine, three and nine patients
presented grade 1, 2 and 3, respectively. Nine out of 21 (43%) and
four  out  of  21  (19%)  patients  were  pre-treated  with  systemic
chemotherapy  and  radiotherapy, respectively.  According  to  the
Japanese classification of intraperitoneal disease extension for gas-
tric cancer, two (10%), 11 (52%) and eight (38%) cases presented
P1, P2, and P3 dissemination, respectively. Eighty percent of the
patients  were  rendered  optimally  cytoreduced  (cc-0/cc-1).  The
IPHP was carried out with the closed abdomen technique, using a
preheated  polysaline  perfusate  containing  CDDP  +  MMC  or
CDDP + DX through a heart-lung pump at a mean flow of 700 ml/
min for 60 minutes from the hyperthermic phase (42.5Ê C).
Results: The overall treatment toxicity and surgical morbidity rates
were 14 and 15%, respectively. The treatment related mortality
was  0%.  Median survival  and median  progression  free  survival
were 26 and 6.7 months, respectively. Median time to local pro-
gression was 16.3 months.
Conclusions: The results of our study are promising and a ran-
domised controlled clinical trial should be addressed for confirma-
tion.
Proffered Papers Ð  Radiation Oncology
Complete Resection And Intra-operative Radiation 
Therapy Improve Outcome Of Retroperitoneal Sarcomas
Pierie JPEN, Betensky RA, Choudry U, Willett CG, Souba WW, 
Ott MJ
Massachusetts General Hospital Cancer Center, Boston, MA 02114, 
USA
Objective: The assessment of long-term outcomes of patients with
retroperitoneal sarcomas (RS) undergoing resection and external
Group 1  Group 2  Group 3  Group 4
Number of patients 24 28 19 16
Number of local 
recurrences
1 (4%) 1 (4%) 6 (32%) 6 (38%)CTOS  abstracts 43
beam radiation therapy (EBRT) with or without intra-operative
electron beam radiation therapy (IOERT). 
Summary and background data: Despite improved imaging, surgi-
cal techniques, and technical innovations in radiation therapy, the
survival  of  patients  with  RS  is  still  poor.  Survival  might  be
enhanced with improved local control, when IOERT is added to
the treatment regimen.
Methods: One hundred and three consecutive patients treated for
primary RS were studied. The median follow-up was 27 months
(range, 1± 193 months). Demographic features, clinical presenta-
tion, stage and histology of the tumor, the type of surgical treat-
ment, and the addition of EBRT and IOERT were analyzed to
determine their impact on survival and recurrence. 
Results: The mean age at presentation was 55 ± 17 years (range,
10± 93 years), with a slight female preponderance (56:47). Sixty-six
percent of the patients presented with of pain or discomfort, 30%
with a palpable mass, 23% with distant disease, and 5% with lymph
node metastases. The mean tumor size was 15 ± 6 cm (range, 3± 34
cm). The most common histologic type was leiomyosarcoma (27%)
with  predominately  high-grade  tumors  (86%).  Complete  gross
resection  of the  tumor was possible  in 61%  of patients  and this
increased survival versus both debulking (hazard ratio [HR] = 0.30,
p = 0.0005) and biopsy (HR = 0.22, p < 0.0001). The 5- and 10-
year survival rates were 62 and 52%, respectively, for those with
complete resection versus 29 and 20% after incomplete resection. 
In all 103 patients, IOERT plus EBRT enhanced survival as com-
pared with EBRT alone (HR = 0.40, p = 0.058). Five- and 10-year
survival rates were 70% after the use of IOERT. In a multivariate
model including all 103 patients, male gender, increasing size of
the tumor, a more advanced stage of the tumor, the resection of
more  than  one  organ,  a  histology  of  malignant  Schwannoma,
incomplete  resection  of the  tumor and the  absence of IOERT,
were associated with a decreased survival.
Among the 62 patients undergoing a complete resection, there was
a trend for IOERT to further augment survival as compared with
EBRT alone (HR = 0.38, p = 0.13), leading to 5- and 10-year sur-
vival rates of 77%. IOERT increased the time to both local and dis-
tant recurrence as compared with EBRT alone (HR = 0.27, p =
0.036) in this group.
Conclusions: Complete gross resection remains the most effective
treatment for retroperitoneal sarcomas. The addition of IOERT to
EBRT is more effective than EBRT alone in increasing survival
and decreasing both local and distant recurrence after complete
tumor resection.
Radiation Morbidity Two Years Post Treatment: Results 
From A Randomized Trial Of Pre- Versus Post-operative 
Radiotherapy
Davis AM, O’Sullivan B, Catton CN, Chabot P, Hammond A, 
Benk V, Turcotte R, Bell RS, Wunder JS, Goddard K, Day A, 
Sadura A, Pater J, and Zee B
Canadian Sarcoma Group and the National Cancer Institute of 
Canada-Clinical Trials Group, Canada
Purpose: The objectives of this study were: (1) to determine if there
was a difference between patients treated with pre-operative (pre-
op) versus post-operative (post-op) radiotherapy in the secondary
endpoints of the SR.2 trial, specifically RTOG skin and subcutane-
ous tissue, bone toxicity, joint stiffness and oedema; and (2) to eval-
uate the relationship of these endpoints to function as measured by
the Musculoskeletal Tumor Rating Scale (MSTS) and the Toronto
Extremity Salvage Score (TESS), at 2 years post-treatment.
Methods: The  sample  analyzed  included  a  subgroup  of  113
patients  from  the  SR.2  study  who  were  randomized to  pre-op
versus post-op radiotherapy and who had primary wound closure.
The morbidity endpoints dichotomized at a score of < 2 or ‡  2
were evaluated by treatment arm using the Chi-square test. Multi-
variate step-wise logistic regression was used to evaluate the effect
of  treatment  arm,  radiation  field  size,  maximal  radiation  dose,
MSTS and TESS scores on skin and subcutaneous tissue, bone
toxicity, joint stiffness and oedema.
Results: There was no difference in skin, bone, or joint toxicity in
the two treatment arms. Twenty-six of 46 in the post-op arm com-
pared with 19 of 67 in the pre-op arm had grade 2 or greater sub-
cutaneous fibrosis (p = 0.003). Oedema grade 2 or greater was
more frequent in the post-op arm (11 of 46) versus five of 67 in the
pre-op  arm  (p  =  0.014).  In  univariate  analysis,  dmax  dose  and
TESS score were associated with subcutaneous fibrosis, bone and
joint toxicity. In multivariate analysis, only field area was associ-
ated with skin toxicity (p = 0.14); field area (p = 0.0002) and max-
imum  radiation  dose  (p  =  0.0563)  were  associated  with
subcutaneous fibrosis  (with treatment  arm confounded by  field
area);  bone  toxicity  was  associated  with  the  TESS  score  (p  =
0.004);  maximal  radiation  dose  (p  =  0.0052)  and MSTS  (p  =
0.0001)  were  associated with  joint  toxicity;  and, field  area was
associated with oedema (p = 0.0054).
Summary  and  conclusions: Patients  treated  with  post-op  radio-
therapy  have  greater  subcutaneous tissue  toxicity  and  oedema.
However, these  effects  are confounded by larger radiation field
area and maximum dose in the post-op treatment arm. Bone and
joint toxicity have a significant impact on patient function.
Real-time Radiotherapy Review Of A Randomized Trial Of 
Pre- And Post-operative Radiotherapy For Localized Soft-
tissue Sarcoma Of The Extremity
Catton CN, Goddard K, O’Sullivan B, James K
Departments of Radiation Oncology, The Princess Margaret Hospital, 
Toronto, and The Cancer Control Agency of British Columbia. 
National Cancer Institute of Canada (NCIC) Clinical Trials Group, 
Kingston, Ont., Canada
Purpose: To evaluate the process and results of real-time radiother-
apy (RT) review of the NCIC SR-2 randomized trial of pre- and
post-operative RT for localized extremity soft-tissue sarcoma (STS).
Material and methods: The trial opened in 1994 and closed in 1997
after the planned interim analysis showed a significant difference in
outcome for the primary endpoint between the two treatment arms.
Ten centers entered 189 patients. Review of RT plans was required
within three fractions from the start of therapy. Copies of simulator
films, isodose distributions, prescription and dose calculations, set-
up photo and diagnostic images were required for the review, and
were to be couriered to the review center before treatment. Plans
were evaluated for compliance to dose and fractionation, and that the
clinical target volume (CTV) margins met minimum requirements,
and were covered by the 95% isodose line, and that dose distributions
were homogeneous to ± 5%. A report of protocol compliance or non-
compliance with recommendations for plan modification was faxed
to the submitting center and mailed to the central trial office (CTO).
The final decision for any changes was left to the treating oncologist.
Records of the reviews and completed treatments were analyzed to
determine protocol compliance for RT given during the trial, and to
determine the effectiveness of the real-time review process.
Results: Five patients did not receive RT, leaving 184 for analysis.
The trial review rate was 161/184 (87%), as 23 eligible cases were
not  reviewed.  One  hundred  and  fifty-three  of  161  treatments
reviewed (95%) met protocol standards, including five plans modi-
fied because of the review. Eight cases (5%) were not modified as
recommended.  Reasons  were:  unknown  (five  cases),  treatment
completed before the review (two cases), disagreement about the
location of the gross tumour volume (GTV) (one case). Review was
completed within the first three fractions in 90/161 cases (56%).
Reasons for review not performed in real time were: sufficient data,
but submitted late, 56/71 (78%); incomplete data submitted, but
updated late, 6/71 (8%); reviewer late in submitting review, 9/71
(12%). Review was not performed because data was not submitted,
or was lost en route (15/23) or incomplete data was never subse-
quently updated (8/23).44 CTOS  abstracts
Conclusions: Extremity STS is one of the most difficult sites to
plan for RT, often requiring complex, and individualized plans,
and RT review was an essential quality control component for the
SR-2 trial. The trial achieved 87% of treatments reviewed, with
95% of these meeting protocol requirements. The real-time review
rate was only 56%. Failure was usually due to the short time avail-
able for the collection and couriering of data between simulation
and treatment. For future trials, on-line data transmission should
improve efficiency and reduce the risk of data being lost in transit.
Thirteen percent of cases were not reviewed, and notification from
CTO to reviewers and centers of upcoming reviews might lessen
the rate of forgotten and lost submissions. CTO should ascertain
that non-compliant plans are modified to meet protocol, or that an
explanation for non-compliance is recorded. 
Proffered Papers Ð  Young Investigator
Regulation Of Osteosarcoma (Os) Metastasis By Igf-i 
Receptor Signaling: A Novel Therapeutic Target
Weber K, Tsan R, Doucet M, MacEwen E, Radinsky R
MD Anderson Cancer Center, Houston, TX 77030, USA
Patients with metastatic OS continue to have a survival of ~20% at 5
years despite aggressive chemotherapy and multiple thoracotomies.
Increased understanding of the biology of OS progression, metasta-
sis, and its resistance to chemotherapy will uncover new molecular
targets. OS overexpresses insulin-like growth factor I receptor (IGF-
I-R), and recent data suggests that OS progression and metastasis
requires a functional IGF-I-R. The purpose of this study was to abol-
ish  IGF-I-R activity in highly  metastatic  OS cells, and to test  its
effects on growth and metastatic properties in vitro and in an ortho-
topic nude mouse model. Cellular proliferation assays of the human
SAOS-2 and metastatic variant SAOS-LM2 OS cells revealed a 40%
increase in proliferation subsequent to IGF-I treatment, compared
with controls. A 30% inhibition of growth was observed following
treatment with IGF-BP-3, a negative regulator of IGF-I. A chemore-
sistance/survival advantage was also observed for SAOS-LM2 OS
cells in the presence of IGF-I as shown by reduction in doxorubicin-
induced apoptosis from 62% (doxorubicin alone) to 21% (doxoru-
bicin + IGF-I) (p < 0.05). Enforced expression of a dominant nega-
tive truncated IGF-I-R (952-STOP) in these cells resulted in a 50±
85% decrease in IGF-I-R autophosphorylation compared with con-
trols  following IGF-I  treatment.  There was also a corresponding
decrease in downstream AKT and MAP kinase activity. OS 952-
STOP clones had a 30% longer doubling time under anchorage-
dependent conditions, and failed to form colonies under anchorage-
independent conditions versus controls. In vivo experiments in an
orthotopic nude mouse model are ongoing to test the contribution of
IGF-I-R to OS growth, metastasis and response to therapy. Prelimi-
nary results show that mice injected with the parental OS cells form
lung metastasis, whereas those injected with the dominant negative
IGF-I-R transfectant cells do not. 
Results Of Two Consecutive Phase Ii Studies And Interim 
Analysis Of A Phase Iii Intergroup Study Of Neoadjuvant 
Treatment Including Regional Hyperthermia (Rht) In High 
Risk Soft Tissue Sarcoma (Hr-sts) Patients
Wendtner CM, Abdel-Rahman S, Falk MH, Lang NK, Krych M, 
Hiddemann W, Issels RD
Med. Klinik III/Grosshadern, Ludwig-Maximilians-University and 
KKG Hyperthermie, GSF, D-81377 Munich, Germany
We report on 113 patients with HR-STS (non-resectable primary/
S1,  recurrent/S2,  inadequately  resected/S3)  located  within
extremities, trunk or abdomen who were treated within a neoad-
juvant phase II protocol (RHT-91 or RHT-95). HR-criteria were:
tumor grade II/III + tumor size (> 8 cm for RHT-91; > 5 cm for
RHT-95)  +  extracompartmental  extension.  The  neoadjuvant
RHT-91 protocol (59 patients) included four cycles of pre-opera-
tive chemotherapy (XT) plus RHT, followed by surgery and four
cycles  of adjuvant XT plus  RHT. In  addition, R1/R2-resected
patients received radiation. The RHT-95 protocol (54 patients)
was identical except that patients after surgery obtained XT with-
out RHT and adequate radiation regardless of resection status.
XT of both studies consisted of etoposide (125 mg/m2) on day 1
+ 4, ifosfamide (1500 mg/m2) on day 1± 4, and adriamycin (50 mg/
m2) on day 1 (EIA). RHT (1 h at 42.5°C) was given on day 1 + 4.
Radiographic response in 52 evaluable patients of the RHT-91
(42%) and in 36 assessable patients of the RHT-95 study (33%)
included 1 + 2 CR, 8 + 6 PR, 13 + 4 MR, 17 + 10 SD and 13 +
14 PD, respectively. Among 74 patients undergoing surgery, the
amputation rate was < 15%. After different median observation
times (RHT-91, 58 months/RHT-95, 30 months), probability of
overall survival (42% versus 48%; p = 0.392) and distant progres-
sion free survival (51% vesrus 64%; p = 0.357) are quite similar
for both studies. Subgroup analysis (S3 versus S1, S2) for overall
survival revealed also no significant difference (47% versus 48%;
p = 0.616). Interestingly, local relapse free survival was in favour
of  the  RHT-91  study,  which  included  pre-  and post-operative
RHT (58% vesrus 57%; p = 0.021).
Based on these results, a randomized prospective phase III inter-
group study (EORTC 62961/ESHO RHT-95) with transatlantic
participation  is  ongoing  comparing  EIA  ±  RHT  in  previously
defined (S1± S3) risk groups, and includes pre- and post-operative
RHT in the experimental treatment arm with local relapse free sur-
vival as the main study endpoint. Since July 1997, more than 100
patients have been randomized. Feasibility  of pre-operative XT
was 95% (270 of 284 cycles in 71 patients evaluable) and that of
post-operative XT 74% (115 of 156 cycles in 39 patients evalua-
ble), respectively. In all patients assessed so far, no grade IV hema-
tological toxicity was observed. Three patients died of acute non-
hematological toxicity (4%). Feasibility of pre-operative RHT was
90% (133 of 148 cycles in 37 patients evaluable) and of post-oper-
ative RHT 59% (45 of 76 cycles in 19 patients evaluable), respec-
tively,  while  almost  no  severe  reactions  directly  attributed  to
hyperthermia were reported. Taken together, treatment within this
international phase III protocol is a feasible and safe approach for
HR-STS patients, while impact on local disease control and sur-
vival has to be awaited.
Proffered Papers Ð  Basic Science/Biology
Differential Expression Of Ezrin In A High And Low 
Metastatic Osteosarcoma Model
Khanna C, Prehn J, Khan J, Nguyen P, Trepel J, Meltzer P, 
Helman L
Pediatric Oncology and Medicine Branches, National Cancer Institute, 
and Cancer Genetics Section, National Human Genome Research 
Institute, National Institutes of Health, Bethesda, MD 20892, USA
Osteosarcoma (OSA) is the most common primary tumor of bone.
Despite  successful  control  of  the  primary  tumor  and  adjuvant
chemotherapy, relapse of OSA in the lungs occurs in over 30% of
patients within 5 years. In order to understand the complex proc-
ess of metastasis from appendicular tumors to the lungs, we have
used cDNA microarray to define differences in gene expression
between clonally related murine model variants of osteosarcoma
that differ in pulmonary metastatic potential. The murine osteosa-
rcoma models are characterized by orthotopic growth at appendic-
ular sites in balb/c mice, spontaneous pulmonary metastasis to the
lungs, and clonally related variants (K7M2 and K12) that differ in
pulmonary metastatic potential. CTOS  abstracts 45
A 4000 gene cDNA microarray was used to compare gene expres-
sion between the primary tumors of the more aggressive (K7M2)
and less aggressive (K12) models. Differentially expressed genes
were defined by a red to green ratio not equal to 1.0 with 99% con-
fidence (> 1.0 or < 1.0 ± 99% confidence interval), a mean maxi-
mum  signal  intensity  greater  than  2000,  and  concordant
differential expression in two separate microarray hybridizations.
Eighty  genes  were  defined  as  differentially  expressed  between
K7M2 and K12. Forty-two genes were over-expressed in K7M2
compared with K12, and 38 genes were over-expressed in K12
compared with K7M2.
A functional approach to the analysis of the differentially expressed
genes was taken, by assigning each gene to six non-mutually exclu-
sive  metastasis-associated  categories  (using  the  PubMed  and
OMIM  databases):  proliferation  and  apoptosis,  motility  and
cytoskeleton, invasion, immune-surveillance, adherence and ang-
iogenesis. The high and low metastatic variants were then evalu-
ated  within  each  of  these  metastasis-associated  processes.
Functional studies demonstrated significant differences in motil-
ity, adherence, and angiogenesis that favored the aggressive behav-
ior in K7M2 compared with K12. For this reason, the differentially
expressed genes with motility, adherence, and angiogenesis associ-
ated functions were considered more likely to explain differences
in the metastatic behavior of K7M2 and K12 than genes associated
with  proliferation  and apoptosis,  invasion  and immune-surveil-
lance.
This approach brought attention to ezrin, a motility and adherence
gene  not  previously  described  in  OSA,  that  was  found  over-
expressed in K7M2 compared with K12 tumors. We have con-
firmed differential expression of ezrin by Northern analysis. Immu-
nocyostaining  for  ezrin  has  confirmed  increased  levels  of  ezrin
protein and demonstrated the enhanced localization of ezrin at the
cell membrane in K7M2 compared with K12 cells. Using North-
ern analysis, we have demonstrated the expression of ezrin in dogs
with naturally occurring osteosarcoma and in 5/5 human osteosar-
coma cell lines.
Ongoing work will attempt to define the biological role of ezrin in
osteosarcoma and the relevance of ERM proteins (ezrin, radixin,
and moesin) in human cases of osteosarcoma.
Molecular Cloning Of Putative Oncogene And 
Antioncogene Involved In The Development Of 
Osteosarcoma 
Toguchida J. Murakami H, Nakamata T, Nakayama T. 
Nakamura T
Institute for Frontier Medical Sciences and Department of Orthopaedic 
Surgery, Kyoto University, Kyoto, Japan
Mutations of the Rb and p53 genes were found in approximately
60% of osteosarcomas, and hereditary mutations of either genes
predispose individuals for the risk of osteosarcomas, suggesting the
major role of these tumor suppressor genes in osteosarcoma. How-
ever, it is not yet clear whether mutations of both genes will be suf-
ficient  or  other  genetic  alterations  will  be  necessary  for  the
development  of  osteosarcoma.  To  address  this  issue,  we  have
undertaken the in vitro transformation experiment. First, we have
established an osteoblast-like cell line, MMC2, from the p53 (± /± )
mice. MMC2 showed several phenotypes as differentiated osteob-
lasts such as the ability to produce calcified nodules in vitro. To
inactivate the Rb gene in MMC2, HPV16E7 was introduced by
the retrovirus vector, and one cell line was established and desig-
nated as MMC2-E7. MMC2-E7 per se seemed to be a non-trans-
formed cell line, because MMC2-E7 failed to make colonies in the
soft agar and no constant tumor formation was observed in vivo.
These  results  suggested  that  genetic  alterations  other  than  the
mutation of the p53 and Rb genes will be involved in the develop-
ment of osteosarcoma. After a prolonged latent period, however,
MMC2-E7 produced tumors in vivo, and a cell line (MMC2-TC)
was established from tumor tissues, which showed several pheno-
types as a fully transformed cell. To isolate the genes responsible
for the final transformation step, the differential display method
was  performed  and  two  fragments,  designated  DDM23  and
DDM36, were isolated. The expression of DDM23 was detected
only in MMC2-TC, but not in MMC2 or MMC2-E7, and there-
fore it was considered to be a new oncogene involved in the process
of  malignant  transformation.  The expression  of  the  other  frag-
ment, DDM36, was lost during the progression from MMC2-E7
to MMC2-TC,  suggesting  that  it  was a  candidate for  the  new
tumor suppressor  gene  in osteosarcoma.  Functional  and muta-
tional analyses of these putative osteosarcoma-involved genes will
provide the clue to understand the molecular mechanism of oste-
osarcoma development. 
Clinico-pathological And Biological Analyses Of The 
Chop-related Fusion Genes In Myxoid Liposarcomas
Hosaka T1,2, Kanoe H1,2, Nakamura T2, Toguchida J1,2
1Institute for Frontier Medical Science and 2Department of Orthopaedic 
Surgery, Kyoto University, Kyoto 606-8507, Japan
The characteristic t(12;16)(q13;p11) or t(12;22)(q13;q12) chro-
mosomal translocations, which lead to gene fusions that encode
the TLS-CHOP or EWS-CHOP chimeric  protein, respectively,
are associated with human myxoid/round cell liposarcomas. How-
ever, the  role of those chimeric  proteins  in the  development of
liposarcomas still remains to be solved. To address this issue, we
have performed  the  mutation  analysis  using clinical  specimens,
and also conducted the  transformation experiment using fusion
genes detected in the mutation analysis.
First, we have performed a reverse transcription-polymerase chain
reaction to detect the TLS-CHOP or EWS-CHOP fusion tran-
scripts in 26 liposarcomas that were diagnosed as either myxoid or
round cell type. TLS-CHOP fusion transcrips were detected in 17
cases with four different subtypes, EWS-CHOP fusion transcrips
were detected in three cases with two different subtypes, and no
fusion transcript was detected in six cases. There was no significant
correlation between any clinical or pathological findings and the
subtypes of TLS-CHOP fusion transcripts. However, two cases
with a novel type of EWS-CHOP fusion transcript, which was cre-
ated by the fusion between EWS exon 10 and CHOP exon 2, dem-
onstrated  enormously  huge  tumors  at  the  diagnosis,  and  both
tumors were treated effectively by chemotherapy. As in vitro stud-
ies, we have cloned entire cDNAs of four different TLS-CHOP
transcripts and introduced them to 3T3-L1 preadipocytes by ret-
roviral transduction. These cells had no apparent growth advan-
tage, and no colonies were found in the soft agar. However, the
adipogenic  differentiation  was  unable  to  be  induced  in  vitro.
DOL54, one of the downstream targets of TLS-CHOP genes, was
upregulated in these cells. These results suggested that the func-
tion of TLS-CHOP gene in the development of liposarcomas is
other than growth progression.
Cytokine Levels In Serum Of The Patients With Soft Tissue 
Sarcomas And Their Relationship To Alterations Of 
Routine Blood Tests
Rutkowski P1, Kaminska J2, Rysinska A2, Steffen J3, Ruka W1
1Soft Tissue/Bone Sarcomas Department, 2Tumor Markers 
Department, and 3Department of Immunology, MSklodowska-Curie 
Memorial Cancer Center-Institute, Roentgena 5, Warsaw, Poland
Introduction: It has been demonstrated that several cytokines may
be  synthesized  and  released  by  many  lymphoid  and  epithelial
malignant tumors, and that raised serum level of various cytokine46 CTOS  abstracts
may affect the prognosis. It has been also reported that cytokine
levels may influence some changes in the blood tests, which was
also found as negative prognostic factors in patients with malig-
nancy. There are only a few reports about cytokine production in
such a rare group of malignant solid tumors as soft-tissue sarco-
mas. The aim of the study was to evaluate the profile of the selected
cytokines in serum of untreated patients with malignant soft-tissue
tumors. Then we attempted to correlate these results with the pre-
treatment  routine  blood  tests  (RBC,  hemoglobin  level  (HGB),
WBC, platelets count, white blood differential count Ð  neutrocyte
count, lymphocyte count (LY), monocyte count).
Materials and Methods: One hundred and forty-four patients (74
males, 70 female; mean age, 50.1 ± 16.9 years) with histologically
proven soft-tissue  sarcomas before treatment were enrolled into
the study. In the study, we evaluated serum level of 13 types of
cytokines and their soluble receptors (IL-IRA, IL-2SR, IL-6, IL-8,
IL-10, EL-6SR, TNFRI, TNFRII, TNFA, GCSF, MCSF, bFGF,
VEGF) with an ELISA method. Peripheral blood samples from 45
healthy volunteers were collected as controls. Statistical  analysis
was performed using Kolmogorov± Smirnov and Mann± Whitney
U tests (p < 0.05).
Results: Significant differences in 11/13 cytokine productions (IL-
IRA, 11-2SR, IL-6, IL-8, IL-10, TNFRI, TNFRII, TNFA, MCSF,
bFGF, VEGF) (p < 0.001) were observed between malignant soft
tissue tumors and the healthy subjects group. Elevated serum level
of a complex of several cytokines (particularly, IL-IRA, IL-2SR, IL-
6,  IL-8,  EL-10,  MCSF,  TNFRI)  correlated  significantly  (p  <
0.001) with the most frequently founded alterations in the blood
tests:  neutrophilia  (29.5%  of  cases),  decreased  HGB  (22.3%),
monocytosis  (22.3%)  and  thrombocytosis  (14.5%).  In  10%  of
patients,  we found lymphocytopenia (LY < 1.0), which demon-
strated  the  relationship  to serum  levels  of IL-6,  IL2SR,  MCSF.
Additionally,  it  was  detected  that  increased  sera  several  cytokin
levels and also blood test abnormalities correlated significantly with
more advanced stage of the primary tumor (size and grade).
Conclusions: The results of this study suggest that cytokine pro-
duction is probably involved in soft tissue sarcoma progression,
what is implied by their increased sera levels in soft-tissue sarcomas
versus controls. The results of the analysis may also suggest that
important biological effects and immunological implications of the
particular cytokines can be reflected in routine blood test abnor-
malities. Sera levels of selected cytokines may be useful matker in
the diagnosis of soft tissue sarcomas.
Wild-type P53 Sensitizes Soft Tissue Sarcoma Cells To 
Doxorubicin By Downregulation Of Mdr1 Expression
Zhan M, Yu D, Lang A, Li L, Pollock RE
MD Anderson Cancer Center, Houston, Texas, USA
p53 mutations occur in almost one-half of all soft issue sarcomas
(STS) and may be a contributing factor in their chemoresistance
to most of chemotherapeutic agents including Doxorubicin (Dox),
the most active single agent in this disease. To examine whether
introduction of wild-type (wt) p53 might increase chemosensitivity
of STS cells harboring p53 mutations, two wt p53 stable transfect-
ants of SKLMS-1 sarcoma cells, SKp53-1 and SKp53-3, and a p53
temperature-sensitive  mutant  transfectant  of  SKLMS-1  cells,
SKAla-14, were used and compared with parental cells SKLMS-1
for their sensitivity to Dox. MTT assays showed that the IC50 of
Dox  decreased  from  2.5  mm  for  SKLMS-1  to  0.25  mm  for
SKp53-1  and 0.18  mm  for SKp53-3  cells.  Clonogenetic assays
showed that the IC50 decreased from 27.5 mg/ml for SKLMS-1 to
2.4 mg/ml for SKp53-1 and SKp53-3 cells. In tumorigenic assays,
cells were injected subcutaneously (s.c.) into SCID mice. When
the resulting tumor volume reached 62.5 mm3, mice were given
Dox (1 mg/kg) s.c. weekly. Consequently, Dox treatment inhibited
tumor  growth  more  effectively  in  mice  bearing  SKp53-1  and
SKp53-3 tumors than in mice bearing SKLMS-1 tumors. Western
blot, northern blot, and immunohistochemical analyses showed
that the mdr1 gene encoded p-glycoprotein expression decreased
in wt p53 transfectants  compared with  SKLMS-1  cells.  Higher
levels of intracellular accumulations of Dox were found in wt p53
transfectants than that in SKLMS-1 cells. No difference in DNA
fragmentation,  Bax  or  Bcl-2  expression  was  detected.  Taken
together, these results suggest that introduction of wt p53 into STS
cells harboring p53 mutation can enhance their chemosensitivity to
Dox by inhibiting mdr1 expression. These results also suggest that
combination  of  p53  gene  therapy  and  chemotherapy  might
increase the therapeutic efficacy in the treatment of STS.
Proffered Papers Ð  Medical Oncology
Expression Of The Trail Receptor Dr4 In Human Soft 
Tissue Sarcomas
Komdeur R, de Jong S, Hoekstra HJ, Molenaar WM, Plaat BEC, 
Van den Berg E, Van der Graaf WTA
University Hospital Groningen, 9700 RB, The Netherlands
Introduction: Nowadays, limb  salvage  is  feasible  in  more  than
75% of patients with a primarily irresectable soft tissue sarcoma
(STS) of the extremity after treatment with hyperthermic isolated
limb perfusion with TNFa  and melphalan (HILP-TM). The TNF
related apoptosis inducing ligand (TRAIL) is a recently described
member of the TNF family of cytokines that rapidly induces apop-
tosis in tumor cells. TRAIL appears to be non-toxic to normal tis-
sues  when  administered  in  non-human  primates.  Six  distinct
receptors for TRAIL have been identified, of which only DR4 and
DR5  can  initiate  cell-death.  Adding  TRAIL  to  the  treatment
schedule  might  further  improve  limb  salvage  rate  for  locally
advanced extremity  STS. HILP offers the  unique possibility  to
introduce TRAIL in humans since unforeseen toxicity would be
limited. The objectives of the current study are: (1) to investigate
the  expression  of  DR4  in  human  STS,  and  (2)  to  determine
whether the expression of DR4 is changed after HILP-TM.
Patients and methods: Twenty-five patients with a primarily irresect-
able extremity STS underwent HILP with TNFa  (3± 4 mg) and
melphalan (10± 13 mg/l limb volume), followed by a delayed resec-
tion. The median period between HILP and resection of the tumor
remnant was 61 days (range, 12± 81 days). Tumor samples were
obtained from the  diagnostic pre-HILP specimen and from the
post-HILP  resection  specimen.  Immunohistochemical detection
of DR4 was scored as described in Table 1.
Results: Of the 25 samples obtained before HILP-TM, 16 scored
positive for DR4 expression (64%) (Fig. 1). After HILP, 18 sam-
ples were evaluable: 12 scored positive (76%) (Figure 2). Statisti-
cal analysis of paired (pre- and post-HILP) samples revealed no
significant  change in DR4 expression. Interestingly, all  synovial
sarcomas (n = 4) were scored negative before HILP-TM, whereas
three were positively stained afterwards.
Conclusions: The  majority  of  these  human  STS  expresses  the
DR4 receptor. Of interest, all four synovial sarcomas scored DR4-
negative before HILP; three of them were positive afterwards. DR4
expression  did  not  significantly  change  in  paired  samples  after
HILP.  However, acute  effects  may  be  missed  due  to  the  long
period between HILP and tumor resection. The high percentage of
initial DR4 positive tumors make TRAIL an interesting agent for
STS when it becomes available for clinical studies.
Dominant Negative IkBa Potentiates In Anti-tumor Activity 
Of Doxorubicin In A Rat Hind Limb Isolated Perfusion Model
Davidson R, Lu X, Chiao P, Pollock R, Feig B
University of Texas M.D. Anderson Cancer Center, Houston, TX 
77030, USA
Introduction: Inhibition  of  NF-kB  activity  has  been  shown  to
potentiate  apoptotic killing  secondary to  chemotherapeutic  andCTOS  abstracts 47
biologic  agents. We hypothesize that direct  gene transfer of the
dominant negative inhibitor (IkBaM) would potentiate the in vivo
tumor response to doxorubicin delivered via isolated perfusion in
a rat hind limb fibrosarcoma model.
Methods: Viable  tumors  were  established  in  the  hind  limb  of
Fisher  rates  weighing  150± 250  g  using  a  methylcholanthrene
induced rat fibrosarcoma (RFS). When tumors reached 5± 10 mm
in greatest dimension, direct intra-tumoral injection with 6 x 1010
pfu  of  either  Ad5IkBaM,  empty  Ad5  vector  (EV)  or  a  similar
volume of phosphate buffered saline (PBS) was performed serially
for 3 days. Rats were then perfused with doxorubicin 1.0 mg/g
body weight/cm3 for 10 minutes at a perfusion rate of 2.4 cm3/min.
Animals were subsequently observed for 21 days with serial record-
ing of tumor volumes. 
Results: There was a reduction in tumor volume from baseline to
day 21 in the Ad5IkBaM treated group (± 21%) as opposed to con-
tinued tumor growth in the EV (+58%) and PBS (+457%) treated
groups. Overall, ANOVA was significant for the three groups (p <
0.001). The graph below shows the percent volume change for the
three groups.
Conclusions: The addition of Ad5IkBaM potentiates the effect of
doxorubicin in this isolated lower extremity perfusion model in the
rat. We believe that inhibition of NF-kB activity leads to increased
apoptotic sarcoma cell killing in concert with doxorubicin or other
effectors that lead to apoptosis. IkBaM may represent an important
adjunct to therapies  based on the induction of apoptosis  in the
future.
A Pilot Study Of Short Course, Intensive, Multiagent 
Chemotherapy For Poor Risk Osteosarcoma
Janinis J, McTiernan A, Cassoni AM, Whelan JS 
The London Bone and Soft Tissue Tumour Service, Meyerstein Institute 
of Oncology, Middlesex Hospital, London W1N 8AA, UK
Aim: To  assess  the  feasibility,  toxicity  and  response  to  short
course, multiagent chemotherapy culminating in peripheral stem
cell supported high-dose chemotherapy (HDC) in patients with
poor risk osteosarcoma (OS).
Patients  and  methods: Between April  1995  and April  1999,  30
patients  entered  the  study.  Median age,  24  years (range, 9± 46
years). Median age for extremity OS, 17 years; for pelvic/axial OS,
30 years. Male to female ratio, 1.7:1. Primary site: extremity OS,
14;  pelvic  OS, 12;  other,  4. Metastases  at  presentation,  15/30.
Chemotherapy consisted of five blocks given consecutively. Block
1: 100 mg/m2 cisplatin, 75 mg/m2 q 14 days x 2 doxorubicin. Block
2 (x 1): 50 mg/m2 cisplatin, 4 g/m2 ifosfamide, and 500 mg/m2
etoposide (stem cell harvest post Block 2). Block 3: 18 g/m2 q 21
days x 2 ifosfamide. Block 4: 12 g/m2 q 7± 10 days x 3 methotrex-
ate. Block 5 (administered around week 21): AUC8 carboplatin
and 400 mg/m2 etoposide on days ± 8, ± 6, and ± 4, 60 mg/kg cyclo-
phosphamide on days ± 6 and ± 4. On day 0, patients underwent
reinfusion of their harvested stem cells.
Results: A total of 226 cycles of chemotherapy (blocks 1± 5) were
administered.  A  significantly  higher  number  of  patients  with
extremity OS received more than 75% of the  intended dose of
chemotherapy or the intended number of cycles for blocks 2, 3,
and 4 compared with those with pelvic/axial OS. HDC was admin-
istered to 11 patients (10 with extremity OS and one with a pelvic
OS). Grade  3  or  4  toxicity  (blocks  1± 4):  neutropenia, 49%  of
cycles; thrombocytopenia, 26%. There were 59 episodes of febrile
neutropenia. There were two treatment-related deaths: one post-
HDC from sepsis, and one during surgery. Responses (30 patients
evaluable): PR, 30%; mR, 17%; SD, 47%; PD, 6%. Histologic
response (22/26 evaluable patients) > 90% tumor necrosis, 23%.
Twenty-seven patients underwent primary surgery. Limb salvage
operation, 20. Eight patients underwent pulmonary metastasec-
tomy.  The  median  survival  time  for  the  whole  group  was  16
months (95% CI, 13± 19 months). The 2-year survival rate for the
whole group of patients was 33% (50% for extremity tumors and
19%  for  pelvic/axial  tumors);  median  follow-up,  16  months
(range, 7± 57 months).
Conclusion: Dose intensive multiagent chemotherapy is feasible
in the  group of patients  with  extremity  OS  but not  those  with
pelvic/axial primaries. A number of factors may account for this
such as higher age group and poor performance status. Inferior
survival rates in the pelvic/axial group are attributed to poor local
tumor control by surgery and less dose intensive treatment. 
A Phase I Trial Of Intraperitoneal Hyperthermic 
Chemotherapy For The Treatment Of Sarcomatosis
Bilimoria MM, Feig B, Mansfield P, Pisters PWT, Pollock RE, Patel 
S, Plager C, Benjamin R, Burgess M, Chase J, Murphy A, Griffin J, 
Mirza, N, and Hunt K
UT MD Anderson Cancer Center, Houston, TX 77030-4095, USA
The appropriate therapeutic interventions for patients with intra-
abdominal disseminated sarcoma (sarcomatosis) remain unclear.
We have previously reported that these patients have a median sur-
vival of 13  months  irrespective  of the  current adjuvant therapy
available (CTOS abstract  #0002, 1999). A phase I study using
tumor debulking coupled with hyperthermic peritoneal perfusion
with  cisplatin  was  initiated  to  determine  the  toxicity,  operative
complications, and effects on time to tumor progression.
Methods: A total  of 25  patients  were enrolled in the  study, of
which 19 underwent complete tumor debulking followed by intra-
peritoneal hyperthermic perfusion with cisplatin. Patients with low
volume liver metastases were eligible for perfusion. The dose of
cisplatin used was modified from an initial 150 to 90 mg/m2. Per-
fusate  time  was  modified  from  120  to  90  minutes.  Seventeen
patients received a 90 mg/m2 dose with a perfusion time of 90 min-
utes.  Inlet  temperature  of  perfusate  was  decreased  from  44  to
41°C. All changes were secondary to toxicity.
Results: Two  patients  were  treated  with  the  initial  parameters
(150 or 120 mg/m2 cisplatin; 44°C inlet temperature; 120 minute
dwell time). A total of 17 patients were treated with the modified
dose of cisplatin (90 mg/m2), the modified perfusate time (90 min-
utes), and the modified inlet temperature (41°C). The median age
of the  patients studied was 52 years (range, 24± 77  years). The
median  number  of  separate  tumor  nodules  removed  was  100
(range, 6± 1000+). Median time on mechanical intubation was 1
day (range, 1± 39  days) with  a median hospital  stay of 15  days
(range, 9± 69 days). Median platelet nadir was 85 K (range, 9± 176
K) necessitating a median of 0 (range, 0± 83) platelet transfusions
in  these  patients.  The  median  hemoglobin  nadir  was  8.2  g/dl
(range, 7.1± 13.4 g/dl), although the median number of periopera-
tive  RBC transfusions was 5  U  (range, 0± 34 U). Four patients
experienced major complications (24%) in this group. One patient
experienced adult respiratory distress  syndrome  associated  with
sepsis,  another patient  experienced pulmonary edema  requiring
prolonged intubation,  and two  others  experienced  renal  failure
requiring temporary hemodialysis (both patients received an initial
dose of cisplatin of 150 or 120 mg/m2). There was one reoperation
for post-operative bleeding and there were no perioperative deaths.
Three patients died as a result of metastases to the liver 7, 11, and
16 months after the procedure. Four patients are alive with no evi-
dence  of  recurrence  4± 8  months  following  the  procedure. The
remaining 12 patients are alive with recurrent disease (five with
recurrent peritoneal disease and seven with primary liver metas-
tases). The median time to local recurrence was 5 months (range,
2± 9 months), while the median time to distant recurrence was 4
months (range, 1.5± 12 months).
Conclusions: This pilot study of tumor debulking and intraperito-
neal hyperthermic perfusion with cisplatin in patients with sarco-
matosis  reveals  that  the  procedure  can  be  performed  without
mortality and with significant morbidity in only one-quarter of the48 CTOS  abstracts
patients.  Although  the  median  time  to  local  recurrence  was  5
months, 24% of the patients remain disease-free at a median of 6
months follow-up. All patients who died following the procedure
died of metastases to the liver suggesting that, although the proce-
dure can control peritoneal disease, patients are still at risk for fail-
ure from liver disease. A phase II investigation of this aggressive
therapy is needed better define response rates and progression-free
in a larger cohort of patients.
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CD99 Engagement: An Effective Therapeutic Strategy For 
Ewing Tumors
Katia Scotlandi1, Nicola Baldini1, Vanessa Cerisano1, Maria 
Cristina Manara1, Stefania Benini1, Massimo Serra1, Pier-Luigi 
Lollini2, Patrizia Nanni2, Giordano Nicoletti3, Ghislaine 
Bernard4, Alain Bernard4, Piero Picci1
1Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, 
Bologna, Italy, 2Istituto di Cancerologia, Università  di Bologna, Italy, 
3IST, Istituto Nazionale per la Ricerca sul Cancro-Genova, Unità  
Satellite di Biotecnologie, Bologna, Italy, and 4Unitù  INSERM 343, 
Hôspital de l’Archet, Nice Cedex 3, France
CD99,  a  cell  surface  protein  encoded  by  the  MIC2  gene,  is
broadly distributed on many cell types, with a particularly strong
expression on immunopoietic cells and on Ewing’s sarcoma cells.
Within the hemopoietic system, CD99 appears to have a role in
the differentiation process of T lymphocytes, by mediating adhe-
sion properties and apoptosis of immature thymocytes and prolif-
eration of mature T cells. In Ewing’s sarcoma, CD99 has long
been considered only as an important marker for the diagnosis of
these lesions. In this paper, we demonstrate that engagement of
CD99 significantly inhibits the in vitro and in vivo growth ability
of Ewing’s sarcoma cells. In particular, ligation  of CD99 with
specific MAbs resulted in a significant induction of apoptosis and
of the homotypic adhesion potential of these cells as well as in a
significant  inhibition  of the  ability  of Ewing’s  cells  to grow in
semisolid medium and in athymic mice. The growth inhibition
was significantly related with the level of expression of CD99 on
the surface of the cells and was time and dose dependent. Analy-
sis of apoptosis and of the proliferation rate revealed that CD99
engagement significantly induced apoptosis of Ewing’s sarcoma
cells but lacked to affect their proliferation ability. Moreover, we
show that anti-CD99 MAbs may be advantageously used in asso-
ciation with conventional anticancer agents. These results pro-
vide a novel entry site for therapeutic intervention, which may
have application in the care of patients with Ewing tumor, and
warrant further studies to clarify the molecular mechanisms acti-
vated by CD99 engagement.
Induction Of Chemoresistence To Doxorubicin In Cells 
Carrying A P53 Germline Mutation Detected In A Li-
fraumeni Family
Sangiorgi L1, Cerone MA2, Soddu S2, Gobbi G1, Lucarelli E1, 
Brach del Prever A3, Picci P1, Helman LJ4
1Rizzoli Orthopedic Institute, Bologna, 2Regina Elena Cancer Institute, 
Rome, 3University of Turin, Turin, Italy, and 4NCI, NIH, Bethesda, 
MD, USA 
A phenotypic Li± Fraumeni family (mother died of breast carci-
noma at the age of 35, brother died of rabdomyosarcoma at the age
of 3, two sisters died of osteosarcoma at the ages of 10 and 14) was
investigated for the presence of germline p53 mutations. SSCP for
exons  4± 11  of  the  gene  on  tumor  DNA  from  the  two  sisters
revealed an abnormal conformer in exon 6. DNA sequence analy-
sis showed a transversion from adenine to cytosine at codon 220
(amino acid change from tyrosine to serine). The same pattern was
observed on microdissected paraffin-embedded tissue of both the
mother and the brother. We generated, by site directed mutagene-
sis, a plasmid encoding the p53SER220 mutation (pLp53-S220).
We transfected fibroblasts from p53 ± /±  mice (F10) with pLp-S220
and pLp53-H175  (a plasmid encoding the p53His175  mutant).
The presence of the two mutations did not increase the prolifera-
tion  rate  of  F10  fibroblast.  Drug  sensitivity  (assessed  by  IC50
value) of the fibroblasts carrying the mutations was evaluated for
doxorubicin, cisplatin and 5-florouracil. Fibroblasts carrying the
p53SER220 and p53His175 mutations showed a selective resist-
ance  for  doxorubicin  with,  respectively,  a  3.5-  and  a  2.9-fold
increase. These data were confirmed by the evaluation of the clo-
nogenic ability of the fibroblasts carrying the different transfect-
ants. In conclusion, the p53SER220 germ-line mutation seems to
induce  a  gain  of  function  in  term  of  chemoresistency  for  the
mutated p53 protein.
Study Of Age As Major Pronostic Factor In Localised 
Ewing’s Sarcoma
Delepine F, Delepine N, Guikov E, Delepine G
Oncologic Paediatric Unit, Avicenne University Hospital, 125 Bd de 
Stalingrad, 93009 Bobigny Cedex, France
Introduction: In Ewing’s sarcoma, the prognostic value of age is
debated. Most early monocentric studies  published  disease  free
survival rate between 10 and 30% for adult patients compared with
20± 60% for children. But other multicentric trials (IESS, CESS or
SFOP)  did  not  find  such  a  difference.  We  imagined  that  the
observed differences could be correlated with the given drug inten-
sities, and analysed our data to prove it.
Material: From January 1986  to January 1999, 48 patients with
localised Ewing’s sarcoma of bone have been treated by our team.
There were 29 males and 19 females with a median age of 18 years
(range, 5± 35 years). Chemotherapy started with a short bi-drug
induction (6 weeks of cyclophosphamide± doxorubicin) surgery in
all cases (en bloc resection when feasible, curettage for vertebral and
sacral  locations).  Post-operative  chemotherapy  used  five  or  six
drugs  (Vincristine± Dactinomycine± Ifosfamide± Cyclophospha-
mide± Doxorubicin or Etoposide± Cisplatinium) for 10 months.
All  patients  have  been  followed-up  with  physical  examination,
plain RX-rays, bone scan, computed tomographies of the lungs
and primary site, every 3 months for 2 years, then every 6 months
for 2 years, and yearly then after.
Results: With a median follow up of 7 years and 6 months, 37 (77
%) patients are event-free survivors.
In this series, the site of the tumor and the tumoral volume had no
impact on disease free survival but only age, body surface area and
response to pre-operative chemotherapy.
The life expectancy of patients under 19 years is 96% (24/25), but
only 56% (13/23) for patients aged 19 or older (p < 0.001). The
disease-free survival of patients with body surface area under 1.3
m2 is 100% compared with 55% for patients with larger surface (p
< 0.001).
The univariate analysis shows that received drug intensities of vin-
cristine  and dactinomycin are the only independent therapeutic
prognostic  factors  (both  correlated  with  age  and  body  surface
area). With the total dose limit of 2 mg vincristine and 2 mg dac-
tinomycin, patients with larger surface area (> 1.3 m2) received
less drugs per square meter than younger patients.
In multivariate analysis, age had no prognostic value, but only the
received drug intensities of Vincristine and Dactinomycin.
Conclusion: In Ewing’s sarcoma, ageis not an independent prognos-
tic factor, but only underlines the importance of given dose inten-
sities of vincristine and dactinomycin.CTOS  abstracts 49
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1Department of Radiology, 5Department of Surgery, 6Department of 
Orthopedic Surgery, and 7Department of Pathology, Leiden University 
Medical Center, Leiden (2300 RC), The Netherlands, and 
2Department of Radiology, 3Department of Surgery, and 4Department 
of Pathology, Netherlands Cancer Institute, Antoni van Leeuwenhoek 
Hospital, Amsterdam (1066 CX), The Netherlands 
Purpose: To assess whether magnetic resonance (MR) imaging,
with the emphasis on dynamic contrast-enhanced MR, can deter-
mine  tumor  response after isolated  limb  perfusion with  recom-
binant tumor necrosis factor-alpha in order to plan the moment of
resection.
Material and methods: We prospectively included a pilot of eight
patients, with proven high-grade soft  tissue  sarcoma, who were
treated with isolated limb perfusion prior to resection. T1- and T2-
weighted, static and dynamic contrast-enhanced MR images were
acquired prior to and following isolated limb perfusion (immedi-
ately before surgery). 
We evaluated tumor volume, signal intensity, and start and pro-
gression  of  tumor  enhancement.  Early  and  rapidly  progressive
enhancing  areas  versus  late  or  non-enhancing  areas  seen  on
dynamic contrast-enhanced images were correlated with the his-
topathologic findings of the  resected  specimens,  except  for one
patient in which tumor resection was postponed because of meta-
static disease. 
Pathologic  response  was  defined  as  complete  response  (CR)  if
100% tumor necrosis was present, partial remission (PR) if 50%
necrosis was present, and no change (NC) if < 50% tumor necrosis
was present.
Results: None of the patients showed pathologic CR, four of eight
patients showed pathologic PR, and three of eight patients showed
pathologic NC. In one patient, only clinical examination was avail-
able, which showed NC. 
Tumor  volume  response  did  not  correlate  with  pathologic
response.
On dynamic contrast-enhanced images, early and rapidly progres-
sive enhancing areas corresponded to residual viable tumor. Late
and gradual enhancing areas or non-enhancing areas corresponded
to (therapy-induced) necrosis, degeneration or fibrosis. 
Discussion: Dynamic  contrast-enhanced  MR  imaging  seems
accurate in classifying response to isolated limb perfusion in soft
tissue sarcoma. Its potential role in planning the moment of resec-
tion of high-grade soft tissue sarcoma of the extremities merits fur-
ther evaluation. 
Upregulation Of Pthrp And Bcl-2 Expression Characterizes 
Early Malignant Transformation Of Osteochondroma 
Towards Peripheral Chondrosarcoma And Is A Late Event 
In Central Chondrosarcoma
Bovee JVMG, Van den Broek LJCM, Cleton-Jansen AM, 
Hogendoorn PCW
Department of Pathology, Leiden University Medical Center, Leiden, 
The Netherlands
Chondrosarcomas are malignant cartilage-forming tumors arising
centrally in bone (central chondrosarcoma), or within the cartilag-
inous cap of osteochondroma (peripheral chondrosarcoma). For
hereditary  multiple  osteochondromas,  two  responsible  genes,
EXT1 and EXT2, have been cloned. Their recently elucidated role
in heparan sulfate biosynthesis and Hedgehog (Hh) diffusion leads
to the hypothesis that EXT inactivation affects fibroblast growth
factor (FGF) and Indian Hedgehog (IHh)/PTHrP signaling, two
important pathways in chondrocyte proliferation and differentia-
tion. We investigated the immunohistochemical expression of mol-
ecules involved in IHh/PTHrP (PTHrP, PTHrP-receptor, Bcl-2)
and FGF (FGF2, FGFR1, FGFR3 and p21) signaling in osteo-
chondromas (n = 24), and peripheral (n = 29) and central (n = 20)
chondrosarcomas. IHh/PTHrP and FGF signaling molecules are
mostly  absent  in  osteochondromas.  Although  no  somatic  EXT
mutations were found in sporadic osteochondromas, the putative
EXT downstream targets  are affected similarly  in sporadic and
hereditary tumors. In chondrosarcomas, re-expression of FGF2,
FGFR1,  PTHrP,  Bcl-2  and  p21  is  found.  Expression  levels
increase  with  increasing  histological  grade.  Upregulation  of
PTHrP and Bcl-2 characterizes malignant transformation of oste-
ochondroma since  PTHrP and Bcl-2  expression  is  significantly
higher in borderline and grade I peripheral chondrosarcomas as
compared  with  osteochondromas.  In  contrast,  upregulation  of
PTHrP and Bcl-2 seems to be a late event in central cartilaginous
tumorigenesis since expression is mainly restricted to high grade
central tumors.
Does The Histologic Subtype Of High-grade Central 
Osteosarcoma Influence The Response To Treatment With 
Chemotherapy And Does It Affect Overall Survival? A 
Study Based On The Material Of Two Consecutive Trials Of 
The European Osteosarcoma Intergroup (Eoi) Consisting 
Of 570 Patients
Hauben E, Weeden S, Pringle J, Van Marck E, Hogendoorn PCW
University of Antwerp, Antwerp, B-2560 Belgium, and Leiden 
University Medical Centrum, 2300 RC Leiden, The Netherlands
Large randomised trials are mandatory when one wants to examine
the  effect  of  different  aspects  (clinical,  treatment  modality  or
other) of pathological condition on overall outcome. This is espe-
cially true when studying a disease in which there is a multi-facto-
rial influence on progression and outcome.
The data on 570 patients with biopsy proven primary central oste-
osarcoma of an extremity, included in two consecutive studies of
the European Osteosarcoma Intergroup, were analysed to evalu-
ate: if the histological subtype of the biopsy specimen correlates
with the subtype of the resected specimen, if there is a relation
between histological subtype and overall survival, and if there is a
relation between histological subtype and histological response to
chemotherapy. 
High-grade osteosarcoma, as defined by established criteria, was
subtyped as either  conventional, chondroblastic, teleangiectatic,
small  cell,  fibroblastic,  osteoclast  rich,  anaplastic  and  sclerotic/
osteoblastic well differentiated. 
A panel of experienced pathologists was appointed to review the
histological diagnosis and to assess the tumour response to chem-
otherapy on the resected specimen of each patient entered into the
trials. 
Subtyping on the biopsy specimen proved to be highly repre-
sentative for the subtype of the whole tumour. In 102 patients
for  which  subtyping  was  performed  on  the  biopsy  and  the
resected  specimen,  there  were only two discrepancies. Of the
568 patients for whom subtype is available, 404 (71%) were of
the common type, 54 (10%) were chondroblastic, 53 (9%) had
fibroblastic tumours, and the remaining consisted of rare sub-
types. 
Good response to pre-operative chemotherapy was defined as greater
than 90% necrosis. The proportion of patients responding well to
chemotherapy  differed  significantly  between  subtypes  (chi-square
test statistics = 11.44, p = 0.01 on 3 degrees of freedom (df)). In com-
parison with the common subtype, there was a higher proportion of
good responders in the fibroblastic group and a lower in the chond-
roblastic.  Good  responders  had  significantly  better  survival  than50 CTOS  abstracts
patients who responded poorly to pre-operative chemotherapy (log-
rank statistic = 25.20, p < 0.01 on 1 df). Survival did not differ sig-
nificantly according to subtype (log-rank statistic = 2.72, p = 0.44 on
3 df), although there is a clear suggestion that patients with chond-
roblastic tumours experience better long-term survival. 
This large set of prospectively collected data provides important
information on the relationship between pathological subtype, his-
tological response and survival. Histological response has a known
prognostic effect  on  survival, and we  have  shown  that  rates  of
response differ by subtype. There is limited evidence that some his-
tological  subtypes  experience  better  survival.  Despite  this  large
multi-institutional  study,  we  have  insufficient  numbers  of  non-
common tumours to examine this unambiguously.
Round-cell And Myxoid Liposarcoma Of The Extremities. 
A Clinicopathologic Study Of 102 Cases
Pellacani A, Pignatti G, Bertoni F, Giunti A, Baldini N
Istituti Ortopedici Rizzoli, 40136 Bologna, Italy
We evaluated the clinical and pathologic features of 102 patients
with biopsy proven myxoid or round cell liposarcoma examined at a
single institution between 1977 and 1999. Routine hematoxylin and
eosin stained slides of all cases were reviewed. Morphologic variables
evaluated included percent of round cell differentiation, percent of
lipoblast differentiation, and presence of tumor necrosis. Clinical
follow-up was available for all patients. Flow cytometry for determi-
nation of DNA ploidy was performed on fresh tissue available from
28 cases. Survival was determined by the Kaplan± Meier test using
the approximate chi-square statistic for the log-rank test.
Age at diagnosis ranged from 12 to 78 years (median, 46 years),
with a significant difference between males (median, 35 years) and
females (median, 66 years). The single most common location was
the thigh (70 cases). Histologically, round cell differentiation was
present in 35 cases. Spontaneous tumor necrosis was noted in 11
cases. By flow cytometry, 27 tumors were diploid and one was ane-
uploid. Twenty-four patients developed metastases at a mean of 22
months after diagnosis.
With statistical analysis, age (> 45 years), male sex (p < 0.05), per-
cent of round cell differentiation (> 25%; p < 0.05), and the pres-
ence of spontaneous tumor necrosis were associated with a poor
prognosis. No correlation was observed between DNA ploidy and
percent of round cell differentiation or clinical outcome.
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Introduction: Transglutaminase is a family of calcium dependent
enzymes that act by catalyzing the cross-linking of proteins during
the  formation  of  N-glutamyl-lysyl  bond  between  two  peptide
chains, and through G protein mediated activation in normal tis-
sues. Great interest in tTGase has come about because of its impli-
cated  role  in  apoptosis,  cell  adhesion,  tumor  growth  and
differentiation and invasive/metastatic behavior.
Malignant fibrous histiocytoma (MFH) is thought to be the most
common soft tissue sarcoma of late adult life. Although several
other  factors  have  also  been  investigated,  prognosis  for  these
tumors has been largely based on size of tumors and grade. Initial
treatment is typically wide surgical resection and radiation therapy.
The aim of our study was to determine if tTGase has predictive
value for metastatic disease or local recurrence in MFH to better
identify those patients that may benefit from adjuvant chemother-
apy.
Methods: This is a retrospective study using pathologic specimens
previously obtained from 1988± 1999 in patients diagnosed with
MFH. Twenty-three patients in this time period for which we have
adequate non-irradiated tissue are included in the study. Thirteen
subjects  were male,  nine  were female. Paraffin-fixed  pathologic
specimens were collected, underwent deparafination and immuno-
histochemical  staining  as  previously  described  by  Aeschliman.1
After  staining with  the  monoclonal antibody was complete,  the
stains for each tumor were graded on a 0± 3 scale by two separate
observers, blinded to each other’s results. 
A retrospective review was performed of patients’ charts as well as
through  telephone  contact  for  those  patients  that  had  limited
follow-up. Information on size of tumor, histologic grade, dates of
recurrence of metastatic disease and death were recorded. Biosta-
tistical analysis was performed to evaluate the relationship of size,
grade, age and tTGase average rating to disease free survival. This
was performed in a multivariate and univariate fashion utilizing
Kaplan± Meier regression curves.
Results: Average  follow-up  was  40  months  (range,  4± 126
months). Eight out of 23 had no local recurrence or metastatic dis-
ease, 2/23 had local recurrence, and 14/23 had metastatic disease.
Univariate analysis demonstrated no statistically significant differ-
ence for disease free survival based on age or histologic grade. Dis-
ease free survival for those with a size of 10 cm was significantly
shorter (p < 0.01) with a median disease free survival of ~3 months
versus ~3 years for those < 10 cm. Additionally, those with a higher
(> 1) tTGase average score had a significantly shorter (p ~ 0.02)
disease free survival of ~4  months versus 2 years for those  £  1.
However, when tTgase was corrected for tumor size, a trend (p £
0.09) was seen for tTgase score in multivariate analyses.
Discussion: Tissue transglutaminase has been shown to be involved
in programmed cell death, cell matrix stabilization and cell adhe-
sion. We found that a higher tTgase (p ~ 0.02) may be associated
with a poorer outcome. These people may benefit from adjuvant
chemotherapy but otherwise would not have previously been iden-
tified to be in a higher risk group. A larger study with more statis-
tical power is needed to determine if the association found here is
significant.
041 Pathologic Fracture In Osteosarcoma: Prognostic 
Significance And Treatment Implications
Ghert MA, Zurakowski D, Gebhardt MC, Thompson RC, Scully 
SP
Duke University Medical Center, Durham, NC 27710, USA
Introduction: The presence of a pathologic fracture in an osteosa-
rcoma has been considered a poor prognostic factor and an indica-
tion  for  immediate  amputation  in  many  tumor  centers.  The
purpose of this study was to determine, in the current era of neo-
adjuvant chemotherapy, if the presence of a pathologic fracture in
an osteosarcoma has prognostic significance, and if limb salvage
can be safely performed in these patients without compromising
clinical outcome.
Methods: In a cooperative effort of the Musculoskeletal Tumor
Society (MSTS), members from eight institutions provided ret-
rospective data on 58 patients treated for a pathologic fracture in
an osteosarcoma, and 55  patients  treated for an osteosarcoma
without pathologic fracture. The two groups were matched for
tumor location and grade. The following variables were analyzed:
age, gender, stage of disease, anatomic location, tumor size, path-
ological fracture, fracture union, fracture displacement, tumor
management  (limb salvage versus amputation), chemotherapy,
surgical margin, vascular invasion and percent necrosis. Survival
analysis  was  performed  with  the  Kaplan± Meier  product-limit
method with variables having a p value < 0.10 based on the log-
rank test entering into the multivariate Cox proportional-hazards
regression  model.  Outcomes  examined  were  survival,  disease-
free survival, local recurrence and distant  metastasis.  Multiple
stepwise logistic regression analysis was used to compare the out-
come  of  limb  salvage versus  amputation  with  respect  to local
recurrence.
Results: The median age of the 113 patients was 17.4 years (range,
2± 69 years). Mean follow-up was 4.0 years (range, 6 months± 12.7
years). Ninety-five  percent of the  patients presented with MSTS
stage IIB disease. All but eight patients underwent induction chem-
otherapy. Of the  58 patients  with  a pathologic fracture, 32 were
managed with immobilization, six with internal fixation, and 16 with
amputation. Overall mortality was 35%, with 14 patients (12%) suf-
fering a local recurrence. All patients who experienced a local recur-
rence  died  of the  disease  process. The  presence  of  a pathologic
fracture was a significant univariate factor associated with decreased
overall survival (p = 0.03), disease-free survival (p = 0.03), increased
local recurrence (p = 0.005) and distant metastasis (p = 0.03). Mul-
tivariate analysis revealed that the presence of a pathologic fracture
was a significant risk factor for local recurrence (p = 0.003). In the
group with a pathologic fracture, 10/41 (24%) treated with limb sal-
vage and 1/17  (6%) treated with  an amputation suffered a local
recurrence. Stepwise multiple logistic regression revealed that limb
salvage was a multivariate risk factor for local recurrence in the path-
ologic fracture group, with those patients undergoing limb salvage
estimated to be nine times more likely to develop local recurrence
than those undergoing amputation (odds ratio, 9.0; 95% confidence
interval, 5.0± 35.5; p = 0.01).56 CTOS  abstracts
Discussion and conclusion: The presence of a pathologic fracture
in an osteosarcoma is an independent predictor of local recur-
rence with limb salvage significantly increasing the risk. Given
the fact that recurrence in an osteosarcoma has a uniformly fatal
outcome, our data  indicate  that  the  presence  of  a  pathologic
fracture  may  be  a  contraindication  to  limb  salvage  in  these
patients.
044 Thallium 201 Uptake In Chondroid Lesions
Templeton KT, Raveill T, Tawfik O
University of Kansas Medical Center, Kansas City, KS 66160, USA
Heterogeneity seen in cartilagenous lesions can make grading and
surgical planning difficult. Low-grade lesions may potentially be
treated  with  less  aggressive  surgery.  However,  if  higher-grade
lesions are missed, the local recurrence rate can be high. In con-
junction  with  standard  imaging  modalities,  thallium  201  scans
have been utilized in the evaluation of tumors to distinguish benign
from malignant lesions. In chondroid lesions, thallium 201 may
help to differentiate low- from high-grade lesions.
Methods: Thallium  201  scans  were  utilized  to  evaluate  25
patients  (15  females,  10  males)  who  had  cartilagenous  lesions
noted on standard radiographs. Four patients were felt  to have
low-grade  lesions  on  open  biopsy.  Thallium  201  scans  were
obtained to evaluate for the presence and location of higher-grade
areas in these  lesions. thallium  201 (5 mCi)  was injected, with
images obtained early (20 minutes) and late (3 hours). SPECT
imaging was used for pelvic lesions. Eighteen patients underwent
either surgical excision/wide resection if they had positive scans or
curettage if their scans were negative but they remained sympto-
matic. The remainder of the patients was followed with routine
clinical and radiographic exams.
Results: The  areas  noted  on  histologic  exam  of  the  operated
lesions to be benign or grade I malignancies demonstrated an aver-
age thallium 201 uptake (compared with the normal contralateral
side) of 1.005 ± 0.125 (range, 0.90± 1.10). This was unchanged on
delayed images. All have been followed radiographically and clini-
cally for over 12 months, without evidence of recurrence. In com-
parison,  those  patients  found  to  have  grade  II  or  III  lesions
histologically  had mean uptake  ratios  of  1.485  ± 0.255  (range,
1.26± 1.64) cts/pixel compared with an equivalent anatomic loca-
tion on the contralateral normal side (p = 0.0001). All four patients
who were felt to have low-grade lesions on initial biopsy had thal-
lium 201 ratios of greater than 1.3 in some area of their tumors. All
underwent wide  resection  and were found to have  grade II± III
lesions. In addition, seven other patients with chondroid lesions
diagnosed  radiographically  and  having  negative  thallium  scans
have been followed with serial clinical exams and roentgenograms.
All of these patients remain asymptomatic and with no change in
their radiographs (follow-up, 4 months± 5 years).
Conclusion: Thallium  201  uptake,  mediated  through  the  Na-K
ATPase dependent pump, is dependent not only on blood flow, but
also on tumor cell viability and activity. A greater degree of uptake is
seen in more active regions of tumors. With the heterogeneity seen
in  chondroid  lesions,  Thallium  201  may  help  elucidate  those
tumors, or regions within  tumors, that  are  more aggressive  and,
therefore, need more aggressive surgical management. 
045 Complications And Morbidity Of Adjuvant Therapy For 
Soft Tissue Sarcoma
Templeton KT
University of Kansas Medical Center, Kansas City, KS, USA
Although adjuvant therapy, combined with surgery, can lead to
local tumor control and salvage of extremity, post-operative com-
plications can delay further treatment and, potentially, lead to loss
of the extremity. This study was designed to analyze those factors
that may contribute to post-operative morbidity.
Methods: The records of 45 patients presenting with extremity
soft tissue sarcomas were reviewed retrospectively. Five patients
were unable to undergo limb salvage, leaving 40 patients that form
the basis of this study. These patients all underwent surgical resec-
tion of their tumors in combination with radiation (pre- or post-
operatively) and/or chemotherapy. They were then followed for at
least 3 months to evaluate for post-operative complications. The
complications  were defined as major (i.e. requiring further sur-
gery) or minor (managed non-operatively).
Results: There were 24 female and 16 male patients with an aver-
age age of 55 years. The most common diagnoses were MFH and
liposarcoma.  The  most  common  locations  for  the  tumor  were
thigh and forearm. Thirty-one patients received radiotherapy, 21
pre-operatively (six with a post-operative boost) and 10 post-oper-
atively only. There were four minor complications, usually slough
of a skin graft, and 16 major complications. The most frequent
major  complications  were  seromas,  primarily  in  those  patients
treated initially with a free tissue transfer into the resection bed,
and dehiscence, seen in those patients closed primarily. Two free
tissue transfers underwent necrosis, presumably due to the anasto-
moses being performed into abnormally large vessels adjacent to
the tumor, which eventually decreased in caliber. No complication
resulted in an amputation. Patient factors that were analyzed and
found not to be related to major wound complications were age,
gender, obesity (measured by body mass index), nutrition (meas-
ured by white cell count and serum albumin), and smoking. Treat-
ment factors that were not related to complications were the use of
chemotherapy, radiation dose, and interval between pre-operative
radiation  and  surgery.  However,  those  receiving  pre-operative
radiation had significantly more complications than those treated
with post-operative  RT alone. Furthermore, those  with a larger
estimated volume of resection, especially if treated with pre-oper-
ative RT, had a higher incidence of complications. Other surgical
factors that correlated with wound complications were the width of
resection  (most  likely  affecting  the  vascularity  of  the  operative
bed), estimated  volume  of  resection  (although  modified  if  free
tissue transfer was performed), and estimated blood loss.  Total
operative time was not significant. Another independent risk factor
for complications was an incisional or excisional biopsy performed
at another institution  prior  to presentation (56%  complications
versus 29%). This was not due to increased resection volume as
the  volume  of  tissue  ultimately  resected  was  lower  (944.7cm3
versus 1888 cm3) for those initially treated elsewhere.
Conclusions: Post-operative  morbidity  appears  to  be  relatively
independent of the patient factors analyzed herein. Morbidity is
more likely to be determined by treatment and tumor-related fac-
tors, such as tumor and therefore, resection volume and width,
estimated blood loss, and prior surgery. These factors may lead to
relative hypoxia in the resection bed.
046 Osteochondroma Of The Femoral Neck
Siebenrock KA, Ganz R
Orthopaedic Surgery, University of Berne, 3010 Berne, Switzerland
Osteochondromas of the femoral neck represent rare intraarticu-
lar  lesions.  The  difficulty  to  obtain  adequate  surgical  access,
especially  when  located  at  the  inferior  and  posterior  femoral
neck, has been expressed already in the literature. The authors
have approached these lesions with a new, versatile approach that
offers the advantage of complete tumor visualization, circumfer-
ential access to the femoral neck combined with the possibility of
entire hip joint inspection, and intraoperative control of adequate
tumor resection. The surgical approach includes a digastric tro-
chanteric osteotomy and subluxation or even dislocation of the
femoral head, thereby respecting the crucial blood supply to the
femoral head. This approach has been used in four patients withCTOS  abstracts 57
osteochondroma  of  the  femoral  neck  presenting  with  pain,
restricted  range  of  motion  and  limping.  Femoro-acetabular
impingement of the bulky osteochondroma against the acetabular
rim could be verified in all cases. In two patients, labral lesions
were found at the impingement site. All four patients had com-
plete or significant relief of symptoms at a mean follow-up of 34
months (18± 48 months) without signs of progressive osteoarthri-
tis or avascular necrosis.
047 Surgical Margins Influence Local Recurrence Of Soft 
Tissue Sarcomas In The Thigh, But Not Survival In 152 
Pateents
Vraa S, Keller J, Nielson O, Jurik AG, Jenson OM
Center for Bone and Soft-Tissue Sarcomas, University Hospital of 
Aarhus, DK-8000 Arhus C, Denmark
In a 19-year period (1979± 1998), 152 consecutive patients with
soft tissue sarcomas in the thigh were surgically treated in the Sar-
coma center in Aarhus. Prognostic clinicopathologic  factors for
local recurrence and survival were studied by use of multivariate
statistical analysis. Twenty-seven patients (18%) had a low-grade
tumor, 26 (17%) an intermediate-grade tumor, and 99 (65%) a
high-grade tumor.1 Twenty-seven patients (18%) were amputated
and 125 (82%) had local resection. Twenty-one patients (14%)
underwent a marginal resection, 82  patients (54%) had a wide
resection, and 49 (32%) had a compartmental resection. Fourteen
patients (9%) developed local recurrence. All patients but one had
the local recurrence surgically removed. The patients with local
recurrence  had  a  significantly  poorer  survival  compared  with
patients  without  local  recurrence.  Forty-nine  patients  (32%)
developed distant metastases. The 5-year recurrence-free rate was
91%. The multivariate analysis selected marginal resection (versus
wide  and compartmental  resection)  and histological-high  grade
(versus intermediate and low-grade) as unfavorable prognostic fac-
tors for local recurrence. The 5-year survival rate was 68%. High
age (versus age less than median age) and hitological high grade
(versus intermediate and low-grade) were selected as unfavorable
prognostic factors for survival in a multivariate  analysis. In the
present study, surgical margin influenced local recurrence but not
the overall survival in sarcomas in the thigh.
Reference
1. Jensen  OM,  et  al.  Histopathologica  grading  of  soft  tissue
tumours, prognostic significance in a prospective study of 278
consecutive patients. Pathology 1991; 163:19± 24.
048 Soft Tissue Sarcomas After 80 Years Of Age. Study Of A 
Series Of 22 Patients
Turcotte R, Barabas D, Isler M, Doyon J, Normandin D
Division of Orthopaedic Surgery, Maisonneuve-Rosemont Hospital, 
Montreal Que., Canada H1T 4B3 
Aim of the study: The management of older patients who have soft
tissue sarcomas (STS) is one of the most challenging problems in
oncology. The aim of this retrospective study was to report the
results of the treatment for the STS in 22 patients older than 80
years of age.
Patients  and  methods: Twenty-two  patients  (10  men  and  12
women) with STS treated between 1991 and 1999 in our depart-
ment were studied. The histologic appearance and grade were cor-
related with subsequent treatment and clinical behavior. 
Based on the type of therapy, four groups were analyzed: in the first
group, patients were treated exclusively by surgical resection (four
patients); in the second group, patients were treated only by radi-
otherapy (two patients); in the third group, surgical resection was
completed by radiotherapy (12 patients); and, finally, the fourth
group patients without therapy (four patients).
Results: The patients age at diagnosis ranged from 80 to 91 years
(average, 84.8 years). Tumors were located in the lower limb in 14
patients, in the upper limb in seven patients, and in the back in one
patient. The histologic types of tumor were the following: malignant
fibro-histiocytoma  (10),  leiomyosarcoma  (7),  liposarcoma  (3),
synovia-sarcoma (1),  and  malignant  schwannoma  (1).  Nineteen
patients had a histologically high-grade tumor (grade III 15/22 and
grade IV 4/22). Three patients had a low-grade tumor (grade II).
The  mean  survival  of  patients  after  diagnosis  was  26.3  months
(range, 1± 113 months). Ten patients  died during the  follow-up,
four deaths were related to the disease and six were not. Metastases
were found in six patients, in four of them at the time of diagnosis. 
In the first group (surgically treated patients), the mean survival was
15.5 months and one patient died of unrelated cause. Local recur-
rence occured in one patient. In the second group (two patients with
radiotherapy only), the mean survival was 5.5 months, both patients
developped diffuse metastases and both died. In the third group (12
patients with surgical resection and radiotherapy), the mean survival
was 31.3 months. Six patients died: one of lung metastasis and five
death were not related with  the  tumor. Three local reccurrences
occurred. In the fourth group (four patients without treatment), all
patients died; three of them related to the disease and one of unre-
lated cause. The mean survival was 3 months.
Conclusion: Patients older than 80 years with STS remain a high-
risk group. Nevertheless, age is not a limitating factor in the surgi-
cal  treatment  of  STS.  These  data  suggest  that  an  aggressive
approach including surgical resection and radiotherapy is appro-
priate in management of older patients with STS. 
049 Primary Leiomyosarcoma Of Bone. A 
Clinicopathologic Study Of 10 Patients
Barabas D, Turcotte R, Isler M, Doyon J, Normandin D
Division of Orthopaedic Surgery, Maisonneuve-Rosemont Hospital, 
Montreal, Que., Canada H1T 4B3
Backround  and  objectives: Primary  leiomyosarcoma  of  bone
(PLMSB) is a very rare malignant tumor with uncertain pathogenic-
ity. In order to improve our understanding of pathological behav-
iour,  prognostical  predictors  and  treatment  of  this  entity,  we
proposed to review all PLMSB surgically treated in our department. 
Methods and results: We retrospectively reviewed 10 patients (five
men and five women) with PLMSB treated between 1991 and 1999
in our department. The mean age was 57.2 years (30± 79 years). The
long bones were preferentially affected; tumor was localized in the
lower limb in eight patients and in the upper extremity in two patients.
At histology high-grade tumor was found in six patients. Surgical
resection  was  performed  in  all  patients,  a limb  salvage  surgery
being possible in nine patients. Surgical resection was completed
by pre- and post-operative chemotherapy in two patients and by
post-operative radiotherapy in three patients. One patient had pre-
operative radiotherapy. The mean follow-up was 31.3 months (12±
72 months). Five patients are alive with no evidence of disease,
four patients died with disease and one patient is alive with lung
metastasis.  Metastases  occured  in  four  patients,  mean  time  to
metastasis was 16 months after surgery. In the four patients who
died, survival averaged 25 months. 
Conclusions: Our experience concerning the diagnosis of PLMSB
is similar  to the reported data. There is an unclear relationship
between histology and prognosis. If metastases occur early, they
are a common cause of death. Survival at 2 years is 60%. Surgical58 CTOS  abstracts
treatment is the therapy of choice. Multiagent chemotherapy and
radiotherapy did not seem to provide an improved prognosis over
a simple ablative procedure. 
050 Giant Cell Tumor Of The Pelvis And Sacrum: Review 
Of Seventeen Cases And Meta-analysis
Leggon RE, Berry BH, Zlotecki R, Reith J, Wood D, Vlasak R, 
Scarborough MT
University of Florida, Gainesville, FL 32610-0246, USA
Seventeen patients with giant cell tumor (GCT) of the pelvis and
sacrum were reviewed. The mean patient age was 33 years and
average follow-up was 8.0 years. Sixteen of 17 lesions were stage 3
(benign, aggressive). Symptom duration averaged 12 months. The
average largest tumor dimension was 11 cm, and one developed
benign pulmonary metastases. The treatment was radiation ther-
apy (RT) alone in nine patients, surgery with intralesional margins
alone (S(IL)) in two, and surgery with wide margins S (W) in four.
Primary RT in eight sacral lesions resulted in one local recurrence
of tumor, four cases in which the tumor involuted and the bone
reformed, and three cases that were stable but without ossification.
Wide surgical margins for pelvic lesions resulted in no local recur-
rences. Two of 12 patients treated with RT developed radiation-
induced  sarcoma  (RIS).  Local  recurrence  occurred  in  23%  of
patients in this series.
Meta-analysis yielded 239 lesions (73 pelvis, 166 sacrum). Recur-
rence rates were 49% for RT (32 of 65 patients), 47% for S(IL) (32
of 68 patients), 46% for S(IL)± RT (38 of 83 patients), 60% for
S(IL) + cryosurgery (six of 10 patients), and 0% for S(W) (0 of 23
patients).  Benign  lung  metastases  developed  in  6%,  secondary
malignancies in 2%, perioperative death in 2%, and multicentricity
in < 1%. The average dose of RT was 4780 cGy. Radiation dosage
studies of 122 cases, including 34 cases of primary RT alone, were
reviewed. Increasing doses of RT (< 4500 cGy versus 4500± 5500
cGy versus > 5500 cGy) did not appear to decrease the rate of local
recurrence. RIS developed in 11% of patients with > 5-year follow-
up. There did not appear to be a benefit to RT in addition to int-
ralesional  surgery.  Disease  status  was  worse  for  sacral  GCT
(ANED, 90%; AWD, 1%; DOD, 6%; DOC, 3%) at an average
follow-up of 8.7 years.
Surgery with wide margins should be considered for GCT of the
ilium, pubis, or lower sacrum to decrease the chance of local recur-
rence and the potential for radiation-induced sarcoma. Treatment
of acetabular lesions must be individualized. Primary RT alone is
most strongly indicated for large lesions of the sacrum.
051 Recent Experience With The Compress¾  Device For 
Compliant Fixation Of Oncologic Endoprostheses
O’Donnell RJ1,2, Martin DL2, Silverstein RM2, Johnston JO1
1Department of Orthopaedic Surgery, Orthopaedic Oncology Service, 
University of California, San Francisco, 1701 Divisadero St., Suite 
280, San Francisco, CA 94115-1652, USA, and 2Department of 
Musculoskeletal Oncology, The Permanente Medical Group, Inc., 1200 
El Camino Real, South San Francisco, CA 94080-3299, USA
Purpose: To determine the early survivorship of the ComPreSs¾
(CPS) prosthesis for compliant endoprosthetic fixation of massive
oncologic defects.
Methods: A  retrospective  review  of  CPS  implants  was  under-
taken. Results with respect to prosthetic failure, local recurrence,
metastatic disease, and death were studied. Radiographs were ana-
lyzed to ascertain evidence of prosthetic loosening.
Results: Twenty-eight  consecutive  cases  comprising  the  entire
experience of a  single  surgeon  with  the  ComPreSs¾   prosthesis
were reviewed. Follow-up averaged 1.43 years (range, 0.25± 3.92
years). There were 18 male and 10 female patients with average
age of 30 years (range, 12± 68 years). There were 21 primary onco-
logic cases, six revision oncologic cases, and one post-traumatic
case. Osteosarcoma (12 cases) was the most common diagnosis.
Prosthetic locations included: distal femur (18), proximal tibia (5),
distal humerus (3), and proximal femur (2).
There was only one (1/28, 3.6%) mechanical distal femoral pros-
thetic failure at 3 months leading to successful revision CPS sur-
gery.  There  was  one  deep  infection  treated  with  debridement,
antibiotics, and prosthetic retention. There were two local recur-
rences  (osteosarcoma,  dedifferentiated  chondrosarcoma  with
pathologic fracture) requiring amputation at 13 and 20 months
post-operatively. Both implants were firmly fixed; both patients
developed metastatic  disease.  There  were  no  other  metastases.
There were no deaths. All remaining prostheses have continuous
radiographic evidence of stable osteointegration.
Discussion: The ComPreSs¾  implant has proven to be versatile,
durable, and effective for primary and revision oncologic indica-
tions. The CPS design attempts to avoid problems of loosening
and stress shielding encountered with both cemented and porous-
coated stems conventionally used in limb salvage reconstructions.
Rigid fixation at the  prosthetic± bone interface prevents motion,
allowing osteointegration and sealing the canal from particulate
debris. High compliance afforded by the washers works to avert
stress shielding. This is expected to enhance long-term prosthetic
survival. A multi-center FDA IDE study of the distal femoral CPS
prosthesis is now underway.
052 How Could The Treatment Of Soft Tissue Sarcoma Be 
Improved On A Regional Basis?
Glencross J1, Silcocks P2, Robinson MH3
1Leicestershire Health Authority, 2Trent Cancer Registry, and 3YCR 
Department of Clinical Oncology, Weston Park Hospital, Sheffield, S10 
2SJ, UK
Background: Bone and soft tissue sarcomas are a rare and heter-
ogeneous group of tumours, rarely seen by most clinicians during
their careers. Early recognition, appropriate and timely investiga-
tions, and treatment are shown to markedly affect outcomes. In the
Trent Region in the UK, a soft tissue sarcoma interest group had
developed outline consensus based guidelines for investigation and
management. The Trent Cancer Registry was asked to undertake
a retrospective baseline audit of the care of such patients in Trent.
Results: Soft tissue sarcomas registered with Trent Cancer Regis-
try in 1995± 1997 and meeting ICD-O criteria for site and mor-
phology were selected. Data were collected from clinical records
against a set of criteria outlined in the protocol in all registering
hospitals. Data included: recording of clinical details, specialities
involved in  management,  diagnostic  and staging  investigations,
completeness  of surgery, histological  reporting, use of adjuvant
therapy and outcome (death or known recurrence)
From 257 registrations, 204 cases were included. Ten percent of
notes were unobtainable; 50%  were initially  referred to general
surgeons, although definitive surgery was performed by surgeons
(40%) and orthopaedic surgeons (33%); 74% saw an oncologist;
55% had a diagnostic CT or MRI scan. Only 52% had adequate
staging investigations; 63% had a biopsy; but 13% were `shelled
out’ at biopsy. Thirty-five percent had wide or adequate excision;
in 48%, primary surgery was incomplete or marginal. Outcome
was poorer in these patients. Histological reporting was variable.
No consistent grading system was used; details on tumour margins
were available for 66% of cases; tumour size stated in 73% of cases;
52%  received  adjuvant  therapy;  10%  being  considered  for
EORTC trial entry. Follow-up was generally by a specialist oncol-
ogy team, although 10% had no recorded follow-up.
A comparison of patients referred to a sarcoma `expert’ prior to
surgical exploration with those not referred was undertaken. FromCTOS  abstracts 59
the patients having surgery, the following pre-operative investiga-
tions were made: CT or MRI before definitive surgery: expert, 23/
25 (92%); non-expert, 51/135 (37%); CT scan to include metas-
tases:  expert,18/25  (72%);  non-expert,72/179  (40.2%);  Biopsy
taken:  expert,  24/25  (96%);  non-expert,  98/179  (55.9%);  No
record of tumour size in notes: expert, 7/25 (28%); non-expert, 37/
179 (20.7%).
Conclusions: The audit demonstrates that optimal care as defined
by the soft tissue sarcoma group in the Trent Region was not pro-
vided  over  this  period  within  the  region.  All  clinicians  should
follow management guidelines and proposals to set up specialist
referral centres should be considered.
053 Indications And Advantages Of Free Flaps In The 
Management Of Soft Tissues Sarcomas: A Retrospective 
Study Of 22 Cases
Bonvalot S, Mamlouk K, Kolb F, Le Pù choux C, Le Cesne A
Department of Surgery, Institut Gustave Roussy, Villejuif, France
Objective: The medical charts of patients from the same institu-
tion presenting locally advanced soft tissues sarcomas of the limbs
and trunk and reconstructed with free flaps were reviewed.
Patients  and  methods: From  October  1997  to March 2000,  22
patients  presenting  locally  advanced  soft  tissue  sarcomas  were
treated with large local resection and free flap reconstruction. A
neoadjuvant chemotherapy was instituted in 10 cases and post-
operative radiation was performed in 16 cases. The average age of
patients was 46 years (SD, 17). There were 14 females and eight
males. Fifteen tumors were located on the limbs and seven on the
trunk. The tumor mean size was 11.5 cm with five grade I, five
grade II, and 12 grade III according to the FNLCC classification.
Two patients presented radio-induced sarcomas. The treatment
was primary  in 12  cases  and 10  patients  presented  a recurrent
tumor, two of whom had previous external beam radiation. Free
tissue transfer to cover the excision site was necessary after: large
skin defects secondary to direct superficial extension in 16 cases or
dictated by an aberrant previous incision in two cases, recurrence
after pedicled flap in two cases, filling of dead space in one case,
and exposition of major vessels in irradiated areas in two cases.
Major vessels and nerves resections were performed concomitantly
in five cases. A total of 23 free flaps were performed with 19 latis-
simus dorsi and four transversal rectus abdomini musculo-cutane-
ous flaps. To insure the vitality of the free tissue transfer when a
vital organ exposition was programmed, such as in trans-thoracic
resection, four flaps were elevated in two stages according to the
`chausson aux pommes’ technique advocated by Servant.
Results: Mean follow-up was 14 months. Margin’s quality was:
R0 in 17 cases (‡  5 mm, n = 11; < 5 mm, n = 6), three of whom
developed pulmonary metastasis; R1 in four cases, two of whom
developed local recurrence after 5 and 6 months; and R2 in one
patient who had no local control post-operatively.
Flap failure was experienced in two cases (one in a 78-year-old
patient and one in a previously irradiated field; a successful second
free flap  was performed in this  latter  patient). Twenty patients
(91%) had an uneventful healing that allowed undelayed adjuvant
radiotherapy when indicated.
Conclusion: Free  flap  transfer  is  a  safe  and  reliable  technique
(with a 91% success rate in our study), which enables broadening
of limb salvage indications, full thickness thoracic resection and
improvement of margin status. 
It provides well-vascularized tissue to cover exposed vital struc-
tures and allow precocious adjuvant radiotherapy.
The use of a distant donor site does not compromise the function
of an already damaged limb as would a local flap and may enhance
motor results in cases of neuro-muscular reanimation.
Tissue transferred from a distant site of the excision area decreases
local dissection and the potential area of local recurrence.
Performing flap transfer before tumor excision allows safe proce-
dure in the case when vital structures exposition is programmed.
054 Aggressive Fibromatosis. A Retrospective Study Of 72 
Patients
Sù rensen A, Keller J, Nielsen OS, Jensen OM
Centre for Bone and Soft Tissue Sarcomas, University Hospital of 
Aarhus, Aarhus, DK-8000, Denmark
Introduction: Aggressive  fibromatosis  (or  desmoid)  has  a  high
recurrence rate as a result of a strong infiltrative growth pattern.
The purpose of this study was to evaluate outcome and influence
of  possible  prognostic  factors  following  surgical  treatment  of
aggressive fibromatosis, and in an immunohistochemical project to
evaluate expression of estrogen receptors.
Materials and methods: Seventy-two primary tumours treated in
the period January 1970± September 1998 were analysed; 19 men
and 53  women. Median age was 31  years (range, 1  month± 77
years). Fifty patients had an extra abdominal tumour and 22 an
abdominal. Median tumour size was 4 cm (range, 1± 27 cm). Log-
rank and Cox regression analyses were used for statistical analyses.
For  immunohistochemical  determination,  deparaffinized  slides
were used.
Results: The overall and relapse-free 5-year survival were 98 and
73%, respectively. A univariate analysis identified age, tumour size
and surgical compartmentalisation as prognostic factors for local
recurrence. Furthermore, radiotherapy was found to have an effect
in extra abdominal tumours. A multivariate analysis identified age
> 31 years, tumour size £ 4 cm and intracompartmental location as
independent positive prognostic factors for local recurrence. No
tumours expressed estrogen receptors.
Conclusions: Aggressive fibromatosis has a high local recurrence
rate. Age, tumour size and surgical compartmentalisation seem to
affect the local recurrence rate. The tumours do not express estro-
gen receptors.
055 Adult Pelvic Sarcomas
Dekker C1, Houtkarnp R1, Peterse JL2, van Coevorden F1
1Department of Surgical Oncology and 2 Department of Pathology, The 
Netherlands Cancer Institute/Antoni van Leeuwenhoek ziekenhuis, The 
Netherlands
Introduction: Soft tissue sarcomas in the pelvis, excluding uter-
ine sarcomas, are rare malignancies. In a retrospective study in
our national cancer referral center, 33 patients (21 males and 12
females) were seen in a 25-year period. In 26 patients, either a
leiomyosarcoma  (18)  or  a  rhabdomyosarcorna  (8)  was  seen.
Thirty-one out of the  33 sarcomas were intermediate or high
grade.
Recurrent disease: Unlike  soft  tissue  sarcomas  in  extremities,  a
high rate of local and distant recurrence (66%) was seen. In 7/22
(32%) of cases with recurrent disease, only local recurrence was
seen, while in the other 15 cases (68%) recurrence presented as
distant disease, synchronous with local recurrence in only one of
these 15. At first presentation, nine patients already had metastatic
disease. Unlike in extremity sarcoma, metastatic disease presented
as pulmonary metastases in 5/22 patients (23%) only.
Survival: All patients with primary metastatic disease eventually
died of disease, as did eight of the other 24 patients. Four of the 24
have evidence of disease, one died of unrelated causes and the
remaining 11 patients are alive and well. Adults (adolescents) with
rhabdomyosarcoma have a 25% NED survival versus those with
leiomyosarcoma (33%). Among the others, patients with liposar-
coma did best.
In  this  retrospective  study,  multimodality  approach  of  these
tumors did not appear to be more effective than single modality
treatment.
Conclusion: Pelvic sarcomas differ from most other sarcomas in pres-
entation and outcome. In the management of these pelvic sarcomas,
these particular characteristics should be taken into consideration.60 CTOS  abstracts
056 Liver Resection For Metastatic Soft-tissue Sarcomas
van Ruth S, Mutsaerts E, van Coevorden F
Department of Surgery, Netherlands Cancer Institute / Antoni van 
Leeuwenhoek Hospital, Amsterdam, The Netherlands
Introduction: Involvement  of  the  liver  as  a  metastatic  site  of
soft-tissue sarcomas (STS) is found in less than 10% of the all STS
patients.  Usually  it  concerns  visceral  or  retroperitoneal  STS.
Untreated, the median survival is about 12 months. Chemother-
apy, especially for GIST tumors, shows disappointing results. In
the literature, resection of STS liver metastases shows prolonged
survival. Five-year survival is  10± 20%.  We selected  the  data of
patients undergoing surgery in our institute for metastatic STS.
Aims of the study: The aims of this study are to evaluate the out-
come  of  liver  resection  performed  on  patients  with  STS  liver
metastases and compare them with results of colorectal and other
non-colorectal liver metastases. Endpoints are perioperative mor-
tality and morbidity, post-operative hospital stay, disease free and
overall survival.
Patients and methods: From our prospective hepatic surgery data-
base, the files of patients with  metastatic  disease  were selected.
Pathological and surgical reports of the STS cases were analyzed.
Of all patients, follow-up data were obtained. Survival was calcu-
lated according to the Kaplan± Meier method.
Results: Six patients with a mean age of 59 years (range, 45± 65
years)  underwent hepatic  resection  and  one  patient  underwent
repeated  metastasectomy  for  recurrent  hepatic  disease  4  years
later. Primary localization of the STS was the lower extremity (n =
1,  pleomorphic  sarcoma),  intestines  (stomach  (n  =  1,  GIST),
rectum (n = 3, GIST)) and retroperitoneurn (n = 1, leiomyosar-
coma). The median disease free interval between primary STS and
liver metastases was 48 months (range, 0± 144 months). Surgical
procedures included right hemiliepatectomy (n = 1), right hemilie-
patectomy combined with segment I resection (n = 1) and five seg-
mental resections (V/Vl, IV, IV, VII, VIII). All metastasectornies
had clear margins. There was no mortality. One major complica-
tion occurred: relaparotomy was necessary because of p.o. hemor-
rhage. The median post-operative hospital stay was 14 days (range,
8± 24 days). The median post resection survival was 32 months
(range, 9± 68 months). Two patients died of their malignancy (new
hepatic metastases, n = 2, one of them with concomitant extrahe-
patic metastases), four patients are still alive, two with evidence of
disease (hepatic metastases, n = 1; extrahepatic metastases, n = 1)
and two of them without evidence of disease, one only but after
repeated hepatic surgery. The survival data was well comparable
with the survival data for resection of colorectal metastases (n =
120), but better than the survival of other noncolorectal metastases
in this database (n = 17).
Conclusion: Liver resection of metastases of soft tissue sarcomas
can be performed safely and may prolong survival in patients with
STS and reach at least as good overall survival figures as in patients
with colorectal carcinomas.
057 Surgery For Sarcoma Of The Spine: Outcome Analysis 
Of 59 Patients Over A 12-year Period
Patrick Boland, Mark Bilsky, Murray Brennan, Robert Woodruff, 
John Healey
Memorial Sloan Kettering Cancer Center, NY, NY, USA
Introduction: Sarcomas may present in the spine, arising as pri-
mary tumors in the bone or neural elements, or as metastatic dis-
ease.  While  sarcomas  are  uncommon  tumors  relative  to
carcinomas, patients with these tumors more often come to surgery
for spine disease because of their relative resistance to irradiation
and chemotherapy. Surgery is often employed in order to preserve
neurologic function, achieve spinal stability and improve local dis-
ease control. This retrospective study examines the role of surgery
in patients with primary, metastatic or recurrent sarcoma of the
spine.
Methods: Fifty-nine  patients  underwent 99 surgical procedures
for sarcomas involving the  spine  between 1985  and 1997.  The
most common histologic diagnoses were leiomyosarcoma (14) and
osteogenic  sarcoma  (9).  Fifty-three  tumors  resected  were  high
grade. The indications for surgery were: neurologic compromise
(69), oncologic (25), and mechanical instability  (5). The initial
type  of  surgery included  laminctomy  (29), vertebrectomy (17),
and spondylectomy (17). Three patients underwent enbloc verte-
brectomy. Fifty-one patients underwent radiation therapy and 39
underwent chemotherapy.
Results: The mean survival from the time of initial diagnosis in all
patients was 45 months. Greater than 90% of patients maintained
the ability to ambulate and 30% of patients regained the ability to
ambulate.
Conclusions: Spine surgery for sarcoma is valuable as a palliative
measure to preserve neurologic function and improve quality of life.
En bloc spondylectomy should be undertaken in patients with no evi-
dence of metastatic disease in whom there is a potential for cure.
063 The Use Of Cemented Allografts For Reconstruction Of 
Segmental Bone Defects After Tumour Resection
Gerrand CH, Griffin AM, Davis AM, Wunder JS, Bell RS, Gross AE
University Musculoskeletal Oncology Unit, Mount Sinai Hospital, 
Toronto, Ont., Canada M5G 1X5
Introduction: Sterilization  of  allograft  bone  by  irradiation  may
increase the risk of fracture. We routinely reinforce large-segment
irradiated allograft bone with pressurized intramedullary cement.
The purpose of this study was to review our experience of this tech-
nique and the outcomes and complications associated with it.
Methods: The prospectively collected records of all patients who
underwent reconstruction of an extremity after tumour resection
with a cement-reinforced allograft and potential for 3 years follow-
up were reviewed.
Results: Thirty-nine patients met the criteria for inclusion. The
diagnosis was primary bone sarcoma in 25 cases, metastatic disease
in 10, soft-tissue sarcoma involving bone in two, multiple myeloma
in one, and osteofibrous dysplasia in one. The allograft was inter-
calary in 17 cases, osteochondral in 14 and used for arthrodesis in
eight cases.
Twenty-three patients were alive at a mean of 5.4 years (range,
3.0± 10.1 years). Fifteen patients died at a mean of 2.3 years. One
case was lost to follow-up. There were fractures of three allografts,
three became infected and seven patients required secondary bone
grafting for non-union. Five allografts were removed. There were
two amputations for local recurrence. 
Discussion  and  conclusion: Intramedullary  cementing  may
improve the mechanical properties of irradiated bone and is asso-
ciated with an acceptably low fracture rate. If cement is excluded
from the graft± host junction and the junction is supplemented with
autograft, the  non-union rate is comparable or better  than that
reported elsewhere. Intramedullary cement fixation may be partic-
ularly  useful  with  irradiated  allografts  since  cementing  likely
reduces some of the harmful mechanical effects of radiation.
068 Treatment Of Non-resectable Soft Tissue Sarcoma Of 
The Limbs By Isolated Limb Perfusion
Vaglini M, Gronchi A, Pennacchioli E, Deraco M, Baratti D, 
Bertulli R, Casali PG, Lozza L, Rasponi A, Dileo P, Pilotti S, 
Azzarelli A
Istituto Nazionale Tumori, Milan, Italy
Intervention: Isolated  limb  perfusion  (ILP)  is  a  sophisticated
technique with theoric advantages. In difficult cases, it is one of theCTOS  abstracts 61
most effective neoadjuvant treatments, able to implement conserv-
ative surgery and local control. A real impact on survival has yet to
be demonstrated.
Patients: From August 1982 to February 2000, we observed 949
patients  affected  by  extremity  soft  tissue  sarcoma  (girdles
excluded): 68 (36 males and 32 females; mean age, 48.3 years)
were judged non-resectable and were then treated by ILP. The
mean follow-up was 30.5 months (range, 0± 174 months). Site, his-
tology and grade were normally represented. The ILP was carried
out with antiblastic drug alone in 45 (64%) patients and antiblastic
+  recombinant  tumor  necrosis  factor  a   (rTNFa )  in  25  (36%)
patients. A delayed resection of the residual tumor was performed
1± 2 months after ILP.
Results: There was no treatment related mortality. Regional tox-
icity, according to the Wieberdink scale, was observed in 25 (36%)
patients grade II, seven (10%) grade III, five (7%) grade IV, and
three (4%) grade V. The later group underwent amputation or dis-
articulation. Ten (14%) patients presented nerve injury. Systemic
toxicity  was  observed  in  five  (7%)  cases.  Limb  salvage  was
achieved in 61/70 (87%). An overall (complete + partial) immedi-
ate response was obtained in 55 (79%) patients. After resection of
the residual tumor, the pathological response rates was 24 (34%)
CR, 31 (44.3%) PR, six (9%) NR, one (1%) PRO and eight (11%)
data  not  available.  Six  (9%)  no-responder  patients  underwent
amputation or disarticulation. In the TNF group, CR was achieved
in 64%, while in the no-TNF group CR was observed in 18% (c 2,
p < 0.05). In the TNF group, the overall response (CR + PR) was
achieved  in  88%,  while  in  the  no-TNF  group  CR  +  PR  was
obtained in 73% (c 2, p = 0.15). Five-year OS in the TNF and no-
TNF group were 65 and 46%, respectively (p = 0.0047).
Conclusions: ILP is an effective treatment with acceptable mor-
bidity and toxicity. The addition of rTNFa  seems to improve the
rate of CR and subsequent survival. Nevertheless, the high limb
salvage rate, observed in our experience, is still the main determi-
nant  to  define  this  approach as first  choice treatment  for non-
resectable or marginally resectable soft tissue limb sarcomas.
069 Soft Tissue Sarcomas Of The Hand And Foot
Lin PP, Guzel VB, Pisters PWT, Zagars G.K., and Yasko AW
University of Texas M.D. Anderson Cancer Center, 1515 Holcombe 
Blvd., Houston, TX 77030, USA
Introduction: Soft tissue sarcomas of the hand and foot pose a spe-
cial surgical challenge because of the difficulty in obtaining wide
surgical margins. This study was designed to evaluate event-free
outcome  in  a  cohort  of  patients  with  hand and foot  sarcomas
treated with predominantly limb-sparing approaches. 
Methods: A retrospective study was performed on 115 patients
with a soft tissue sarcoma of the hand or foot between 1980 and
2000 who were evaluated, treated, and followed at this institution.
The medical records were reviewed to evaluate clinicopathologic
prognostic factors, treatment,  and event-free outcome. Kaplan±
Meier analysis was used to assess survival, and the log-rank test
was used to compare different curves.
Results: Most  patients  (95%)  were treated after previous, pre-
referral surgery at an outside institution. Most tumors (75%) were
T1 lesions (< 5 cm), and most (80%) were intermediate or high
grade. Patients who were treated by wide re-excision had a 10-year
local relapse-free survival of 88%, and this was significantly better
than the corresponding rate of 58% for patients who did not have
re-excision  (p  =  0.05).  Radiation  improved  local  control  for
patients who did not undergo re-excision (p = 0.02). However,
radiation did not improve local control for patients who had wide
re-excision. The overall survival rates for patients with localized
disease were 76 and 65%, respectively. Survival was significantly
worse for patients who had regional metastasis. Radical amputa-
tion as initial surgical treatment did not decrease the likelihood of
regional metastasis and did not improve survival. 
Conclusion: Limb sparing surgery is possible in most patients with
soft tissue sarcomas of the hand and foot. Aggressive, wide re-exci-
sion is an effective method of achieving a high rate of local control.
Radiation seems appropriate when margins are close or positive.
There does not appear to be a survival benefit to immediate radical
amputation
070 Long-term Follow-up Of Giant Cell Tumor Of The 
Sacrum Treated With Selective Arterial Embolization And 
Other Modalities
Lin PP, Guzel VB, Moura MF, Morello FA Jr, Benjamin RS, 
Gokaslan ZL, Weber KL, Yasko AW
University of Texas MD Anderson Cancer Center Box 106, Houston, 
TX 77030, USA
Introduction: Giant cell tumor of the sacrum is difficult to man-
age. Standard treatment, including surgery and radiation, are asso-
ciated with significant complications and high relapse rates. The
goal of this study is to evaluate the long-term outcome of arterial
embolization.
Methods: From 1975 to 2000, 21 patients were treated for giant
cell tumor of the sacrum, of which 10 had failed previous treat-
ment. Eighteen patients underwent selective arterial embolization,
of which eight had bland embolization and 10 had chemoemboli-
zation  with  intra-arterial  cis-platin.  One  patient  did  not  have
embolization because of hypovascularity. Two patients underwent
total  sacrectomy.  The  mean  number  of  embolizations  was  3.8
(range, 1± 7). The median follow-up time was 105 months (range,
6± 205 months).
Results: Of the patients who underwent embolization, four failed
to show a positive radiographic response (decrease in vascularity
and  increase  in  peripheral  bone  formation).  Three  additional
patients had late failure of treatment. In the most favorable model,
the rate of local control with embolization was 64% at 5 years and
51% at 10 years by Kaplan± Meier analysis. Patients undergoing
chemoembolization with intra-arterial cis-platin did not have sig-
nificantly  better  local  control  than  bland  embolization  without
chemotherapy, but this was not randomized, and in certain cases a
positive effect was noted with cis-platin. Radiation provided long-
term control in two patients after failure of other treatments. Three
patients  developed radiation sarcomas. Aggressive surgical  exci-
sion was effective in obtaining local control, but functional results
varied widely.
Discussion and conclusion: The treatment of sacral giant cell tumor
continues to be problematic. Both surgery and radiation can result
in significant morbidity. Arterial embolization has some efficacy,
but one-half of the patients will ultimately fail treatment. Never-
theless, it is a potentially useful modality. A minority of patients
can  have  their  disease  controlled  by  embolization  alone. Many
patients show a partial response and this may make surgical exci-
sion safer and less morbid. A multimodality approach may provide
optimal results.
071 Survivorship Of Segmental Prosthetic Arthroplasty For 
Limb Salvage Following Bone Sarcoma Resections
Yasko AW, Lin PP, Weber KL
The University of Texas M. D. Anderson Cancer Center, Houston, TX 
77030, USA
Introduction: Prosthetic arthroplasty is the most common method
of reconstruction of segmental bone defects following resection of
bone sarcomas. The purpose of this study was to determine the
survivorship of the reconstructions in short- and long-term follow-
up.62 CTOS  abstracts
Methods: A  retrospective  study  was  performed  on  all  patients
diagnosed with a bone sarcoma between 1980 and 1995 who were
treated with a limb-sparing osteoarticular resection and prosthetic
arthroplasty  reconstruction.  Prosthetic  survival  was  calculated
with  endpoints of  analysis based  on  any event,  any prosthesis-
related event and aseptic loosening of the prosthesis, which led to
prosthetic revision, removal or limb amputation.
Results: A total of 237 reconstructions were performed involving
the  distal  femur  (n  =  111),  proximal  tibia  (n  =  43),  proximal
humerus (n = 47), and proximal femur (n = 36). All implants were
fixed with polymethylmethacrylate cement. A total 174/237 (73%)
did not require a re-operation at last follow-up evaluation. Early
complications (within 1 year post-operatively) developed in fewer
than  2%  of  patients.  Aseptic  loosening  occurred  late  and
accounted for the majority of events resulting in prosthetic failures
(51%). Amputations were performed in 10% of patients prosthe-
sis-related complications or tumor recurrence.
Prosthetic Arthroplasty Survival (prosthetic-related events)
Conclusion: The  early  outcome  of  prosthetic  arthroplasty  was
extremely favorable, supporting this method of reconstruction fol-
lowing excision of high-grade bone sarcoma. Long-term survival of
prosthetic arthroplasty can be anticipated following tumor resec-
tion about the shoulder and hip. Aseptic loosening continues to be
the primary cause of prosthetic failure, especially about the knee.
072 Pathologic Fractures In Osteosarcoma
Saghieh SS, Lin PP, Weber KW, Jaffe N, Patel SR, Benjamin RS, 
Yasko AW
The University of Texas M. D. Anderson Cancer Center, Houston, TX 
77030, USA
Introduction: The majority of patients with osteosarcoma can be
treated with  limb  salvage surgery.  However, those  who present
with a pathologic fracture may be at a higher risk for local recur-
rence and poorer survival.
Method: This is a retrospective study of 65 patients diagnosed
with osteosarcoma associated with  a pathologic fracture treated
between 1981 and 1998. Medical records, pathology reports and
radiologic studies were reviewed in all of these patients, and prog-
nostic variables evaluated for local recurrence and overall survival.
Results: There were 37 males and 28 females. Twenty-seven were
younger than 17 years, and 13 were older than 45 years. Fifty-two
patients presented with localized and 13 with metastatic disease. The
distal femur was the most frequent site (40%) of involvement. Limb
salvage surgery was performed for 34 patients (52%). Amputation
was performed for 31 (48%). The overall survival for patients with
localized disease was 62% at 5 years. From all variables studied for
patient survival, only localized disease (versus metastatic disease) and
favorable chemotherapy response (versus poor response) were posi-
tive prognostic factors. Twelve (18%) local recurrences developed,
nine (26%) after limb salvage and three (9%) after amputation. Of
the prognostic variables analyzed for local recurrence, none reached
statistical  significance. However, limb  salvage surgery for patients
with localized disease who had a prior non-oncologic surgery resulted
in a high percentage of local failures (4/5 patients (80%)). 
Conclusion: Overall survival in patients with osteosarcoma who
sustain a pathologic fracture is not compromised; however, local
control  can  be  jeopardized  especially  in  patients  who  undergo
extensive non-oncologic surgery prior to diagnosis and who subse-
quently are treated with limb salvage surgery. Although local con-
trol of the tumor must be individualized, amputation may be the
surgery of choice for this high-risk group. 
080 Combined Surgery, Brachytherapy And External 
Irradiation Of Locally Advanced Soft Tissue Sarcomas: A 
Feasible Approach
Pedersen JG1, Krarup-Hansen A2, Daugaard S3, Höjlund B4, 
Rosendal F2, Larsen jS2, Lund B1, Engelholm SA2
1Department of Orthopaedic Surgery, 2Department of Radiation 
Oncology, 3Department of Pathology, and 4Department of Radiology, 
National University Hospital (Rigshospitalet), DK-2 100 Copenhagen, 
Denmark
Background: Locally  advanced  disease  of  soft  tissue  sarcomas
(STS) is a major surgical task: maximum local control versus min-
imum surgery and disability.
Aim: To  reduce  the  amount  of  extensive  surgery,  to  improve
local control by immediate use of post-operative turnour (T) bed
brachytherapy (brt) followed by external beam irradiation (RT),
and to reduce morbidity.
Materials and methods: Sixteen patients (pts) (median age, 60 years;
range, 29± 75 years; female/male, 9/7) with a blank chest X-ray had an
MR/CT scan and a diagnostic biopsy. Fifteen pts had a primary T
larger than 5 cm, and one less than 5 cm; nine were located at the
lower and four at the upper extremity, and three superficial at the tho-
rax; two had a grade (gr) I T, 10 a grade II and three a grade III; and
eight  had  liposarcoma,  three  myxofibrosarcoma,  two  leiomyosar-
coma, one myogenic sarcoma, one synovial sarcoma, and one malig-
nant haemangiopericytoma. All  pts  underwent surgical  procedure
(10 intralesional excision, four marginal, two wide) and intraoperera-
tive  implantation  of  microSelectron  (mSr)  flexible  applicators
(median, 6; range, 3± 18), each tube with a maximal loading length of
23 cm. The following day, the tubes were connected to the PDR-mSr
treatment unit and a mean dose of 22 Gy (range, 20± 30 Gy) was
applied at a dose rate of 0.6 Gy/hour; one pulse per hour with a CT
scan calculated 100% at reference points 5 mm from the catheters.
The tubes were extracted immediately after finishing the brt. The
volume implants  were reconstructed from orthogonal radiographs
and the 3D-dose distribution calculated in CADPLAN using a geo-
metric  optimisation  algorithm  for  stepping  source  implants.  The
mean treatment volume was 104 ml (range, 45± 200 ml). Conven-
tional fractionated compartmental external beam RT was initiated at
day 22 (range, 9± 34 days) and a total cumulated mean dose of 49 Gy
(range, 44± 50 Gy) in 2-Gy fractions was given.
Results: Fifteen pts are alive, 14 with no sign of local recurrence at
a median follow-up of 16 months (range, 12± 49 months); one pt
died of lung metastases at 27 months; one pt with intralesional exci-
sion had multi-focal local recurrence of dedifferentiated liposarcoma
(grade II > grade III); one pt is alive with lung metastases. One pt
(brt, 30 Gy; external RT, 50 Gy) had quite a severe RT-induced
damage and needed skin-transplantation, after which the pt recov-
ered. Brt was reduced to 20 Gy and no further events of RT damage
were observed. Overall, only minimal disability was observed.
Conclusion: Combined  modality  treatment  of  locally  advanced
STS is a safe and feasible approach. This early report needs further
confirmation in a long-time observation large-scale study.
065 Combined Therapy For Retroperitoneal Soft Tissue 
Sarcomas: Pre-operative Radiation And Surgery
Gronchi A, Azzarelli A, Baratti D, Lombardi F, Gandola L, 
Navarria P, Bertulli R, Casali PG, Pennacchioli E, Rasponi A, 
Dileo P, Pilotti S
Istituto Nazionale Turnori, Milan, Italy
Intervention: Surgery is the standard treatment of retroperitoneal
soft tissue sarcomas (RSTS), but is affected by a high failure rate.
5 year 10 year 15 year
Distal femur 83 63 60
Proximal tibia 90 56 56
Proximal femur 91 76 76
Proximal humerus 94 87 87CTOS  abstracts 63
Adjuvant radiation may improve local control and possibly sur-
vival.  We report  the  results  of a  phase  I± II  study  on  radiation
therapy (RT) delivered in a pre-operative setting, to determine the
treatment feasibility and its possible benefit on surgical quality.
Patients and methods: From September 1996 to December 1999, 41
patients  affected  by  RSTS  were  referred  to  our  institution.
Twenty-one of  them,  affected by  primary  or  recurrent  disease,
were eligible for the combined therapy. As regards to the histology,
14 were liposarcoma, five were leiomiosarcoma, one rhabdomiosa-
rcoma and one abdominal gastro-intestinal stromal tumor. Seven-
teen  were  low  grade  and  four  high  grade.  A  CT-based
computerized treatment plan was obtained in all patients to deter-
mine treatment volume. Personalized shields were realized to con-
firm dose distribution. The scheduled dose was 50 Gy. Surgery
was then planned between the 30th and the 60th day after the end
of RT.
Results: One  patient  received  only  32  Gy  for  gastro-intestinal
intolerance. All the other patients completed the treatment without
significant toxicity. One patient progressed soon after RT and was
not operated. All the other 20 patients underwent surgery 32± 46
days after the end of RT. A complete removal of the tumor was
possible in 15  cases: resection  was extended to viscera with  10
nephrectomies,  seven  colectomies,  two  distal  pancreatectomies,
one splenectomy, one gastric resection and one resection of the
inferior vena cava. No major surgical difficulties were encountered.
In the remaining five cases not completely resected, a sarcomatosis
was found at laparotomy. One patient died 3 months later due to
related  abdominal  complications.  One  patient  died  12  months
later due to local abdominal recurrence, and two died 22 and 32
months later, respectively, due to distant metastasis. The remain-
ing 11 patients are all alive with a median follow-up of 25 months
(range, 6± 40 months), eight of whom free of disease.
Conclusions: Pre-operative radiation is feasible and safe. A control-
led  study  with  strict  inclusion criteria  is  now recommended to
investigate the possible benefit of the combined treatment on sur-
vival.
066 Chordoma: Natural History And Treatment Results In 
55 Patients
Gronchi A, Azzarelli A, Baratti D, Lozza L, Bertulli R, Casali PG, 
Pennacchioli E, Rasponi A, Dileo P, Pilotti S
Istituto Nazionale Tumori, Milan, Italy
Intervention: Chordoma is a rare neoplasm with poor prognosis as
already observed by several authors. Our experience reports one of
the largest series in the literature and confirms the need of new
adjuvant treatments.
Patients: We observed at our institution 55 patients affected by
chordoma. The neoplasm was located in the sacrum in 49 cases, at
the base of the skull in three and in the vertebral bodies in three.
The median age at the time of the diagnosis was 58 years (range,
2± 77 years); 34 patients were male and 21 female; median diame-
ter was 13 cm (range, 2± 30 cm). During the 1970s, advances in
pre-operative staging, more reliable surgical techniques and a clear
definition of oncological adequacy were the basis of a new rationale
treatment of sacral chordoma. Since 1977, patients underwent sur-
gery  with  intent  of  radicality.  The  technique  of  operation  per-
formed  in  29  patients  was  high  amputation  of  the  sacrum  by
posterior approach, with the aim to perform an uncontaminated
removal of the entire lesion and surrounding normal tissue. Radi-
otherapy was considered in case of marginal or intralesional oper-
ations.
Results: Surgical margins were rated as wide in nine patients, mar-
ginal in 17 and macroscopically intralesional in three. Post-operative
radiation therapy was performed in nine patients with marginal/int-
ralesional surgery; one patient underwent pre-operative RT. Sacral
chordoma recurred in 17 out of these 29 recent operated patients.
Local failure, mainly located in the ischiorectal area, developed in 13
cases, distant isolated metastases (lung) in one patient, and both
local and distant failure in three, with involvement of lung in two
cases and distant subcutaneous dissemination in one. As regard to
resection margins definition, local ± distant failure developed in six
out of nine (66.7%) patients with wide margins and in 11 out of 17
(64.7%) patients with marginal operation.
Conclusions: Although  chordoma  is  considered  a  low-grade
lesion, surgical treatment to obtain effective local control is diffi-
cult, due to late diagnosis and anatomical site. In the present study,
wide surgical margins were obtained only in 31% of the operated
patients and recurrence rate was high. Distant metastases, isolated
or concurrent to local failure, were detected only in four out of 29
patients (13.7%). Therefore, strong effort in achieving complete
surgical excision is mandatory, as well as in developing more effec-
tive adjuvant therapies.
087 Periosteal Chondrosarcoma: Experience Of The Istituto 
Ortopedico Rizzoli.
Fabbri N, De Paolis M, Vanel D, Mercuri M, Picci P
Department of Musculoskeletal Oncology, Istituto Ortopedico Rizzoli ±  
Bologna, Italy
Periosteal chondrosarcoma is a rare primary malignant tumor of
the bone surface. Due to its rarity, the differential diagnosis with
other primary tumor of the bone surface can be difficult and the
potential for metastasis remains unclear. Studies reporting series of
patients homogeneously managed at the same institution are scant
in the literature. From 24,855 bone tumors filed at our institution,
26 cases of periosteal chondrosarcoma were identified; two cases
were  excluded  for  incomplete  imaging  studies.  A  retrospective
study of the remaining 24 cases was undertaken. Clinico-patho-
logic features were reviewed and analyzed along with follow-up in
order to define diagnostic criteria and understand prognosis of this
condition.
There were 18 males and six females, and average age was 33 years
(range, 17± 65  years). A palpable mass  and dull pain averaging
more than 18 months of duration were the most common symp-
toms at presentation.
Tumor location was the femur in 14 cases (12 distal, two proxi-
mal), humerus in seven cases (five proximal, two shaft), tibia in
two cases (two proximal) and iliac wing in one case. Imaging stud-
ies showed a frequently lobulated juxtacortical mass, usually sug-
gestive of cartilaginous matrix on both plain X-rays and CT or
MRI scan. Although abnormalities of the cortex were present in all
the cases, medullary involvement could be detected and histologi-
cally confirmed only in two cases.
Information regarding the surgical margin and a minimum follow-
up longer than 3 years were available in 18 patients (average, 11
years; range 3± 30 years). Surgical margin was adequate (wide) in
10 cases and inadequate (wide/contaminated or marginal) in the
remaining eight cases. All the patients were disease free; three local
recurrences  were  managed  with  further  surgery.  None  of  the
patients  developed metastasis.  There  were no  local  recurrences
when the surgical margin was adequate. In our experience, prog-
nosis is excellent after adequate surgical management and risk of
metastasis is very low. 
088 Desmoplastic Fibroma: Experience Of The Istituto 
Ortopedico Rizzoli
Fabbri N, Trentani F, Vanel D, Mercuri M, Picci P, Bertoni F
Department of Musculoskeletal Oncology, Istituto Ortopedico Rizzoli ±  
Bologna, Italy
Desmoplastic fibroma is a rare benign tumor of bone. Despite its
benign nature, a marked tendency for local recurrence has been64 CTOS  abstracts
reported in the past. However, studies reporting series of patients
homogeneously managed at the same institution are scant in the
recent literature.
From  24,855  bone  tumors  filed  at our  institution,  16  cases  of
desmoplastic fibroma were identified. A retrospective study of this
group of patients was undertaken; clinico-pathologic features were
reviewed and analyzed along with follow-up in order to define bio-
logic aggressiveness and potential for local recurrence of this disor-
der.
There were nine males and seven females, and average age was 22
years (range, 9± 36 years). Swelling and pain usually lasting more
than  6  months  were  the  most  common  presenting  symptoms.
Tumor location was the femur in five cases (three proximal, two
distal), tibia in three cases (two proximal, one distal), humerus in
two cases (one proximal, one shaft), fibula in two cases (one prox-
imal, one distal), and calcaneus, periacetabular region, sacrum and
L2 body in one case each.
Imaging studies constantly showed a purely lytic defect, sharply
marginated towards the bone and contained by paper thin cortex
towards the surrounding soft tissues. Staging of the tumor accord-
ing to MSTS was stage 2 in 12 cases, stage 3 in three cases, and
stage 1 in one case.
Information regarding the surgical margin and a minimum follow-
up longer than 3 years were available in 14 patients (average, 5
years; range, 3± 22 years). Surgical management consisted of wide
resection in nine cases and intralesional curettage in five cases; in
three cases, the use of phenol or liquid nitrogen was added to the
curettage as a local adjuvant.
All the patients were disease free. None of the patients developed
metastasis. In our experience, prognosis is excellent after adequate
surgical  management, either  wide resection  or aggressive  curet-
tage.
089 Hemangiopericytoma Of Bone: The Rizzoli Experience
Campanacci L, Fabbri N, Vanel D, Mercuri M
Department of Musculo Skeletal Oncology, Istituto Ortopedico Rizzoli, 
Bologna, Italy
Hemangiopericytoma is a rare malignant vascular tumor, originat-
ing from the perivascular cells. Usually arising in the soft tissues, it
is extremely rare in the skeleton. We coud not find large series
reports in the literature.
Treatment is surgery, sometimes associated with radiation and/or
chemotherapy. At the Rizzoli  Institute, since September 1900  to
date, 24,855  cases of bone and soft tissue tumors and pseudotu-
moral lesions are filed. Out of 6434 cases of malignant bone tumors
(excluding metastases), only 13 cases of hemangiopericytoma pri-
mary of the bone were observed (two of which were consultations).
There were four males and nine females, aged 8± 79 years (average,
41 years). Pelvic bones and/or lumbo-sacral spine were involved in
six cases, a rib in one, upper and lower limbs in three cases each
(femur in two, fibula in one, and humerus in three). In two cases,
the lesion involved two adjacent bones.
Symptoms were always present since a long period of time (from 6 to
60 months; average, 25.5 months). Radiologically, all cases presented
as purely ostelitic, containing trabecular septae, with expanded corti-
cal bone; in 10 cases, a soft tissue mass was also present. In two cases,
small osteolitic images distal to the primary lesion were observed; two
cases presented with a pathological fracture.
Among the 11 cases treated at our institution, five were managed
with surgery alone, one with surgery and radiation-therapy; three
patients were treated by chemotherapy and radiation therapy (sur-
gery was not possible at presentation). One case (8-year-old girl)
was cured with chemotherapy alone.
Six patients died of the disease (all developed lung metastases, one
a local recurrence) after 5 months to 6 years; five are continuous
disease free at 4± 21 years of follow-up.
Hemangiopericytoma still represent a difficult issue for diagnosis
and  treatment,  its  course  can  be  rapidly  aggressive,  and  lung
metastases can appear even after years; the role of chemotherapy is
still uncertain in improving the outcome. Delaied diagnosis has an
ominous prognosis.
090 Soft-tissue Sarcoma (Sts) Ð  Adherence To Guidelines
Nijhuis PHA1, Schaapveld M2, Otter R2, Hoekstra HJ1
1Department of Surgical Oncology, Groningen University Hospital, 
Groningen, The Netherlands, and 2Comprehensive Cancer Center 
North-Netherlands, Groningen, The Netherlands 
Introduction: Because many general surgeons are unfamiliar with
these rare tumors, a reasonable number is found by chance, often
after  inadequate  resection,  leading  to  complex  definitive  treat-
ment.  Therefore,  guidelines  for  diagnosis  and  treatment  were
developed. As the diagnostic management is essential for definitive
treatment, adherence to these guidelines is important.
Methods: Primary STS, registered by the Comprehensive Cancer
Center North-Netherlands from January 1989± January 1996, were
analyzed retrospectively with regard to adherence to the diagnostic
guidelines. Urogenital STS, gastro-intestinal  STS, and Kaposi’s
sarcomas were excluded.
Results: Three hundred and fifty-one STS were analyzed. In the spe-
cialized center, 69% of patients were younger than 60 years, whereas
in district hospitals 63% were older than 60 years. With increase of
age, referral to the center declined in a linear fashion. For all guide-
lines, adherence was significantly better in the center (Table 1). 
Conclusions: In many aspects of the diagnostic process of STS,
existing  guidelines  were  not  followed,  especially  in  community
hospitals. Adherence to all individual guidelines was significantly
better in the specialized center. In order to improve compliance
with future STS guidelines, appropriate guideline development,
dissemination,  and  implementation  programs  should  be  devel-
oped. Concentration of STS in a limited number of hospitals and
intensified collaboration with specialized centers seem advisable.
Special attention should be paid to older patients, which were sig-
nificantly more often not referred to a specialized center.
091 Pre-operative Radiation Therapy In The Treatment Of 
Soft Tissue Sarcomas
Virkus, Mollabashy A, Reith JD, Berrey HB, Zlotecki RA, 
Scarborough MT
University of Florida, Gainesville, FL 32610, USA
This report presents the results of a cohort of patients with a soft
tissue  sarcoma  treated  with  a  standard protocol  including  pre-
operative radiation therapy (PRT) and surgical resection, assessing
wound complications, local recurrence, and oncologic outcome.
A standard protocol of PRT followed by en bloc resection was per-
formed in 218 patients with a primary soft tissue sarcoma from
1984 to 1999. Wound complications were defined as minor (local
wound care), moderate (operative I&D), major (STSG or flap),
and amputation. Wound complications are reported for the entire
patient population. Oncologic results are reported on a subset of
patients that excluded patients who were stage III at the time of
resection, or received chemotherapy. There were 114 males, 104
females,  with  an  average  age  of  56  years  (range,  8± 86  years).
Thirty-six patients received chemotherapy. At the time of resec-
tion, 13 patients were stage IA, 16 were stage IB, 63 were stage
IIA, 111 were stage IIB, and 15 were stage III. Ten patients had an
intralesional surgical margin, 91 marginal, 115 wide, and two rad-
ical. Primary wound closure was obtained in 187 patients, nine
needed a split-thickness skin graft, 20 a rotational flap, and two a
free flap for closure. Only six patients underwent primary amputa-
tion. Mean oncologic follow-up was 53 months.
The  overall  wound  complication  rate  was  32.6%  (minor,  10%;
moderate,  13%;  major,  7%;  amputation,  1%).  If  minor  wound
problems treatable with short-term local wound care are excluded,CTOS  abstracts 65
the wound complication rate was 22.9%. When stage III and chem-
otherapy patients were removed, 172 patients remained for onco-
logic  outcome  analysis.  Seventy-three  (42%)  developed  late
metastases, predominantly to the lungs (82%). Eighteen patients
developed a local recurrence, which was 15.1% of those patients
with a minimum of 2 years of follow-up. The recurrence rate in
patients with prior surgery at an outside institution was 24%, versus
12% if initial surgery was at our institution. At latest follow-up, 80
patients  (46%) were continuously disease  free, six  (3%) ANED,
eight (4%) alive with disease, and 65 (38%) dead of disease. The 2
and 5-year survival rates were 77 and 66%, respectively. 
The ideal timing of adjuvant radiation therapy remains to be deter-
mined. PRT allows for a smaller radiation dose and field to be
delivered, theoretically decreasing the morbidity of radiation. Our
local control rate is similar to that seen in other studies where a
high percentage of adequate surgical margins is obtained. Twenty-
two percent of our patients required a return to the operating room
for wound complications. This is similar to the wound complica-
tion rates in studies where post-operative XRT or no XRT is used.
Distant control continues to be a difficult problem in the treatment
in soft tissue sarcomas.
095 Outcome Following Local Recurrence In Osteosarcoma
Grimer RJ
The Royal Orthopaedic Hospital Oncology Service, Bristol Road South, 
Birmingham, UK
Purpose: Local recurrence of osteosarcoma is generally thought to
be  a  death  sentence,  with  few  patients  surviving.  This  paper
addresses this question and attempts to identify possible prognos-
tic factors and treatment options for patients with local recurrence.
Method: All patients who had developed a local recurrence fol-
lowing  treatment  of  a  non-metastatic  high-grade  osteosarcoma
were included in this review. Patients with metastases at the time
of diagnosis were excluded. Eighty-one patients were found to ful-
fill the above criteria. LR arose at an average of 16 months (range,
3± 49 months). Sixteen of the patients were already known to have
lung metastases and a further 27 were found to have metastatses
within 3 months of treatment of the LR. Another 25 developed
metastases later, leaving only eight patients who did NOT subse-
quently develop metastases.
Results: Overall survival was most clearly related to whether or
not metastases were present at the time of presentation with LR. In
patients with  known metastases  or ones that appeared within 3
months, there were no survivors past 30 months. For those with no
metastases within 3 months, the survival was 40% at 5 years from
the time of LR. Even in those 25 who developed metastases later,
the survival was 30% at 3 years and 23% at 5 years. Disease free
interval was not significant.
Conclusion: LR accompanied by metastases is currently a death
sentence. Experimental treatments for these patients may be justi-
fied. In patients with solitary LR, aggressive treatment is justified
and has a similar outlook to that for lung metastases alone. 
107 Combined Surgery, Brachytherapy And External 
Irradiation Of Locally Advanced Soft Tissue Sarcomas: A 
Feasible Approach
Pedersen JG1, Krarup-Hansen A2, Daugaard S3, Hojlund B4, 
Rosendal F1, Larsen JS2, Lund B1, Engelholm SA2
Departments of 1Orthopaedic Surgery, 2Radiation Oncology, 
3Pathology, and 4Radiology, National University Hospital 
(Rigshospitalet), DK-2100 Copenhagen, Denmark 
Background: Locally  advanced disease  of  soft  tissue  sarcomas
(STS) is a major surgical task: maximum local control versus min-
imum surgery and disability.
Aim: To  reduce  the  amount  of  extensive  surgery,  to  improve
local control by immediate use of post-operative turnour (T) bed
brachytherapy (brt) followed by external beam irradiation (RT),
and to reduce morbidity.
Materials  and  methods: Sixteen  patients  (pts)  (median  age,  60
years; range, 29± 75 years; female/male, 9/7) with  a blank chest
X-ray had an MR/CT scan and a diagnostic biopsy. Fifteen pts had
a primary T larger than 5 cm, and one less than 5 cm; nine were
located at the lower and four at the upper extremity, and three
superficial at the thorax; two had a grade (gr) I T, 10 a grade II and
three a grade III; and eight had liposarcoma, three myxofibrosar-
coma, two leiomyosarcoma, one myogenic sarcoma, one synovial
sarcoma, and one malignant haemangiopericytoma. All pts under-
went surgical procedure (10 intralesional excision, four marginal,
two  wide)  and  intraopererative  implantation  of  microSelectron
(mSr) flexible applicators (median, 6; range, 3± 18), each tube with
a maximal loading length of 23 cm. The following day, the tubes
were connected to the PDR-mSr treatment unit and a mean dose
of 22 Gy (range, 20± 30 Gy) was applied at a dose rate of 0.6 Gy/
hour; one pulse per hour with a CT scan calculated 100% at refer-
ence points 5 mm from the catheters. The tubes were extracted
immediately  after  finishing  the  brt.  The  volume  implants  were
reconstructed from orthogonal radiographs and the 3D-dose dis-
tribution calculated in CADPLAN using a geometric optimisation
algorithm  for  stepping  source  implants.  The  mean  treatment
volume was 104 ml (range, 45± 200 ml). Conventional fractionated
compartmental external beam RT was initiated at day 22 (range,
9± 34 days) and a total cumulated mean dose of 49 Gy (range, 44±
50 Gy) in 2-Gy fractions was given.
Results: Fifteen pts are alive, 14 with no sign of local recurrence
at a median follow-up of 16 months (range, 12± 49 months); one pt
died of lung metastases at 27 months; one pt with intralesional
excision had multi-focal local recurrence of dedifferentiated liposa-
rcoma (grade II > grade III); one pt is alive with lung metastases.
One  pt  (brt,  30  Gy;  external  RT,  50  Gy)  had  quite  a  severe
RT-induced damage and needed skin-transplantation, after which
the pt recovered. Brt was reduced to 20 Gy and no further events
of RT damage were observed. Overall, only minimal disability was
observed.
Conclusion: Combined  modality  treatment  of  locally  advanced
STS is a safe and feasible approach. This early report needs further
confirmation in a long-time observation large-scale study.
109 Unplanned Excision For Soft Tissue Sarcoma: 
Identification Of A Subgroup With Bad Prognosis
van Geel AN, Eggermont AMM, Schmitz PIM
Department of Surgical Oncology and Statistics, University Hospital 
Rotterdam/Daniel den Hoed Cancer Center, Rotterdam, The 
Netherlands
Introduction: Unplanned excision  (UE)  for soft  tissue  sarcoma
(STS) is a frequent procedure. Unclear is the influence on progno-
sis.
Material and methods: From 1986 to 1993, 86 patients (32.7% of
all referred patients) were treated after UE of STS elsewhere (sub-
fascial; limbs, girdles and trunk, > 5 CMS). All patients had CT or
MRI before definitive treatment; minimal follow-up was 5 years. 
Results: Thirty-one  patients  (36.1%)  had  complications
(hematoma) after UE. In 46 patients (53.5%), residual tumor was
seen on CT/MRI and found at pathological examination in 66
patients (76.7%). In one-half of the patients, definitive treatment
was considered to be more complex, resulting in increased morbid-
ity.
Conclusion: After multivariate analysis, a group of patients  (35
patients = 40%) with a significant bad prognosis was found: older
than 60 years with a second treatment with increased complexity
and morbidity independent of this treatment is radical or not. This66 CTOS  abstracts
group can be considered as a high-risk group eligible for adjuvant
chemo therapy trials. 
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029 Potential Impact Of High Technology Radiation 
Treatment For Sarcomas To Improve Patient Outcome
Herman Suit, Karen Doppke, Jong Kung, J. Michael Collier, Ira 
Spiro, Thomas Delaney
Department of Radiation Oncology, Massachusetts General Hospital, 
Harvard Medical School, Boston, MA, USA
The  available  radiation  treatment  techniques  employed  in  the
management of the mesenchymal tumors cause substantial quan-
tities of non-involved tissues/structures to receive important dose
levels. The consequence is that there is a non-negligible frequency
of treatment associated morbidity. This is in the form of: excess
fibrosis,  wound  healing  delay  or  breakdown,  late  appearing
damage in major nerves and vessels, pathological fracture and the
rare radiation induced malignant neoplasm. There are several new
techniques, which will achieve full coverage of the defined target
tissue for each treatment session, but with major reductions in the
volume of normal tissues/structures included in the high dose vol-
ume. As complications of treatment cannot develop in unirradi-
ated tissues, there is predicted a major lowering of the frequency
and severity of treatment related morbidity. These new techniques
are principally intensity modulated X-ray therapy, intensity modu-
lated  proton  beam  therapy,  on-line  diagnostic  quality  imaging,
Monte Carlo based dose calculations, etc. The presentation will
assess  the  impact  of  these  developments  on  three  relatively
common clinical problems. These are lesions located in the: (1)
medial proximal thigh, (2) thoracic vertebral body, and (3) retro-
peritoneal region.
031 Effects Of Irradiation And Radio-protectant On Rat 
Growth Plate Morphology
Damron TA, Spadaro JA, Farnum CE, Margulies BS, Strauss J
Upstate Medical University Department of Orthopedic Surgery, 
Syracuse, NY 13224, USA
Introduction: Previous work in our laboratory has shown a benefi-
cial effect on rat limb growth from administration of the radiopro-
tectant amifostine. The histological correlates of these quantitative
measurements of limb length have not previously been described.
Purpose: The purpose of this paper is to detail the histological
changes over time in the rat growth plate (GP) following irradia-
tion with and without the radioprotectant amifostine.
Methods: Histological  specimens  were  examined  from  84
Sprague± Dawley male  rats, 4 weeks old, previously included in
reports detailing limb length effects. Groups of n = 6 included for
analysis were `cage controls’ at 6 weeks, irradiation only; (single
dose, 12.5 and 17.5 Gy) at 6 weeks, `radioprotectant pretreatment’
(100 and 300 mg/kg amifostine for the 12.5 Gy groups, and 100
mg/kg for the 17.5 Gy groups) at 6 weeks, and `early timing’ (0.5,
1, 2, 3, and 4 weeks post 17.5 Gy with and without 100 mg/kg ami-
fostine). Irradiation was administered to the right distal femur and
proximal tibia; the left leg served as the control.
Results: Morphology of the irradiated GP changed consistently
over time. At 0.5 weeks, a subtle decrease in cellular profiles with
maintenance of overall zonal architecture was evident. At 1 week,
cellular profiles were notably reduced, and zonal architecture was
nearly lost. At 2 weeks, the GP was composed of sparsely situated
terminal, hypertrophic-appearing chondrocytes. At 3 weeks, cellu-
lar profiles increased via clonal bodies. At 4 and 6 weeks, clonal
bodies predominated.
The growth plate cellular profile area following irradiation hit a
nadir at 2 weeks and rebounded at the third week toward normal.
TRAP staining showed an increase in osteoclasts between the 2
and 3 week time periods that corresponded to an relative decrease
in GP height over the same interval.
Epifluorescent growth rates reached a nadir 1 week following irra-
diation and slowly returned toward normal thereafter.
Growth plate overall height was greater for controls than irradiated
specimens at all time periods, but these effects were much greater cen-
trally than peripherally. Amifostine effects, however, were observed
more consistently at the periphery rather than in the central GP.
Discussion: Irradiation results  in a predictable  pattern of histo-
logic changes, with the greatest effects observed at 1 week in the rat
proximal tibia. Prereatment with amifostine is unable to preserve
normal GP morphology despite its maintenance of longitudinal
growth, but many parameters are statistically improved compared
with the irradiated specimens.
032 Bone Density Effects Of Radiation And The 
Radioprotectant Drug Amifostine In A Rat Model
Morgan H, Damron TA, Margulies B, Spadaro J
Upstate Medical University Department of Orthopaedic Surgery, 
Syracuse, NY 13224, USA
Purpose: The purpose of this project was to examine the effects on
the bone density measurements of irradiated rat femurs with and
without the radioprotective drug amifostine (AMF).
Methods: Seventy-two weanling Spague± Dawley rats were rand-
omized into treatment groups. In all treated animals, the right knee
(distal femur and proximal tibia) was irradiated with single-frac-
tion 17.5 Gy, while the left leg was used as an internal control. Ani-
mals  were  sacrificed  at  0.5,  1,  2,  3,  4,  and 6  weeks  following
irradiation, 12 per time period. One-half of the animals in each of
the groups received 100 mg/kg amifostine 20 minutes prior to irra-
diation.  For  the  bone  density  analysis,  the  skeletonized  femurs
were placed into a cylindrical holder and suspended in deionized
water. Bone density (g/cm) was determined using peripheral quan-
titative computed tomography (pQCT; Norland XCT 2000, Fort
Atkinson, WI), resolution 90 microns.
Results: The  irradiated  slices  maintained  a  significantly  higher
BMD than controls through 6 weeks in the most proximal meta-
physis and through 3 weeks in the distal metaphysis (Fig. 1). The
slice closest to the metaphysical side of the physis demonstrated a
unique early peak BMD at 2 weeks, which decreased dramatically
by 3 weeks. The BMD for rats that received amifostine was signif-
icantly lower through 3 weeks than for rats that received radiation
alone (p < 0.02 for 0.5, 2, and 3 weeks).
Discussion: Three conclusions are drawn from the current data.
First, at early time periods following irradiation, BMD within the
irradiation field is greater than control in this animal model Sec-
ond, a 2-week early peak in BMD occurs in the juxta-physeal met-
aphysis. Third, amifostine has a significant effect in holding BMD
close to normal in the juxta-physeal region. We hypothesize that
the sensitive marrow elements, particularly in this case the mono-
cyte  precursor  of  osteoclasts,  are  more  sensitive  to  irradiation
damage than the osteoblasts, given the slower turnover of the latter
cells. In addition, we hypothesize that the early 2-week peak in
BMD occurs only in the distal metaphysis due to the greater rela-
tive contribution of provisional calcification to BMD there, since
this  calcification  is  a  passive  process  that  is  likely  to  continue
despite radiation effects, particularly when unchecked by resorp-
Survival Overall  Loc. rec. free  Dist. rec. free 
2 years 86.0  85.8  84.6 
5 years  74.3  72.1  70.6 CTOS  abstracts 67
tive activity of chondroclasts and osteoclasts. These hypotheses are
supported by histological observations.
033 Pattern Of Local Recurrence After Conservative 
Surgery And Radiotherapy For Soft Tissue Sarcoma. 
Cleator SJ, Cottrill C, Harmer CL
Sarcoma Unit, Royal Marsden Hospital NHS Trust, London SW3 
6JJ, UK
Purpose: Over  the  past  two  decades,  our  centre  has  adopted  a
policy  of  conservative  surgery  followed  by  adjuvant radical-dose
radiotherapy for all medium- and high-grade soft tissue sarcomas.
From the patients treated in this manner at the Royal Marsden Hos-
pital over the past 15 years, we analyzed 17 who had relapsed locally.
We  discuss  technical  factors  that  may  have  contributed  to  local
relapse in some cases, and the geographical relationship between
sites of recurrence and the phase 1 and 2 radiotherapy volumes. 
Patients and methods: We examined those cases recorded on our
soft tissue sarcoma database between January 1986 and September
1999 who had recurred locally following surgery and radical post-
operative radiotherapy. We excluded patients with residual macro-
scopic disease following surgery and any patients with metastatic dis-
ease at presentation. We recorded details relating to original tumour
stage,  histological  type,  grade  and  surgical  margins.  The  cohort
included eight patients with T1 (47%) and nine patients with T2
tumours (53%). The tumours were grade 1, 2 and 3 in two (12%),
six (35 %) and nine (53%) number of cases, respectively. The major-
ity of patients were treated with a phase I volume corresponding to
the entire muscle compartment that received 50 Gy in 25 fractions
over 5 weeks. The phase II was a reduced volume corresponding to
the tumour bed and received 10 Gy in five fractions during the sixth
week of treatment. Four of the patients were treated according to a
hyperfractionated regimen consisting of 72 Gy in 60 fractions twice
daily over 6 weeks with volume reduction after 60 Gy. 
Results: Mean time to local recurrence was 26 months. Four (23%)
patients recurred within the phase I volume, nine (53%) recurred
within the phase II volume, and three (18%) outside the irradiated
volume. One recurrence was marginal. Eight patients who relapsed
had  positive  surgical  excision  margins  originally.  In  six  patients,
there had been deviations from our radiotherapy protocol, usually
unavoidable, which may have accounted for treatment failure; these
included all three out of field recurrences. Of the 11 patients for
whom it was possible to adhere strictly to protocol, two recurred in
the phase I volume and nine in the phase II volume. With a mean
follow-up  time  since  completion  of  radiotherapy  of  63  months,
seven patients have died and, of these, six were disease related. 
Conclusion: A dose greater than 60Gy may be necessary despite
initial complete surgical resection. Prospective, multi-centre data
collection and ideally a randomized trial are required to formulate
an improved treatment policy.
036 Treatment Outcome In Patients Radiated For Spinal 
And Paraspinal Tumors
DeLaney TF, Ancukiewicz M, Hornicek FJ, Spiro IJ, Harmon 
DC, Suit HD
Massachusetts General Hospital, Boston, MA 02114, USA
Objective: Tumors of the spine and paraspinal soft  tissues  can
present difficult management challenges because of the proximity
of the spinal cord, which limits resection margins and radiation
dosage. A retrospective review of treatment outcome in a cohort of
these patients managed in a single institution was undertaken to
assess prognostic factors and treatment techniques important for
favorable treatment outcome.
Materials and methods: Fifty-seven patients with spinal and par-
aspinal tumors treated with radiotherapy between 1971 and 1998
were  identified  in  our  sarcoma  database.  Nine  patients  with
Ewing’s sarcoma/PNET were identified for separate analysis, leav-
ing 48 patients for analysis for this study. Outcome was assessed
according to the following tumor and treatment variables: site (spi-
nal/paraspinal), tumor grade, surgical margin status, and radiation
dose.
Results: Twenty-four lesions were in the spine and 24 were in par-
aspinal soft tissue. Forty-two patients had malignant tumors with
the  following  histologies:  neurofibrosarcoma/malignant  schwan-
noma  (9),  malignant fibrous  histiocytoma  (7),  chondrosarcoma
(5), chordoma (5), osteosarcoma (4), fibrosarcoma (3), and others
(9). Six patients had benign lesions: desmoid (2), giant cell tumor
(2),  aneurysmal  bone  cyst  (1),  and  hemangioma  (1).  Median
tumor size was 8.5 cm (range, 1.2± 18 cm). Local treatment con-
sisted of combined surgery and radiotherapy in 45 patients and
radiotherapy alone in three patients. Median radiation dose was
60.2 Gy (range, 22.4± 78.6 Gy). Five patients received brachyther-
apy as a component of treatment, with a median implant dose of
28.7 Gy, while two patients received intra-operative radiotherapy.
Chemotherapy  was  administered  to 15  patients.  Overall  5-year
survival was dependent upon tumor grade: 0± 1, 89%; 2, 48%; 3±
4, 36% (p = 0.10). Overall 5-year survival was similar for spinal
(72%) and paraspinal (63%) lesions (p = 0.96). Local control was
85% for spinal lesions and 66% for paraspinal lesions (p = 0.59).
There was a trend towards improved local control in patients with
negative surgical margins (81%) compared with patients in whom
the margins were positive (55%) (p = 0.30). No clear relationship
could be demonstrated between radiation dose and treatment out-
come.
Conclusions: Similar to other sites, tumor grade is of prognostic
importance in patients with spinal and paraspinal tumors. In spite
of the large tumor size (median, 8.5 cm) seen in this patient popu-
lation  and  the  limits  on  surgical  resection  and  radiation  dose
imposed by proximity of the spinal cord, combined modality treat-
ment with surgery and radiotherapy produced local control in the
majority of patients. Improved therapeutic strategies are necessary
for patients with positive surgical margins and paraspinal tumors,
in whom local control remains suboptimal. 
038 Pre-operative Radiotherapy In Adult Soft-tissue 
Sarcomas
T. Morysinski, W. Ruka, P. Rutkowski
Soft Tissue/Bone Sarcomas Department, M. Sklodowska-Curie 
Memorial Cancer Center Institute, Warsaw, Roentgena 5, Poland
Introduction: Soft-tissue sarcomas are characterized by high local
recurrence potential after inadequate treatment. The aim of the
study was to analyze the results of the surgical treatment of the
soft-tissue sarcomas combined with pre-operative radiotherapy.
Materials and methods: Between 1984 and 1999, 167 patients (84
male, 83 female; mean age, 49.2 years) treated in our institution
were enrolled into the study. Twenty-five patients (15%) repre-
sented stage IA,B (according to UICC/AJCC 1987 classification),
and 142 (85%) represented stage IIA,B + IIIA,B. All patients with-
out distant metastases (MO) were included into the study consec-
utively.  Primary  tumors  represented 64  (38%) cases, and local
recurrence  or  scar  after  non-radical  excision  103  (62%).  The
tumors were mainly located in lower limbs (121 patients; 72%).
Most of the tumors were > 10 cm in diameter (75%). Tumor char-
acteristics according to histological type were: 38 (23%) synovial
sarcoma,  33  (20%)  malignant  fibrous  histiocytoma,  27  (16%)
liposarcoma, 23 (14%) malignant schwannoma, 20 (12%) fibrosa-
rcoma,  and  26  (15%)  others.  Irradiation  fields  contained  the
tumor (primary, recurrent or scar) with drain sites and the margins
~ 5 cm. The patients were divided into two groups: group I, 134
patients underwent pre-operative radiation in total dose of 200068 CTOS  abstracts
cGy (400  cGy/fraction) followed by surgical  resection  3± 5  days
later; and group II, 33 patients underwent `conventional’ radiation
in total dose of 4000± 5000 cGy (200 cGy/fraction) with operation
6 weeks later. Median follow-up time was 36 months for survivals.
The Kaplan± Meier method and the log-rank test were used for sta-
tistical analyses.
Results: The 5-year overall survival in group I was 69% and that
in group II was 47% (p < 0.05). The 5-year local-recurrence free
survival in group I (75%) was significantly better than that in group
II (56%) (p = 0.006).
Conclusions: Pre-operative radiotherapy in adult soft-tissue sarco-
mas used five fractions to a total dose of 2000 cGy regimen applied
3± 5 days before the operation is connected with better tumor local
control rates and demonstrates benefit for overall survival in com-
parison with a conventional pre-operative radiotherapy group.
098 Malignant Peripheral Nerve Sheat Tumors (Mpnst): A 
Retrospective Analysis On 125 Patients
Voican D, Billard C, Terrier P, Bonvalot S, Vanel V, Le Pù choux 
C, Missenard G, Le Deley MC, Le Cesne A
Soft Tissue Sarcoma Unity, Institut Gustave Roussy (IGR), Villejuif 
94805, France
Purpose: To evaluate the prognostic factors in adult patients (pts)
with initial localized MPNST. 
Patients: between 1980 and 1997, 125 pts were treated at IGR.
Surgery of primary tumor was performed in all cases. A complete
resection was achieved in 84% of pts. Adjuvant chemotherapy and
radiotherapy were given in 33 and 42% of pts, respectively. The
median age of pts was 39 years (range, 15± 77 years). Tumor sites
were as follows: extremity,  31%;  thorax, 21%;  abdomen, 22%;
head and neck, 18%; and pelvis, 9%. The median tumor size was
9 cm (range, 1± 30 cm). Neurofibromatosis type I (NFI) is present
in 20% of pts. 
Results: Median follow-up time was 9 years (range, 3± 25 years).
Relapses were observed in 69% of pts (local, 56%; distant, 19%;
both, 25%). The 5- and 8-year overall survival were 50 and 42%,
respectively. High histologic grade, tumor size > 10 cm, NF1 asso-
ciation, non-extremity tumors and primary incomplete resection
are unfavorable prognostic factors for overall survival in univariate
analysis.  High-grade  MPNST,  non-extremity  tumors  and  NFI
phenotype are correlated to overall survival in multivariate analy-
sis. A high treatment-related morbidity was observed in NFI pts
with MPNST. 
Conclusion: Optimal  resection  seems  to  be  the  best  predictive
parameter for a favorable outcome in localized MPNST. Adjuvant
treatments  are  recommended  in  pts  with  high-grade  locally
advanced MPNST.
099 Is Adjuvant Radiation Therapy (Rt) Indicated After 
Optimal Resection For Soft Tissue Sarcoma (Sts) Of The 
Extremities? 
Le Cesne A, Khanfir K, Terrier P, Alzieu L, Bonvalot S, Vanel D, 
Le Pù choux C
Soft Tissue Sarcoma Unity, Institut Gustave Roussy, Villejuif 94805, 
France
Background: The impact of adjuvant RT on both local control
and distant relapse is not clearly established after wide excision of
extremity STS.
Purpose: We performed a retrospective  analysis on behavior of
patients (pts) who underwent a large resection in our institution
(first  or  second  resection  in  case  of  incomplete  surgery)  and
received or not adjuvant RT. All histological specimens were care-
fully analyzed and only pts with free tumoral margins (ftm) were
retained for analysis. Histopathological  classification was as fol-
lows: minimal RO (mRO) resection (ftm < 10 mm) and optimal
RO (oRO) resection (ftm ‡  10 mm).
Patients: From 1975 to 1996, 133 pts with a median age of 44
years were operated at IGR. The median tumor size was 6  cm
(range,  1± 18  cm).  Ninety-three  pts  (70%)  primary  resected  in
other centers were reoperated, and residual tumor cells were found
in 54% of pts. Sixty-nine pts (17 oRO and 52 mRO) received adju-
vant RT and 64 pts did not (54 oRO and 10 mRO). Characteristics
of pts (age, tumor size, grade, adjuvant chemotherapy) were simi-
lar in both RT and no-RT groups. 
Results: Median follow-up time was 10 years (range, 3± 25 years).
Thirty-three pts had a local relapse: 11 in the RT group and 22 pts
in the control group (p = 0.01). Grade and ftm are correlated to
overall survival, and adjuvant RT is correlated to relapse free sur-
vival in univariate analysis. A positive impact of RT on local con-
trol was only seen in pts with a mRO resection (p = 0.005) and in
pts with residual tumor cells after re-excision (p = 0.001). RT has
no influence on 5- and 10-year overall survival. 
Conclusion: Optimal  resection  seems  to  be  the  best  predictive
parameter for a favorable outcome in  terms  of local control in
localized STS. Adjuvant RT is indicated in mRO resections and in
case of residual tumor cells after definitive surgery, but its role after
oRO resection has to be validated by a prospective randomized
trial
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001 Insulin And Igfs Signaling In Soft Tissue Sarcomas: Role 
Of Irs-1 And Irs-2 Proteins
Bogetto L, Cervi M, Spessotto P, Mucignat MT, Canzonieri V, De 
Paoli A, Perris R, Colombatti A
Centro di Riferimento Oncologico -National Cancer Institute, Aviano 
33081, Italy
Insulin  is  a  pleiotrophic  hormone  with  both  metabolic  and
mitogenic effects on cells. Insulin receptor substrate 1 and 2 pro-
teins (IRS-1/2) are the principal intracellular substrates of insulin
(and  IGFs)  receptor(s)  that  undergo  tyrosine  phosphorylation
immediately after ligand stimulation. They act as docking proteins
transmitting the receptor signal to downstream effector proteins
containing SRC homology 2 domains, such as the p85 regulatory
subunit of phosphatidyl-inositol 3-kinase (PI 3K), and the growth
factor receptor binding protein 2 (Grb2). Together, these interme-
diate  signals  stimulate  a  variety  of  different  biological  effects,
including glucose transport, glycogen synthesis, gene expression,
cell migration, and cell proliferation. Although IRS-1 and IRS-2
contain common functional units and share some unique signal-
ling pathways, it is not yet clear if they play redundant or selective
roles in insulin action in different tissues, even if data provide evi-
dence that  they are not functionally interchangeable substrates.
These two proteins show differential expression in several carci-
noma tissues and cell lines: IRS-1 results highly expressed in hepa-
tocellular and breast carcinomas, whereas pancreatic carcinomas
overexpress IRS-2. Little is known about the role of IRS-1 and 2
in soft tissue sarcomas (STS) as well as about the insulin and IGFs
signalling in the biology of these tumours. We have analyzed the
expression pattern of IRS-1, IRS-2, IR, and IGF-1R in a number
of cell lines derived from our patients, and have selected two malig-
nant fibrous histiocytoma-like (MFH) sarcoma cell lines (97441
and 98337)  for their differential expression of IRS-1 and IRS-2
molecules and their different behaviour in vitro under basal condi-
tions or under stimulation with insulin. From each tumour, three
morphologically  different  sub-lines,  named  A,  B  and  C,  were
obtained. 97441 A and 98337 A cells show high expression of IRS-
1, whereas IRS-2 predominates in 97441  B cells; 98337  B cells
lack  both  IRS-1  and IRS-2.  The  C  populations  of  97441  and
98337  show only a weak IRS-1  expression  and no IRS-2.  TheCTOS  abstracts 69
IGF-1R expression is almost the same among the different sub-
lines, whereas a slight increase of IR appears only in 97441 B cells.
Extending our study on in vitro migration and invasion of these
cells, we found that insulin does not modify the migration activity
of 98337 A and B (on different ECM molecules), whereas it con-
siderably  increases  the  invasive  capability  of  98337  A.  These
results indicate a possible role of insulin in dissociating the migra-
tion and the invasion signalling pathways. To study the effect of
IRS molecules that are differentially expressed, we are transfecting
these cell lines with vectors containing sense or antisense IRS-1/2.
002 Ecm Interactions And Production Of Proteolytic 
Enzymes In Malignant Fibrous Histiocytomas
Spessotto P, Mucignat MT, Wasserman B, Burino I, Bogetto L, 
Cigana A, Frustaci S, Perris R, Colombatti A
Centro di Riferimento Oncologico, National Cancer Institute, Aviano 
33081, Italy
We have established several novel cell lines from surgical specimens
of recurrent metastases  of  different  type of soft  tissue  sarcomas,
focusing our attention on malignant fibrous histiocytomas (MFH),
which were found to undergo spontaneous growth behaviour-con-
version in vitro, loosing progressively their anchorage dependence
without incurring into apoptotic processes. From each of two of this
type of sarcoma, three sub-lines different for morphological criteria
were obtained: we defined large and big spindle cells as `sub-line A’,
smaller and less adherent fibroblastic cells as `sub-line B’, and cells
growing in suspension as `sub-line C’. The malignancy of these cells,
evaluated by a colony forming unit assay, was higher for sub-lines B
and C than A in both cell lines. In order to verify whether these sar-
coma cells could represent a useful model to study three different
steps in the process of metastasis, we looked for their binding activity
to extracellular matrix (ECM) molecules, capacity to invade and to
produce proteolytic enzymes. As regards ECM static and dynamic
interactions, we found that the three sub-lines differed for the ability
to adhere to a variety of ECM substrates and for migratory/invasive
behaviour, but  these  differences  were  not  the  same  for  the  two
MFHs. The distinct behaviour of the sub-lines was also observed for
the production of degradative enzymes. Zymographic analyses were
performed  for the  production of  the  metalloproteinases  2  and 9
(MMP-2 and MMP-9), and of the urokinase-type activator of plas-
minogen (uPA), which are highly correlated with malignancy in car-
cinomas. The sub-lines of the two sarcomas displayed a production
pattern different either under normal culture conditions or after acti-
vation; it seemed that the induced production of MMP-9 and the
increase in uPA secretion were correlated with a more aggressive
phenotype. Extending our study on other proteolytic enzymes with
a RT-PCR approach, we observed that  the  MMP expression  of
MFH sub-lines was identical for MT1-MMP, MMP-3 and MMP-
13 but completely different for MMP-7 and MMP-11. In conclu-
sion, our results  suggest  that  interactions  with  ECM  and MMP
expression and production could be consistent `markers’ to distin-
guish apparently similar sarcomas in different categories of biologi-
cal aggressiveness/malignancy.
008 Doxorubicin And Valspodar (Psc 833) Combined 
Therapy In Canine Osteosarcoma According To P-
glycoprotein Expression
Cagliero E1, Scotlandi K2, Morello E3, Manara MC2, Buracco P3, 
Baroetto R1, Ferracini R1
1Istituto per la Ricerca e la Cura del Cancro, Candiolo 10060, Italy, 
2Istituti Ortopedici Rizzoli, Bologna 40136, Italy, and 3Dipartimento 
di Patologia Animale,Torino 10126, Italy
Background: Osteosarcoma of the appendicular skeleton is one of
the  most  life-threatening  canine neoplasms.  Only 10%  of dogs
treated with surgery alone survive 1 year after treatment. Even with
the current most effective treatment, surgery combined with adju-
vant chemotherapy, 65% of dogs die within 1 year and 85% within
2 years. In human osteosarcoma, it has been shown that P-glyco-
protein (Pgp), which confers multidrug resistance (MDR) to some
anticancer agents, including doxorubicin, might be a major cause
of failure of disease control. We evaluated Pgp expression in oste-
osarcoma of dogs treated with combined administration of doxo-
rubicin  and the  MDR  modulator  PSC  833,  and examined the
pharmacokinetic between the two drugs.
Patients and methods: Dogs presenting appendicular osteosarcoma
without detectable lung metastaseis at the time of diagnosis under-
went surgery consisting  of amputation or of limb  sparing tech-
niques  when  applicable.  Post-operatively,  dogs  received
doxorubicin alone in the first cycle, and in the following four cycles
they received a combination of doxorubicin and PSC 833. Accord-
ing to predictable pharmacokinetic interactions, doxorubicin dose
was reduced of 30%. Several blood samples were collected for the
determination of doxorubicin and PSC 833 levels. Pgp expression
was  monitored  on  tumor  tissue  samples  from  surgical  excision
prior  to  treatment  using  immuno-histochemistry  with  anti-Pgp
monoclonal antibodies. 
Results: All the dogs treated were tested for Pgp expression prior
to filing for treatment. Pgp was found to be expressed in 13/15
(87%) of the samples. At the time of doxorubicin administration,
adequate blood concentrations (i.e. 2.5 mM) of PSC 833, which
are needed to reverse MDR, were achieved at the dose of 7.5 mg/
kg/day. Dogs did not show clinical or laboratory findings of toxic-
ity. In order to maintain the same exposure and to control dose-
related  toxicity  of  doxorubicin, we  verified  that  similar  plasma
levels of doxorubicin were achieved after both the standard full
dose and with the reduced dose in animals given PSC 833. 
Discussion: Current treatment of canine osteosarcoma using sur-
gery and adjuvant therapy is not satisfactory. Combination therapy
with doxorubicin and PSC 833 allows a decrease in doxorubicin
dose  infusions  with  equivalent  therapeutic  exposure.  The  high
incidence of Pgp expression in tumor samples prior to treatment
confers to the study a rationale for downmodulation of MDR. Fur-
ther investigations are needed to evaluate concentrations of doxo-
rubicin  in the  tumor  tissues  and to  validate  the  efficacy of the
treatment in ongoing clinical trials.
104 P16INK4A Gene And Osteosarcoma
Benassi MS, Molendini L, Gamberi G, Merli M, Ragazzini P, 
Magagnoli G, Picci P
Laboratory of Cancer Research, Rizzoli Institute, 40100 Bologna, Italy
Introduction: The  p16INK4A  putative  tumor  suppressor  gene
expresses two different mRNA  transcripts, alpha and beta. The
alfa transcript p16INK4a, a cyclin D/cdk4 inhibitor, prevents inac-
tivation of the retinoblastoma protein (pRb). The beta transcript
p14ARF,  protects  p53  protein  by  binding  with  MDM2,  and
upregulates the p21 protein.
Aim: In order to define the role of the p16INK4A gene in human
osteosarcoma (OS), we studied gene status and expression of the
molecules involved in p16 regulatory system.
Materials  and  methods: Thirty-five  high-grade  formalin-fixed,
paraffin embedded and frozen OS samples were studied by immu-
nohistochemistry (IHC) and immunoblot. Exons 1 and 2, 5¢ CpG
island methylation of the p16INK4A  gene and semiquantitative
analysis of the CDK4 gene were performed by specific PCR. 
Results: IHC  analysis  revealed  an  increased  expression  of  p16
protein in 14/35 OS. p16 staining intensity ranged from moderate
to strong. Of these, six with pRb positive expression simultane-
ously showed cdk4 overexpression (6 x) and CDK4 gene amplifi-
cation  (8± 10  x).  No  deletions  or  mutations  were  found  in
p16INK4A gene, but nine p16-negative OS showed 5¢ CpG meth-
ylation. A weak to moderate expression of p14ARF protein was
detected in 15/35 OS; of these, 11 had active p53 and 10 immuno-
reacted to p21protein. 
Conclusions: These results suggest that two important cell cycle
regulatory pathways are involved in OS pathogenesis.70 CTOS  abstracts
Intramural Oxygen Status In Soft Tissue Sarcoma: 
Prognostic Value With Respect To Different Treatment 
Modalities
Peter Hohenberger, Mathias Schlafke, Birger Bida
Divison Of Surgery and Surgical Onocolgy, Charite, Humboldt 
University of Berlin, Germany
Purpose: Intramural oxygen partial pressure (pO2) was reported
to be predictive for the likelihood of distant metastases in human
soft tissue sarcoma if pO2 was < 10 mmHg (Brizel, Cancer Res
1996; 56:941). However, those  patients  were treated by 50 Gy
irradiation, and it is well known that oxygenation interferes with
the  efficacy  of  radiation  therapy.  We  were  interested  to  know
whether pO2 is also of predictive value in patients treated surgically
and represents an independent prognostic marker.
Methods: In 73 patients suffering from soft tissue sarcoma of
the  limb  or  trunk,  intratumoral  oxygen  partial  pressure  was
measured  polarographically.  We  used  an  O2-sensitive  fine
needle  probe  (KIMOC,  Eppendorf,  Germany;  n  =  41).  The
mean of pO2, range and proportion of the hypoxic tissue fraction
(< 5 mmHg) was evaluated and depicted in histogramas of 200
measurements per tumor. The tissue temperature was recorded
along the puncturing canal. Another 32 patients were analysed
by use of an intratumoral implant probe p(ti)O2 with a sensitive
surface of 7.1 mm2 (LICOX; Med. Systems Corp., Greenvale,
NY,  USA)  during  neoadjuvant  combined  modality  therapy.
Tumor vascularisation was divided into hyper-, iso-, hypo-, and
avascular pattern according to angiogram and compared with
the oxygenation status. DFS was measured by the Kaplan± Meier
method, and the log-rank technique was used to compare DFS
of different groups of patients. Spearman correlation coefficients
were calculated to examine the relationship of tumor oxygena-
tion and vascularity.
Results: The mean pO2 values were from 0.6 to 69 mmHg. G1
tumors showed a markedly higher pO2 (51.4 mmHg) in contrast
to G2 and G3 tumors with 32 mand 29 mmHg, respectively. The
proportion  of  hypoxic  fractions  was  significantly  lower  in  G1
tumors (6.3%) versus G2/3 tumors (15 and 18%, respectively; p
= 0.01) Liposarcomas showed the highest pO2 values and there
was no correlation to vascularity as determined by angiogram.
There were no significant differences in the proportion of patients
developing  distant  metastases  whether  their  primary  tumors
showed mean pO2 exceeding or being less than 10 mmHg. Meas-
urements of pO2 obtained during neoadjuvant treatment, how-
ever,  showed  considerable  differences  between  histological
subtypes but also within the same group.
Conclusions: Tumor pO2 is not a general marker of risk of distant
metastases in soft tissue sarcoma if patients are treated without radi-
otherapy. However, extreme differences between tumors of identical
type may severely interfere with drug uptake f.e. during neoadjuvant
treatment. Intratumoral pO2 might be very useful tool to control for
effects of systemic or regional drug treatment of sarcomas.
Acknowledgement: Part of this  work was supported by grant of
Deutsche Forschungsgemeinschaft SFB 273/C 13.
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010 Results Of A T10-derived Protocol Based On Pre-
operative High-dose Methotrexate With Individual Dose 
Adjustment In The Treatment Of Primitive Osteosarcoma
Duffaud F, Digue L, Volot F, Bouvier C, Curvale G, Poitout D, 
Favre R
Hôpital La Timone, Marseille 13385, France
From  January  1987  to  December  1997,  42  adolescents  and
adults with high-grade osteosarcoma were treated at La Timone
University Adults Hospital with a T10-derived protocol using
high-dose methotrexate (HDMTX) with individual dose adjust-
ment. The male/female  ratio was 3:1  and the  median age 24
years  (range,  14± 53  years).  Primary  tumor  sites  included
extremities  (90.4%),  axial  bones  (7.2%),  and head  and neck
(2.4%).  Seven  patients  (16.7%)  presented  with  initial  lung
metastases.  Pre-operative  chemotherapy  included  4-weekly
cycles of HDMTX with individual dose adjustment followed by
citrovorum factor rescue. HDMTX was administered in 8-hour
perfusion  to  achieve  a  serum  MTX  concentration  of  1.000
mmol/l (Cmax) at the end of the infusion. Definitive surgery was
performed 10± 14 days after the  last HDMTX cycle. Twenty-
nine patients (72.5%) had conservative surgery and 11 patients
(27.5%) underwent amputation. The histologic response to pre-
operative chemotherapy evaluated according to the method of
Huvos grading system was rated `good’ (‡  90% tumor necrosis)
in 11.2% of patients or `poor’ (< 90% tumor necrosis) in 88.8%
of patients. `Good’ responders received post-operative chemo-
therapy based on HDMTX, pirarubicin and BCD (Bleomycin-
Cyclophosphamide-Dactinomycin). whereas `poor’ responders
received a `salvage’ regimen including ifosfamide, pirarubicin,
cisplatin ± etoposide during 18 weeks. No toxic death occurred
and severe toxicities (WHO grade III/IV) due to chemotherapy
were moderate. Individual MTX dose adjustment according to
the patient’s pharmacokinetic profile was optimum (mean Cmax-
obtained  was  1001  ±  75.4  m mol/l).  Mean  delivered  dose  of
HDMTX was higher than that recommended by Rosen (13.1 g/
m2 versus 8± 12 g/m2). With a median follow-up of 55 months
(range, 11± 139 months), the 5- and 8-year overall survival (OS)
rates  were  65.7  and 61.3%  for  the  entire  group. For  the  35
patients with localized disease at diagnosis, the 5- and 8-year OS
rates were 75.8 and 70.4%. For the same group, event-free sur-
vival (EFS) rates were 64.6 and 55.5% at 5 and 8 years. Four-
teen patients  (33.3%) relapsed: eight  patients  developed lung
metastases, two developed a local recurrence and four presented
both. The difference in OS and EFS rates at 5 years between
`good’ and `poor’ responders was not significant. In multivariate
analysis, tumor size, dose intensity and pre-operative MTX dose
intensity  were  independent  prognostic  factors  for  OS  (p  =
0.0004, 0.04, 0.007). Our OS and EFS rates are similar to those
reported in recent studies despite the low rate of `good’ respond-
ers to pre-operative chemotherapy obtained. Our post-operative
`salvage’ chemotherapy regimen is effective for `poor’ respond-
ers  yielding  identical  EFS  and  OS  rates  as  those  of  `good’
responders. 
013 Preliminary Results Of A Phase 2 Trial Of Oral 
Piritrexim In Patmients With Malignant Fibrous 
Histiocytoma (Mfh)
Patel SR, Jenkins J, Hays C, Beech J, Burgess MA, Papadopoulos 
NE, Plager C, Pisters PWT, Feig BW, Hunt K, Pollock RE, 
Benjamin RS
The Sarcoma Center, University of Texas M.D. Anderson Cancer 
Center, 1515 Holcombe Blvd., Houston, TX 77030, USA
Piritrexim is a Epid-soluble antifol with a very high affinity for
dihydrofolate  reductase. It enters  the cell  by passive diffusion
and has been shown to inhibit growth of methotrexate-resistant
cells  in  vitro.  A  phase  1  trial  of  the  intravenous  preparation
revealed a response in a patient with MFH. We studied the oral
preparation in patients with metastatic MFH who had received
one prior chemotherapy regimen. Patients were required to have
histologic  confirmation,  measurable/evaluable  disease,  ECOG
PS £ 2 and reasonable organ function. Piritrexim was adminis-
tered at a starting dose of 25 Ing p.o. TID x 5 consecutive days
each week for 3 weeks followed by 1 week rest off treatment. A
total of 10 patients have been treated at our center and are eval-
uable  for  response  and toxicity.  The  median  age  is  55  years
(range, 29± 77 years). There were five males and five females, all
with ECOG PS = 1. All patients had one prior chemotherapyCTOS  abstracts 71
regimen, five patients had prior radiation and 10 patients had
prior surgery. Two patients have shown a radiographic response.
One patient with a primary tumor in the right thigh (and lung
metastases) had a 53% reduction in the measurement of the pri-
mary  tumor,  thus  qualifying  for  a  partial  response.  Another
patient with metastatic disease in the lungs had a 26% reduction
in the size of the lung nodule after 5 months of treatment. Unfor-
tunately, his treatment had to be discontinued since the sponsor
terminated  their  plans  for  further  development  of  the  drug.
Follow-up CT scan of the chest on this patient 6 weeks off treat-
ment prior to planned surgery reveals a near complete response
with only one tiny residual abnormality. A total of 26 cycles are
evaluable for toxicity. One patient each in one cycle each expe-
rienced grade 3 nausea, vomiting and fatigue. Overall, the treat-
ment  was  well  tolerated.  In  conclusion,  oral  piritrexim  does
seem  to  have  some  biologic  activity  in  patients  with  MFH.
Unfortunately, our trial has been terminated as per the sponsor’s
request, and therefore no more data will be available to truly
assess the activity of this drug.
014 Extraskeletal, Adult Ewing Family Of Tumors (Eft): 
Combined Treatment In 42 Patients
Casali PG, Bertulli R, Santoro A, Lombardi F, Spreafico C, Dileo 
P, Gandola L, Navarria P, Gronchi A, Quagliuolo V, Valente M, 
Brega Massone P, Mastore M, Rolfo CD, Rasponi A, Cataldo I, 
Pilotti S, Azzarelli A
Istituto Nazionale Tumori, Milan, Italy
Background: Only small series of `extraskeletal’ Ewing’s sarcoma
or pPNET are available, after first report in 1975. Both skeletal
and extraskeletal cases in adults are also rare.
Intervention: From 1988, over 10 years, 42 chemoradiotherapy-
naive patients in the adult age (range, 16± 58 years; median, 24
years) with diagnosis of extraskeletal Ewing’s sarcoma or pPNET
were  prospectively  treated  with:  primary  chemotherapy  (Ifosfa-
mide + Epirubicin  + Vincristine, x 4± 7); surgery, if  feasible, in
non-metastatic patients; radiotherapy + Cisplatin and Vincristine;
consolidation chemotherapy (Ifosfamide + Dacarbazine + Actino-
mycinD, or Etoposide + Cisplatin or Ifosfamide, or high-dose Ifos-
famide, x 2± 6).
Patient characteristics: Of 42 patients, 36 had only local disease:
31 had visible disease, five were NED at entry after diagnostic sur-
gery; tumor originated from thorax (12), limbs (11), paravertebral
region (7), pelvis (3), and head and neck (3). All ED patients are
evaluable for response to primary chemotherapy, save for one who
received  symptomatic  concurrent  chemo-radiotherapy.  Six
patients had evaluable metastatic disease (to lungs ± liver ± bone).
Tumor size was > 10 cm in 55% of isolated local lesions. Median
follow-up for all patients is 86 months.
Results: Response to chemotherapy was achieved in 72% of 36
evaluable patients. Among 30 patients with local disease, com-
plete responses were 30% (6/9 were pathologically detected). The
10-year  actuarial  RFS  was  46%  in patients  with  local  disease.
Patients with limb and head and neck lesions had a RFS of 70%,
versus 31% in patients with thoracic, paravertebral and pelvic dis-
ease. None of six patients with metastatic disease stayed disease-
free.
Conclusions: (1) In this series of adult patients with extraskeletal
EFT, long-term RFS was superimposible  to childhood series of
skeletal origin accrued in the same years, particularly if tumor size
is considered. (2) The complete response rate seems lower. This
might be relevant in mutuating treatments from protocols for skel-
etal disease. (3) A subgroup of patients with worse prognosis, due
to origin from thorax, paravertebral region, and pelvis, was identi-
fied in this series. This is worth confirming. If so, these high-risk
patients  would need, and certainly  metastatic  patients  do  need
other/new approaches. 
015 Aggressive Fibromatosis: A Conservative Approach To 
Inoperable Disease Based On Low-dose Chemotherapy 
With Methotrexate + Vinblastine
Azzarelli A, Gronchi A, Bertulli R, Casali PG, Lozza L, Baratti D, 
Pennacchioli E, Rasponi A, Dileo P, Rolfo CD, Pilotti S
Istituto Nazionale Tumori, Milan, Italy
Intervention: Over a 10-year span from 1989, 30 patients (pts)
with inoperable aggressive fibromatosis were conservatively treated
with chemotherapy alone, in the  framework of a pilot study on
Methotrexate + Vinblastine.
Patients: Thirty patients (median age, 27 years; M/F, 13/17),
with  primary  (20%)  or  recurrent  (80%)  inoperable  aggressive
fibromatosis  (arising  from  scapular  girdle  in  12  pts,  limbs  in
eight,  head  and  neck  in  three,  pelvis  in  three,  paravertebral
regions in two, chest wall in two), were treated conservatively, by
administering Methotrexate 30 mg/m2 + Vinblastine 6 mg/m2,
given every 7± 10 days for a median interval of 1 year (range, 4±
27 months). Only two pts underwent surgery, with a debulking
intent in both cases, followed by radiation therapy. Radiotherapy
was given to another two pts as well. All the other pts received
chemotherapy alone.
Results: Eighteen  patients  (60%)  showed  stable  disease  or
minor  tumor  shrinkage  with  symptom  relief.  Partial  response
was detected in 12 patients (40%). While no complete response
was observed, no patient had tumor progression during treat-
ment. After a median follow-up of 75 months, the 10-year actu-
arial  progression-free  interval  is  67%.  Toxicity  was  mild,
including neutropenia, increase in transaminases, paraestesias.
Subjective  intolerance  to  such  a  long-term  treatment  was  of
major concern: in 15 pts, the decision was shared to stop their
treatment after less than 40 courses. However, progression was
detected in four out of six pts who stopped after less than 20
courses.
Conclusions: A low-dose chemotherapy regimen like Methotrex-
ate + Vinblastine allowed us to conservatively manage aggressive
fibromatosis in two-thirds of pts with inoperable disease. Optimal
treatment length is left to be determined, although it seems that
some  threshold  for  effectiveness  does  exist.  Tolerability  might
increase with recently proposed similar regimens, like Methotrex-
ate + Vinorelbine. Low-dose chemotherapy stands amongst cur-
rently  available  choices  in  aggressive  fibromatosis,  and  may
constitute a reasonable option in the subset of pts with inoperable
disease.
016 Metastatic Angiosarcoma ±  Recent Treatment Results 
Harmon DC
Massachusetts General Hospital, Boston, MA 02114, USA
Metastatic angiosarcoma is often viewed as an unfavorable form
of sarcoma. We were surprised to find two long-term remissions
among  patients  treated  aggressively  as  well  as  a  string  of
responders to milder chemotherapy, so we reviewed the charts
of all  patients  evaluated at MGH in  the  past  8  years.  Of  20
patients seen in consultation for metastatic angiosarcoma, four
declined any therapy, primarily because of older age or compli-
cating medical illnesses.  Two patients were treated elsewhere
and follow-up is not available. The 14 remaining patients had
17 courses of treatment. There were 11 major responses, seven
that were complete or near-complete, with two possible cures.
One patient treated with carboplatinum/taxol for undifferenti-
ated  tumor  got  a  4-month  near-CR  before  dying  of  toxicity
shortly after a pathology review at MGH showed angiosarcoma.
Of 10 patients who received MAID chemotherapy (mesna, dox-
orubicin,  ifosfamide,  dacarbazine),  three  had  CRs  (complete
responses) including two continuous remissions of over 6 years.
One of these long-term survivors was treated with radiation to
his partially resected maxillary sinus primary and consolidated72 CTOS  abstracts
with  MAID  and  a  carboplatin/cyclophosphamide  stem  cell
transplant after resection of a lymph node metastasis. The other
survivor had two brain metastases resected at diagnosis, then
radiation to a hard-to-diagnose scalp primary, then MAID for
lymph  node metastases.  The  third  CR  lasted  only  4  months
after  MAID  alone,  but  another  patient  with  a  PR  (partial
response)  to MAID alone  at  5+  months  is  approaching CR.
Another patient, who got MAID followed by stem cell trans-
plant, relapsed and then got a 1-year near-CR to single-agent
vinorelbine, relapsed and got a second 1-year near-CR to vinor-
elbine. Thereafter, one patient, who had no response to MAID,
got a 5-month PR to vinorelbine. Three patients too old to get
MAID received vinorelbine alone instead, and one got a near-
CR  of  6+  months  and  two  had  PRs  of  13  and  7+  months.
Aggressive multi-agent, multi-modality treatment for those who
can tolerate it and milder single-agent vinorelbine for those who
cannot may be an appropriate policy for dealing with metastatic
angiosarcoma.
078 Expression Of Fas Ligand And Fas In Human Soft 
Tissue Sarcomas Before And After Hyperthermic Isolated 
Limb Perfusion With Tnfa  And Melphalan 
Komdeur R, Molenaar WM, de Jong S, Hoekstra HJ, Plaat BEC, 
Van den Berg E, Van der Graaf WTA
University Hospital Groningen, 9700 RB, The Netherlands
Introduction: Hyperthermic isolated limb perfusion with TNFa
and melphalan (HILP-TM) has improved the limb salvage rate for
primarily irresectable soft tissue sarcomas (STS) of the extremity
to > 75%. Apart from the effect of TNFa  on the tumor-associated
vasculature, it may also act as a cytotoxic agent either directly or
indirectly.  TNFa   can  upregulate the  expression  of  Fas  Ligand
(FasL) and Fas; FasL is a member of the TNF family and rapidly
induces  apoptosis  after binding to its  receptor Fas. TNFa  and
cytostatics may (partially) exert their anticancer effect via the Fas±
FasL pathway. 
Objectives: (1) To determine whether the expression of FasL and
Fas is changed after HILP-TM. (2) To evaluate the relationship
between FasL and Fas expression, tumor response and apoptotic
index.
Patients and  methods: Thirty-five  patients with a primarily irre-
sectable  extremity  STS underwent HILP with TNFa  (3± 4 mg)
and melphalan  (10± 13  mg/l  limb  volume). The  median  period
between HILP and resection of the tumor remnant was 60 days
(range, 12± 103  days). Tumor  samples  were  collected  from  the
diagnostic pre-HILP specimen and from the post-HILP resection
specimen. For assessment  of tumor response and immunohisto-
chemical analysis of FasL and Fas, see Tables 1 and 2. Using the
TUNEL method, the apoptotic index was quantified as the per-
centage of apoptotic tumor cells.
Results: Six  patients  had  CR  (17%),  leaving  no  viable  tumor
tissue  for  immunohistochemistry;  25  patients  revealed  a  PR
(71%); four patients had NC (11%). Before HILP, 15/33 (45%)
and 15/19 (79%) samples scored positive for FasL and Fas, respec-
tively (Figs. 1 and 3). After HILP, the samples for FasL and Fas
stained positively in 11/28 (39%) and 13/15 (87%), respectively
(Figs. 2 and 4). For evaluable paired samples taken before and
after HILP, no significant changes in FasL or Fas were seen. The
mean percentage of apoptotic cells increased from 0.91 to 2.09%
after HILP (p < 0.05). Statistical analysis revealed no correlation
between FasL/Fas  expression  and tumor response  or  apoptotic
index. 
Conclusions: No significant changes were found in FasL and Fas
expression after HILP-TM. FasL and Fas expression did not pre-
dict  the  tumor  response  to  HILP-TM  or  apoptosis.  However,
these results may be influenced by the protracted period between
HILP and tumor resection and absence of evaluable tumor tissue
after HILP-TM in patients with CR.
085 Influence Of Locally Advanced And Recurrent Disease 
On Survival Of Patients With Advanced Soft Tissue 
Sarcomas. A Retrospective Analysis Of The Eortc Soft 
Tissue And Bone Sarcoma Group (Stbsg) 
Reichardt P, Van Glabbeke MM, Mouridsen HT, Verweij J, 
Radford J, Rodenhuis S, Azzarelli A, Le Cesne A, Buesa J, Keizer 
HJ, van Oosterom A, Kirkpatrick AL, Nielsen OS
EORTC Soft Tissue and Bone Sarcoma Group and EORTC Data 
Center, Brussels, Belgium
To establish the influence of locally advanced, recurrent and met-
astatic disease on survival of patients with advanced soft tissue sar-
comas, a retrospective analysis using the database of the EORTC
STBSG was conducted. A total of 1622 patients treated in five dif-
ferent studies with anthracycline based chemotherapy as first-line
treatment of advanced soft tissue sarcomas were included in the
analysis.  Patients  were  grouped  into  five  categories:  locally
advanced, recurrent disease, metastatic disease, locally advanced
plus metastases, and recurrent disease plus metastases. Informa-
tion on age, sex, performance status, histology by pannel diagnosis,
grade, and time of recurrence or metastases since first diagnosis are
available on all patients.
Overall response rates in the five categories were 26, 32, 28, 24,
and 19%,  respectively,  which  was  significant  with  a  p  value of
0.016 (overall chi-square test).
The median overall survival in the five categories was 416, 345,
388, 275, and 303 days, respectively, which was significant with an
overall p value of 0.0001 (log-rank test). Univariate comparison of
patients with locally advanced disease and patients with recurrent
disease showed a significant difference with a p value of 0.0127.
Comparing patients with local recurrence alone with patients with
metastases ± local or recurrent disease did not reveal a statistically
significant difference (p = 0.8397). Patients with locally advanced
disease versus all other patients had a significantly superior survival
with a p value of 0.0001. In the multivariate analysis, using the
published model for risk factors (Van Glabbeke et al., J Clin Oncol
1999;  17:150± 157),  the  independent prognostic  value  of  three
additional variables was tested: presence of locally advanced dis-
ease, presence of recurrent disease, and presence of metastases. As
expected, age, grade, liver  involvement and performance  status
remained highly  significant.  Looking at the  new variables, only
presence of recurrent disease was an independently statistically sig-
nificant negative factor for survival with a p value of 0.0325.
Conclusions: Response rates are the lowest in patients with locally
advanced disease plus metastases and especially recurrent disease
plus metastases, probabely due to higher tumor burden. Presence
of recurrent disease represents an independent risk factor associ-
ated with inferior survival and should therefore be considered as a
stratification factor in trials where the principal end-point is sur-
vival.
086 Chemotherapy For Metastatic Chondrosarcoma Of 
Bone: Single Institution Experience In 14 Patients
Pink D, Tilgner J, Dörken B, Reichardt P
Department of Hematology, Oncology and Tumorimmunology, Robert-
Rössle-Klinik, Universitätsklinikum Charitù , Humboldt-University, 
13122 Berlin, Germany
Chondrosarcoma is a rare malignant tumor of cartilage producing
cells and the second most common primary neoplasia of bone after
osteosarcoma. The majority of patients  are between 30 and 60
years of age. The pelvic girdle is the predominant site of primary
disease. Most tumors are well differentiated and surgery is the only
established treatment option. High-grade chondrosarcomas, how-
ever,  tend  to  develop  distant  metastases  mainly  in  the  lungs.
Chemotherapy for metastatic disease has not been investigated to
any extent and published data do not exist beyond occasional case
reports.CTOS  abstracts 73
From 1993 to 1999, 14 patients with metastatic chondrosarcoma
of bone not amenable to surgical resection of metastases recieved
chemotherapy in our institution. The median age of the patients
(seven males and seven females) was 54 years (range, 31± 71 years).
Primary tumors were mainly located in the pelvis (five patients).
Other primary locations were equally distributed between thorax,
upper  and  lower  limb  (three  patients  each). Histology  showed
high-grade lesions in nine patients, low grade in two patients and
dedifferentiated  chondrosarcoma  in  three  patients.  Metastases
were predominantely located in the lungs (13 cases). One patient
presented with  liver  metastases  only. Additional locations were
bone,  skin,  lymph  nodes  and  brain  (one  case,  respectively).
Median time  interval from first  diagnosis to metastases  was 10
months (range, 0± 32 months).
Chemotherapy  consisted  of dose-intensive  epirubicin/ifosfamide
combination in eight patients, high-dose ifosfamide in one patient,
doxorubicin, ifosfamide, cisplatin ± methotrexat in four patients
and another anthracyclin-based combination in one patient. Six
patients recieved second-line chemotherapy with high-dose ifosfa-
mide (three patients) and cisplatin/gemcitabine  (three patients).
Three patients were treated with oral trofosfamide as maintenance
therapy.
Treatment  results  of  first-line  chemotherapy  were  a  partial
response in three patients, stable disease in five patients and pro-
gression  in  six  patients.  Response  duration  was  6,  6  and  12
months. Disease stabilisation lasted from 4 to 12 months. Median
overall survival from diagnosis of metastases was 20 months for PR
and SD patients (range, 6± 80+) and 10.5 months (range, 4± 34) for
patients with progressive disease.
Conclusions: Chemotherapy resulted in a response rate of 21%
and an overall progression arrest rate of 57%. Response to treat-
ment resulted in a doubling of the overall survival time from 10.5
to 20 months. Chemotherapy should be considered for patients
with metastatic chondrosarcoma with inoperable disease or as part
of a multimodality treatment regimen.
097 Osteosarcoma Over The Age Of 40
Grimer RJ
on behalf of the European Musculoskeletal Oncology Society. The Royal 
Orthopaedic Hospital Oncology Service, Bristol Road South, 
Birmingham B31 2AP, UK
Purpose: To ascertain whether patients over the age of 40 have a
different disease pattern and prognosis to younger patients with
osteosarcoma.
Background: Osteosarcoma is principally a disease of adolescents,
but 13% of all patients with osteosarcoma will be over the age of
40 and, to date, have been excluded from most national trials of
treatment of osteosarcoma. A collaborative study from EMSOS
has collected data on these patients.
Material: Data on 486 patients have been contributed from 13
centres. The ages ranged from 40 to 89 with a mean of 54; 275
were male and 211 female. The most common sites were femur
followed by pelvis and tibia, and 84 had a secondary osteosarcoma:
42 related to Paget’s disease and 42 secondary to radiation. Thirty
patients had `low grade’ osteosarcoma, the remainder having high
grade  tumours,  of  which  57  had  metastases  at  presentation.
Almost half the patients had chemotherapy. Surgery consisted of
amputation  in  118  and limb  salvage  surgery  in  252,  with  113
having endoprostheses and 15 having allografts. One hundred and
eighty-four were felt to have had adequate surgical margins and
102 had close or inadeqaute margins. Eighty-five patients had radi-
otherapy, of which 41 were palliative.
Results: The overall survival rates were 37% at 5 years falling to
27% at 10 years. The 5- and 10-year survival rates for stages 1,2
and 3 turnours were, respectively: 78 and 62%, 41 and 28%, 9 and
9%. Patients over the age of 60 and patients who did not have ade-
quate treatment, not surprisingly, fared worse, as did all patients
with  secondary  osteosarcoma.  The  median  survival  time  for
patients with Paget’s osteosarcoma was 7 months and that for radi-
ation sarcoma was 12 months. For patients with stage 2 tumoursn
the effect of age was such that the 5-year survival rates were 45%
for those younger than 60 and 28% for those over 60. There was
little  information about effectiveness of chemotherapy but there
was a trend for those with a good response to fare better than those
without. Local recurrence arose in 7% of those having amputations
and  22%  of  those  having  limb  salvage  surgery.  It  was  closely
related to margins of excision with 27% of those having inadequate
margins developing local recurrence compared to 12% of those
with adequate margins.
Conclusion: Osteosarcoma  over  the  age  of  40  requires  just  as
much care and multidisciplinary working as osteosarcoma in the
younger age group. Patients with secondary osteosarcoma have a
dismal outlook. Chemotherapy and effective surgery remain the
mainstay of treatment.
110 Feasibility Of Pre Or Post-operative Combined 
Chemotherapy And Radiation-therapy In Adult Soft Tissue 
Sarcomas Of Extremities
Frustaci S1, Buonadonna A1, Boz G1, Berretta M1, Rupolo M1, 
Bertola G1, Innocente R1, Gherlinzoni F2, De Paoli A1
1CRO-IRCCS, National Cancer Institute, Aviano, and 2Orthopedic 
DivISION, General Hospital, Gorizia
Adjuvant chemotherapy (CT) impacts favorably on DFS and OS.
Pre or  post-operative  radiation therapy  (pre-, post-op  RT)  and
wide excision allow limb preservation with local control success
comparable to radical (ablative) surgery. However, the long inter-
val between diagnosis and start of CT could be responsible for the
appearance of resistant cellular clones and possibly micro-metas-
tases. Therefore, the anticipation and combination of CT with RT
could be worthwhile in terms of prognosis. Based on this hypothe-
sis, we started a pilot study to evaluate the feasibility and toxicity
of this integration.
Methods: Eligibility:  high  grade  (grade  3± 4  Broder), polymor-
phous, sub-fascial spindle cell sarcomas of extremities and/or gir-
dles, size > 5 cm or any dimension if a relapse; age > 16 and < 65
years; PS < 2 ECOG; no previous CT or RT. Chemotherapy: Epi-
rubicin, 60 mg/m2, days 1± 2; Ifosfamide, 3 g/m2, days 1± 3, with
fractionated equivalent dose of Mesna; G-CSF, 300 mg/die s.c.
from day +9 to day +16. Treatment was given every 21 days. Radi-
ation therapy: Conventional treatment divided in two phases in the
pre-operative setting: 22 Gy/11 Fr between cycles 1 and 2 of CT;
22 Gy/11 Fr between cycles 2 and 3 of CT; and a third phase of 16
Gy/Fr between cycles 4 and in the post-operative setting.
Results: From September 1996, 14 patients have been enrolled,
seven as neo-adjuvant therapy and seven as adjuvant therapy. Tox-
icity: On 41 evaluable cycles of CT: leucopenia grade 3± 4, 51%;
thrombocytopenia grade 3± 4, 14%; anemia grade 3± 4, 9%; nonhe-
matological toxicity grade 3± 4, 32% (stomatitis  4%); cutaneous
(erithema  21%),  mucositis  (proctitis  7%).  All  seven  patients
treated  in  pre-op  setting  underwent  conservative  surgery;  one
patient had major complication (infected seroma). No complica-
tions were noted in post-op group.
Feasibility: The average median dose intensity of CT was 84%
(60± 100%). The RT was performed in foreseen doses and time
interval in 13 of 14 patients. In one patient, RT was delayed due
to  thrombocytopenia  (field  of  RT  included  great  vessels).  The
median time interval between biopsy and start of chemotherapy in
our adjuvant previous study was 92 days (range, 17± 288 days),
while in this experience it was 9 days (range, 5± 34 days).
Preliminary  Conclusions: Integration  of  CT  with  RT  allowed  a
preservation of dose intensity of 84% with a compliant toxic pro-
file. The accrual is ongoing in order to obtain sufficient data on
toxicity to define a new neo-adjuvant cooperative randomized trial. 74 CTOS  abstracts
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081b Strategy Of Treatment In Desmoid Tumors 
(Aggressive Fibromatosis In Children And Adults): To 
Avoid Absolutely Radiotherapy
Delepine N, Alkallaf S, Markowska R, Cornifie H, Belarbi L, 
Delepine G
Oncologic Paediatric Unit, Avicenne University Hospital, 125 Bd de 
Stalingrad, 93009 Bobigny Cedex, France
Desmoid tumor is a histologic benign tumor. Nevertheless, fre-
quent relapses are able to threaten life or conservation of limb. To
point out the best indications of treatment, we reviewed our cases.
From  1981  to  1998,  we  treated  50  patients  with  fibromatosis
(mean age, 28 years; range, 1± 70 years). Locations were inferior
limb (19), superior limb (17), axial (9), head and neck (5). Seven-
teen patients were seen at first hand, 33 with relapses. Treatment
was adapted to each patient, in function of age, history, and risks
of spontaneous evolution.
En bloc extratumoral resection was performed each time when
surgery did not expose to heavy functional sequellaes (22). The
other patients were treated by large resection, but never invalid-
ant. Fourteen patients received pre- or/and post-operative chem-
otherapy.  TEn  received  Interferon  cc,  and  nine  received
tamoxifen.
Results: Mean  follow-up  is  5  years  3  months.  Thirty-four
patients are in complete remission, nine in stable disease, six evo-
lutive disease, and one died with thoracic complications. Follow-
ing repeated surgery, functional sequellaes are numerous: eight
nerve  palsies,  eight  articular  stiffnesses.  Major  functional
sequellaes  came  from  surgery  with  radiotherapy.  In  one  case,
radiotherapy of a cervical lesion led to impossibility of surgery and
to death.
The analysis of our series leads to schematising the indications of
treatment.
1. If the desmoid tumor does not threaten life or limb, only surgery
is needed as large as possible, avoiding functional sequellaes.
2. When  tumoral  relapses  appear,  treatment  with  Tamoxifen
must be discussed.
3. When the tumor invades noble structures that could be hurt by
surgery and lead to dramatic sequellaes, pre-operative chemother-
apy is useful, in order to soften the tumor and to help surgery.
Conclusion: In this unforeseeable illness, backgrounds of indica-
tions are respective risks of spontaneous evolution and of treat-
ment. Besides surgery, needed fast all cases but often insufficient,
the value of interferon, tamoxifen and/or chemotherapy must be
considered.
The most important concept is the necessity to adapt a well-bal-
anced treatment avoiding sequellaes and particularly radiotherapy.
This last attitude leads to most heavy sequellaes and therapeutic
deadlocks.
081 Treatment Of Pelvic Ewing’s Sarcoma With 
Multidisciplinary Treatment
Delepine N1, Delepine G1, Delepine F2, Alkallaf S1, Cornille H1, 
Sokolov T3
1Oncologic Paediatric Unit, Avicenne University Hospital, 125 Bd de 
Stalingrad, 93009 Bobigny Cedex, France, and 2 Bone Tumor Center, 
Sofia, Bulgarie, and 3CHU de Rouen, Orthopaedic Department, 
France
Introduction: Despite  the  improved  survival  of  patients  with
Ewing’s sarcoma, pelvic location remains a bad prognostic factor.
This retrospective analysis tries to point out the reasons of such a
situation, and to evaluate the  impact  of modem comprehensive
approach on prognosis.
Material  and  methods: From  February  1977  to  June 1998,  53
patients have been treated by our group for Ewing’s sarcoma of
pelvic bones. Thirty-two were males, 21 females, aged 6± 35 years
(median, 16.3 years). At first screening, 15 patients had already
metastases and 38 presented with localised disease.
Treatment included chemotherapy for all patients according to the
current protocol at the time of presentation: four drugs (Vincris-
tine± Dactinomycin± Cyclophosphamide± Doxorubicin), five drugs
(Vincristine± Doxorubicin± Cyclophosphamide± Dactinomycine  +
ifosfamide) or six drugs association (Ifosfamide± Vincristine± Dox-
orubicin± Cyclophosphamide± Dactinomycine + Etoposide or Cis-
platinium).  Local  treatment  used  radiotherapy  alone  for  24
patients, surgery alone in 18 and a combination in 11.
All patients have been followed up every 3 months for 2 years,
every 6 months for 2 other years, and then yearly.
Results: With a median follow-up of 10 years, the 5-year actuarial
event free survival rate for all patients is 31%; 13% for primary
metastatic patients and 40% for patients seen with localised disease
(p < 0.001). In primary localised tumor, the major prognostic fac-
tors are the adequacy of surgical resection (p < 0.01) and the high
dose intensity of chemotherapy, particularly during the induction
(p < 0.05).
Patients treated by radiotherapy had a 44% risk of local recurrence,
17% life expectancy, and a 13 month median survival compared
with an 80% life expectancy and 80 month median survival for
patients after wide resection.
Conclusion: (1)  Primary  metastatic  patients  require  a  new
approach. (2) Early wide resection of the primary and adequate
dose intensity of a six-drug chemotherapy gives the best results in
pelvic Ewing’s despite large tumoral volume or even incomplete
response to pre-operative chemotherapy.
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024 Biological Characterisation Of Soft Tissue Sarcomas 
Nielsen MM1, Hansen O1, Starklint H2, Knoop A1, Rose C3
1Department of Oncology, Odense University Hospital, DK-5000 
Odense C, Denmark, 2Department of Pathology, Vejle Hospital, and 
3Department of Oncology, Lund University Hospital, Sweden
Introduction: In  an  effort  to  identify  better  prognostic  factors
concerning patients with soft tissue sarcomas (STS), the impor-
tance  of  specific  biological  characteristics  (changes  in  tumour
suppressor  genes,  oncogene  expression,  and  growth  rate)  has
been addressed in a number of prognostic studies. Unfortunately,
no consensus can be drawn from these studies, mainly due to lim-
ited number of studies and lack of proper methodology. There-
fore, we decided to study the two suppressor gene products, p53
and the pRb1, the oncogene product mdm2 Ð  all three involved
in the cell cycle control Ð  and the proliferation marker MIB1.
Aim: To analyse the prognostic significance of the clinical factors
and the markers p53, pRb1, mdm2 and MIB1 in patients with
STS.
Material: All patients with primary STS of the extremities, trunc,
retroperitoneum, and head and neck were recruited from a prede-
fined  geographical  area  during  the  period  1  January  1970± 31
December 1994. A total of 383 patients were included, of these 28
patients had metastatic disease, leaving 355 patients available for
the survival analysis with a median follow-up of 13 years and 9
months; 154 patients had either a relapse or a progression of the
tumour. Two hundred and sixteen patients died.
Methods: The clinical data was retrospectively collected by review
of medical files. The expression of p53, pRb1, mdm2, and MIB1
in the tumours were detected using immuno-histochemistry. The
survival analyses were performed using both univariate and multi-
variate methods with overall survival as end-point.
Results: We were able to create a prognostic model based on age
at diagnosis, large size, high grade, deep sited tumours, retroperito-
neal  location  that  could  identify  four  significantly  different  risk
groups of patients with localised STS, with four different survival
probabilities. The immunohistochemical markers MIB1 and pRb1CTOS  abstracts 75
had independent prognostic value when adjusted for the effect of
the  clinical  prognosticator, while  p53  and mdm2  did not. High
expression of MIB1 and pRb1 was correlated to poor prognosis.
However, none of the indexes including the immunohistochemical
markers predicted patient outcome better than the index including
only clinical data. 
Conclusion: The already known clinical prognosticators are still
considered to be the best variables in predicting overall survival of
patients with STS.
017 Good Pathological Response To Neoadjuvant 
Chemotherapy In Patients Showing Clinical Or 
Radiological Progression Of Disease ±  3 Clincal Cases
Plummer R, Lucraft H, Murray S, Malcolm A, Dildey P, Grainger 
A, Baudouin C, Verrill M
North of England Bone and Soft tissue Tumour Service, Freeman 
Hospital, Newcastle Upon Tyne, NE7 7DN, UK
Neoadjuvant chemotherapy has an established role in the treat-
ment  of head and neck carcinoma, breast cancer and osteosar-
coma. As well as an increase in the limb/breast conservation rate,
pathological response to neoadjuvant chemotherapy is  an inde-
pendent  prognostic  marker  in  osteosarcoma1  and  breast  carci-
noma.2 We report three cases of soft tissue sarcoma treated with
neoadjuvant chemotherapy. 
Case 1: A 50-year-old man presented with malignant fibrous his-
tiocytoma of the right thigh. After two cycles of neoadjuvant dox-
orubicin (75 mg/m2), there was clinical and radiological disease
progression, and he proceeded to immediate surgery. There was
90% tumour cell necrosis in the operative tumour specimen. Fur-
ther doxorubicin was given as adjuvant therapy.
Case 2: A 47-year-old woman presented with a high grade liposa-
rcoma of the right thigh. She received one cycle of neoadjuvant
doxorubicin (75 mg/m2). There was clinical progression of the pri-
mary tumour, and she  went forward to surgery immediately. A
high degree of tumour necrosis was seen in the pathological speci-
men.
Case  3: A  44-year-old  man  presented  with  a  right  thigh  high
grade malignant fibrous histiocytoma. He received three cycles of
ifosfamide  (5 g/m2)/adriamycin (50  mg/m2). MRI scan showed
enlargement  of the  tumour, with  central necrosis. The surgical
pathological  specimen  showed  evidence  of  chemotherapeutic
damage with scattered tumour cells in a background of reactive
collagen and extensive haemorrhage.
Each of these patients received pre-operative chemotherapy with
the aim of enabling limb conservation. In each case, there was
clinical  and/or  radiological  disease  progression  within  three
cycles of chemotherapy, and patients had early surgery. Histo-
logic examination of each operative specimen revealed extensive
tumour cell necrosis.
These favourable pathological responses were at odds with the clin-
ical  and radiological  evidence of  progressive  disease  by  standard
response  criteria.  Two of  these  patients  were  in  clinical  trials  of
chemotherapy and were recorded to have progressive disease when
there was clearly an antitumour effect. In cases of early progression
of a primary soft tissue sarcoma on chemotherapy, we recommend
that investigators should consider either biopsy or dynamic gadolin-
ium enhanced MRI scanning to detect pathological responses, which
are unexpected on clinical and conventional radiological assessment
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018 Malignant Fibrous Histiocytoma Arising Within A 
Solitary Osteochondroma 
Carluke I, A Grainger, Murray SA, Malcolm AJ
The North of England Bone and Soft Tissue Tumour Service, The 
Freeman Hospital, Newcastle upon Tyne NE7 7DN, UK
Malignant change of exostoses in patients who have multiple oste-
ochondromas is well recognised. Chondrosarcoma is most com-
monly seen, although osteosarcoma and other soft tissue sarcomas
have  been  described.  Malignant  fibrous  histiocytoma  arising
within an exostosis in a patient who had multiple osteochondromas
has been reported in the literature. We report an almost unique
case of MFH occuring within a solitary osteochondroma arising
from the proximal tibia of a 21-year-old male.
This was treated by en bloc excision, with allografting of the result-
ant defect.  Pathological  examination  and immunohistochemical
staining  showed  a  focus  of  hypercellular  spindle  cell  tumour
embedded in a collagenous matrix, with marked positivity to SMA,
within co-existent osteochondroma and bursa.
019 Sacrococcygeal Soft Tissue Ependymoma
Carluke I, Murray SA, Malcolm AJ
The North of England Bone and Soft Tissue Tumour Service, The 
Freeman Hospital, Newcastle upon Tyne NE7 7DN, UK
Ependymomas are glial derived tumours arising mostly intracrani-
ally or within the spinal cord, cauda equina or filum terminale.
Extra spinal  ependymomas do occur, although rarely, and have
been described arising within the pelvis and mediastinum, as well
as the sacrococcygeal region. Sacrococcygeal ependymomas repre-
sent about 5% of all primary ependymomas. Metastatic behaviour
is not predictable either clinically or histologically, although both
recurrence and metastasis occur more frequently than in the intra-
dural variety. Recommended treatment is wide excision.
We  describe  four  cases  of  sacrococcygeal ependymoma treated
with  wide  excision.  Histological  appearances  were  typical  with
immunocytochemical  staining  for  glial  fibrillary  acidic  protein
(GFAP) strongly positive.
020 Tissue Microarray Blocks: An Efficient Method For 
Screening Soft Tissue And Bony Sarcomas 
Thomas D, Baker L, Giordano T
University of Michigan Comprehensive Cancer Center, Ann Arbor, MI 
48109, USA
As the human genome project reaches conclusion, the number of
oncology-related genes and corresponding antibodies and nucleic
add probes will continue to proliferate. Evaluation of these new
markers using conventional tissue-based assays will require signif-
icant resources. The recently developed tissue  microarray tech-
nique allows for the efficient screening of large numbers of tumor
specimens with multiple probes. To date, no one has applied this
technique to the screening of soft tissue and bony sarcomas. Basi-
cally, the technique involves the cutting of several core tissue biop-
sies (diameter, 0.6 mm; height, 3± 4 mm) taken from representative
`donor’ paraffin embedded tumor blocks and precisely arrayed into
a `recipient’ paraffin block. Several tissue microarray blocks con-
taining multiple  cores from soft tissue and bony sarcomas were
produced containing over 100 sarcoma specimens. 
Sections cut from these arrays allow parallel detection of DNA or
RNA by nonradioactive in situ hybridization and protein by immu-
nohistochemistry. At least 200 consecutive 5 m m thick sections can
be cut from each tumor block. This allows consecutive analysis of
a large number of molecular markers.76 CTOS  abstracts
In order to validate this approach of using small representative
cores, the original donor blocks were also examined retrospectively
for the expression of oncology-related markers such as telomerase
reverse transcriptase (by in situ hybridization and immunohisto-
chemistry),  p53,  Mb-l,  ErbB2  (by  immunohistochemistry)  and
apoptosis (by TUNEL assay), and were shown to correlate well
with the results obtained with the tissue microarray blocks.
This technique represents an effective means of screening large
numbers of specimens with multiple probes and antibodies.
Acknowledgements: Kindly  supported  by  the  Walther  Cancer
Institute.
021 Myofibroblast Modulation In Desmoid Tumors
Baldini N, Barbanti-Brodano G, Zini N, Bertoni F, Giunti A
Istituti Ortopedici Rizzoli, 40136 Bologna, Italy
Myofibroblasts play a role in several conditions, including fibroma-
toses. During granulation tissue contraction, a high proportion of
myofibroblasts develop the  expression  of a-smooth  muscle actin.
When  contraction  stops,  myofibroblasts  containing  a-smooth
muscle actin disappear, and the scar becomes less cellular and com-
posed of typical fibroblasts. Similarly, during the development of
fibrocontractive diseases, fibroblasts acquire contractile features and
produce the centripetal force leading to retraction. For this purpose,
myofibroblasts develop connections to the surrounding extracellular
matrix. The mechanisms leading to the modulation of myofibrob-
lasts remain to be explored. We evaluated a retrospective series of 24
cases of desmoid tumors in order to analyze the expression of a-
smooth muscle actin and of CD68 antigen, which identifies reactive
mononuclear cells, on paraffin-embedded tissue sections by immu-
nohistochemistry.  A positive  staining  for  a-smooth  muscle  actin,
identifying myofibroblasts among the spindle cell component of the
lesion, was found in 11/24 cases (46%), whereas the occurrence of
CD68-positive  mononuclear  cells  was  detected  in  19/24  cases
(79%). Ultrastructurally, CD68-positive cells were found to corre-
spond to two cell types, i.e. macrophages and mast cells. It may be
hypothesized that these elements modulate myofibroblasts through
a paracrine mechanism. It is well known that mast cell proliferation
is accompanied by fibrotic changes, possibly through the release of
heparin, a molecule that  is capable to increase a-smooth  muscle
actin expression.  Moreover, macrophages  release  growth factors,
such as GM-CSF, that are implicated in the modulation of myofi-
broblasts. It is conceivable that therapeutic agents that interfere with
the functional status of spindle cells may be used as a tool for the
inhibition of growth of desmoid tumors, as previously demonstrated
in other fibrocontractive diseases.
023 Her2/neu Expression In Osteosarcomas And Other 
Bony Sarcomas
Thomas D, Giordano T, Sanders D, Arrowsmith P, Baker L
University of Michigan Comprehensive Cancer Center, Ann Arbor, M1 
48109, USA
Osteosarcoma and skeletal Ewing’s sarcoma are the most common
primary bone tumors in the pediatric age group. Both are aggressive
malignancies with a tendency for early and rapid pulmonary metasta-
sis. Advances in surgical oncology and adjuvant pre-operative chem-
otherapy have increased the overall 5-year survival to approximately
70%.  However, although this  represents  the  majority  of  patients,
those who relapse rarely respond to salvage therapy. Clearly, there is
a  need  for  alternate  adjuvant  chemotherapy  for  these  patients.
Recently, there have been conflicting reports about the expression of
c-erb B2 proto-oncogene product in osteosarcomas and Ewing’s sar-
coma. The c-erb B2 proto-oncogene encodes the human epidermal
growth factor receptor 2 (Her2/Neu); a membrane bound tyrosine
kinase, which when over expressed in rodent fibroblasts causes malig-
nant transformation. Several groups of authors have claimed that a
high percentage of osteosarcomas express Her2/Neu and that either
this portends a poor prognosis or was associated with a decreased risk
of relapse. Archival cases of osteosarcomas (n = 38, including pre-
and post-treatment samples; age range, 6± 27 years) and Ewing’s sar-
coma (n = 11; age range, 16 months± 22 years) were retrieved and the
diagnosis confirmed. Specimens were assessed for Her2/Neu onco-
gene expression by standard immunohistochernical techniques. Sev-
eral cases demonstrated cytoplasmic staining, but none showed the
membranous staining characteristic of over-expression by breast car-
cinomas.  To  validate  the  negative  immunostains,  reverse  tran-
scriptase polymerase chain reaction of RNA extracted from archival
material  also failed to demonstrate the presence of mRNA  for c-
ErbB2, even though appropriate internal controls were positive. Our
results demonstrate that ErbB2 expression in either osteosarcomas
and Ewing’s sarcoma is not common and thus not likely to be an
important prognostic factor, and further that therapy with recom-
binant  humanized anti-HER2  monoclonal antibodies may not be
appropriate therapy for these patients.
Acknowledgements: Kindly  supported  by  the  Walther  Cancer
Institute.
074 Matrix Gene Expression And Cellular Phenotyping In 
Chondroid Chordoma Reveals Focal Maturation Of 
Neoplastic Chordoid Cells Mimicking Histogenesis Of 
Developing Nucleus Pulposus
Gottschalk D, Fehn M, Patt S, Saeger W, Kirchner T, Aigner T
Institute of Pathology, FAU Erlangen-Nürnberg, Germany
Introduction: Beside  conventional  chordoma  (cchor),  so-called
chondroid chordoma (chon chor) is described as a specific sub-
type. However, since its first description, conflicting results have
been reported on the existence of this cartilaginous tumor variant,
and several studies suggested chon chor being in fact low-grade
chondrosarcomas. In the present study, we used molecularbiolog-
ical in situ localization techniques for mRNAs of different collagen
types and the proteins as marker gene products, indicating differ-
ent phenotypic or developmental stages of chondrocytes, to eluci-
date further the origin and histogenesis  of the chondroid tumor
compartment in chon chor.
Materials and methods: Seven specimen of chon chor and 14 of
cchor were routinely fixed immediately after removal and embed-
ded in paraffin. Additionally, four samples of fetal vertebral col-
umns with remnants of chorda dorsalis (cd) tissue were included.
Histomorphological  evaluation was  performed  with  HE,  GAGs
were visualized by toluidine blue, and the presence of collagens by
Masson± Goldner’s staining.
Immunohistochemistry: Deparaffinized  sections  were  enzymati-
cally pretreated and stained with primary antibodies against colla-
gen  type  I,  II,  III,  VI  and  X,  aggrecan  proteoglycan,  S-100,
vimentin, EMA, CK-19  and Pan-CK. In situ hybridization was
performed as described by our group elsewhere.
Results: We could clearly demonstrate the multifocal deposition
of  the  cartilage-specific  type II  collagen  protein  and mRNA  in
cchor and chon chor, and thus clearly demonstrate the chondro-
genic potential of all chor irrespective the appearance of ouvert car-
tilage formation. Aggrecan expression was present throughout all
chor and, thus, a very characteristic gene product of these neo-
plasms also in the absence of chondroid differentiation. There was
a clear biochemical resemblance of cchor and the chordoid tumor
compartment of chon chor to the cd. Respectively, the chondroid
tumor compartment of chon chor resembled the adult, matured
nucleus pulposus (np). Noteworthy, no type X collagen could be
demonstrated in any of our chor, explaining the lack of chondroid
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type X-collagen could be used as a marker gene product to differ-
entiate between cartilaginous entities.
Discussion: In the present study, we investigated the biochemical
composition of the extracellular tumor matrix as well as the matrix
gene expression pattern in conventional and chondroid chordomas
in comparison with cell and tissue morphology as well as the cyto-
protein profile of the neoplastic cells. Herein, the analysis of the
matrix gene expression pattern allows one to identify and charac-
terize cartilaginous cell differentiation within the neoplasms, which
is  not unequivocally possible  by  histomorphological, ultrastruc-
tural or cytoprotein analysis. Using this approach, we could iden-
tify  and  trace  the  cellular  differentiation  pattern  in  chordomas
including the chondroid variants and could identify chondroid dif-
ferentiation sui generis as a characteristic facette of a subset of chor-
domas, here mimicking the histogenesis of the developing np.
093 Host Immune Response In Osteosarcoma
Casanova J, Reith JD, Berrey BH, Enneking WF, Scarborough MT
University of Florida, Gainesville, FL 32610, USA
Background: Few previous studies document the role and signifi-
cance of the host immune response in high-grade osteosarcoma.
This retrospective analysis examines the nature of the inflamma-
tory response found in and around osteosarcomas and the relation-
ship to disease free and overall survival.
Patients  and  methods: All patients  had stage  IIB osteosarcomas
about the knee (distal femur, proximal tibia). Group A included 20
patients who were biopsied and treated with neoadjuvant chemo-
therapy and surgical resection. Group B included 73 patients who
underwent surgical resection of their tumor and were treated with
post-operative  chemotherapy.  All  histologic  slides  examined
included tumor and the adjacent reactive zone. Each case was eval-
uated with  antibodies to CD3, CD4, CD8, CD20,  and TIA-1
using standard avidin± biotin  complex  methods. The number of
CD3-, CD8-, and CD20-positive inflammatory cells was further
quantified by histomorphometry.
Results:
Conclusions: An  increased  number  of  inflammatory  reaction
around osteosarcomas appears to be related to better survival, par-
ticularly when patients are given neoadjuvant chemotherapy. Pres-
ence of high numbers of T-cell tumor infiltrating lymphocytes (CD-
3, CD4-, CD8-positive cells) correlates with improved survival. B
cells  and natural killer  cells  (CD20- and TIA-1-positive,  respec-
tively) appear to play a less significant role in the immune response.
094 Molecular Predictors Of Outcome In Patients With 
Osteosarcoma
Reith JD, Casanova J, Berrey BH, Enneking WF, Scarborough MT
University of Florida, Gainesville, FL 32610, USA
Background: A variety of molecular markers related to survival,
including bcl-2, p53, p-glycoprotein, CD95 (Fas), CD95-ligand
(Fas-L), CD44,  and CD44v, have been studied in a variety of
human neoplasms, particularly carcinomas. Their significance in
patients with  osteosarcoma is largely unknown. The purpose of
this  archival  study  was  to  determine  if  there  is  a  correlation
between expression of these factors and disease free and overall
survival for patients with osteosarcoma.
Patients and methods: All patients had stage IIB osteosarcomas
originating  around  the  knee  (distal  femur,  proximal  tibia).
Group A included 20 patients who underwent biopsy and were
treated with neoadjuvant chemotherapy and surgical resection.
Group B included 73 patients who underwent primary surgical
resection of their tumor followed by post-operative chemother-
apy. Tumors were evaluated with antibodies to bcl-2, p53, Fas,
Fas-L,  CD44,  CD44v6,  and  p-glycoprotein  using  standard
avidin± biotin complex methods. Expression of the various anti-
gens  was  compared  with  disease-free  and  overall  survival,
accounting for percent necrosis (Group A) and margin status
(Groups A & B).
Results:
Conclusions: CD95  appears  to  have  a  `protective’  function  in
patients with osteosarcoma, probably by allowing tumor cells to
proceed  through  apoptosis  pathways  to  cell  death.  Although
CD44v6, a vascular adhesion molecule, was identified in only 14%
of the total cases, its expression correlated with subsequent devel-
opment of metastases and death (11 of 13 patients developed pul-
monary metastases, 10 dying of disease). Although p-glycoprotein
did  not  reach  statistical  significance,  there  was  a  trend  toward
death from disease in patients expressing it.
103 A Case Of Gastro Intestinal Sarcoma Tumor (Gist) 
Revealed By A Mediterranean Kaposi’s Sarcoma In An Hiv-
negative Patient: Casual Association Or Not?
Vincent Baty1, Isabelle Ray-Coquard1, Eric Fontaumard1, 
Dominique Ranchere-Vince2, David Tavan1, Jean-Yves Blay2
1Clinique Eugene Andre, and 2Centre Leon Berard, lyon, France
Mediterranean  Kaposi’s  sarcoma  (KS)  typically  runs  a  chronic
course  in  elderly  patients  and may  be  associated  with  secondary
malignancies. HHV-8 has been well documented to be associated
with all forms of KS. Gastrointestinal stromal tumors (GIST) are a
recently described entity whose etiology remains unknown. The pos-
sible role of human herpes-virus 8 (HHV-8) in this disease has not
been reported. We hereafter report the first case of an association of
a colonic GIST with KS in an HIV-negative patient. A 72-year-old
Spanish woman was admitted with a few months history of flat skin
lesions and nodules on her left knee. The histopathological study of
skin  biopsies  demonstrated  Cutaneous  Kaposi’s  sarcoma  (CKS).
Endoscopic explorations of the gastrointestinal tract were performed
as a standard staging procedure and revealed a stenotic tumor on the
transverse colon. The histopathological and immunochemistry stud-
ies of colonic tumor enabled identification of a GIST. A segmental
surgical resection was subsequently performed. The tumor size was 4
x 1.5 x 1.5 cm3. The association of Kaposi’s sarcoma and smooth
muscle tumors of the gastrointestinal tract is extremely rare since only
one case has been reported in an HIV-positive patient. Infection with
Antibody Total Group A Group B p value
CD3 82/93 (88%)  20/20 
(100%)






CD4 74/93 (80%) 17/20 (85%) 57/73 (78%) < 0.01
CD8 75/93 (81%) 18/20 (90%) 57/73 (78%) < 0.002
CD20 49/93 (53%) 10/20 (50%) 39/73 (53%) Not 
significant
TIA-1 30/93 (32%) 9/20 
(45%)




positive Group A Group B p value
bcl-2 0/93 0/20 0/73 Not 
significant
p53 17/93 (18%) 6/20 (30%) 13/73 (15%) Not 
significant
CD95 9/93 (10%) 1/20 
(5%)
8/73 (11%) < 0.05
CD95-L 52/93 (56%)16/20 (80%)36/73 (49%) Not 
significant
CD44 28/93 (30%)11/20 (55%)17/73 (23%) Not 
significant
CD44v6 13/93 (14%) 6/20 (30%) 7/73 (10%) < 0.03
p-Glycoprotein 46/93 (49%) 8/20 (40%) 38/73 (52%) 0.1078 CTOS  abstracts
HHV-8 is identified in more than 95% of KS and has been demon-
strated in other skin cancer in immunosuppressed patients, and for
angiosarcoma in  a  HIV-negative  patient.  Conversely, latent  EBV
infection has been demonstrated in low-grade leiomyosarcoma (LS)
in HIV-positive patients but neither in adjacent Kaposi s sarcoma
lesions nor in LS occuring in immunocompetent hosts. Thus, our
case is remarkable since the association of LS and CKS has not been
reported previously in a non-HIV patient, and suggests a possible
association between HHV-8 infection and GIST. The presence of
Epstein± Barr virus and HHV-8 DNA sequences is investigated on
both CKS and GIST tissue specimens, and the results will be availa-
ble for presentation at CTOS. 
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009 Hypoxia In Human Soft Tissue Sarcomas: Adverse 
Impact On Survival And No Association With P53 
Mutations 
Nordsmark M1,2, Alsner J1, Keller J3, Nielsen OS2, Jensen OM4, 
OvergaardJ1
1Department of Experimental Clinical Oncology, 2Department of 
Oncology, 3Department of Orthopaedic Surgery and 4Department of 
Pathology, Danish Cancer Society, Aarhus University Hospital. 
Nörrebrogade 44, bldg 5, DK-8000 Aarhus C, Denmark
Pre-clinical studies have suggested that cells with mutations in the
tumour suppressor gene, p53 have a reduced apoptotic potential
under hypoxic conditions and that this may lead to progression of
neoplastic  cells  into a  more  malignant  phenotype. The  present
study correlated tumour oxygenation and p53 status in human soft
tissue  sarcomas  (STS)  and  compared  oxygenation  status  with
treatment outcome after 5 years follow-up. Pretreatment tumour
oxygenation measurements  were performed in 33  patients  with
STS  using  polarographic  needle  electrodes  (Eppendorf,  Ger-
many), and status of the p53 gene was determined in 32 of those
by PCR using DNA extracted from paraffin-embedded (n = 2) sec-
tions or frozen biopsies (n = 30). Overall median of the tumour
median  pO2  was  15  mmHg  (range,  1± 58  mmHg).  Only  six
tumours had p53 mutations and no association was found between
mutant p53 and hypoxia. Twenty-eight cases could be evaluated
by  actuarial  survival  estimates.  At  a  median  follow-up  of  74
months, 12 patients had died. When stratifying into well-oxygen-
ated and hypoxic tumours by overall median pO2, patients with
hypoxic tumours had a poorer disease specific survival probability
(log-rank, p = 0.05) and a poorer overall survival (log-rank, p =
0.01) at 5 years. In conclusion, we demonstrated that hypoxia was
a  marker  for  metastatic  disease  and  poorer  overall  survival  in
human STS. Moreover, tumour oxygenation and p53 status were
not associated.
Acknowledgements: Supported by grant form the Danish Cancer
Society.
101 The Functional And Local Results Of Limb Sparing 
Procedures In Upper Girdle Neoplasms Treatment
Dardzinski R, Ruka W, Koziol A, Rutkowski P Maria
Sklodowska± Curie Memorial Cancer center, Warshaw, Poland
Thirty-one patients (15 females and 16 males) were operated on in
Maria Sklodowska-Curie Memorial Cancer Centre from 1980 to
1999  (altogether  33  operations  were  performed). Mean  age  at
operation  was  37.0  years  (range, 13± 68  years). Fifteen  tumors
involved the scapula, while in 16 cases neoplasms were located in
proximal humerus.
In three cases, soft tissue sarcoma was diagnosed, and all other
cases were primary bone tumours. All patients with osteosarcoma
received both pre- and post-operative chemotherapy. In cases of
soft tissue  sarcomas, neoadjuvant chemotherapy was also intro-
duced. The follow-up periods of patients ranged from 6 to 236
months (mean, 42 months).
All  surgical  procedures  were  classified  according to  the  system
elaborated by Malawer. There were six operations of the V1 type
and 11 resections of the V type. Less extensive procedures were
performed in 16 patients Ð  three, seven and six operations in types
I, II, and III, respectively. Only in one case was internal prosthesis
inserted;  all  other  patients  were  operated  without  bone  length
reconstruction. External orthopaedic devices were used instead. 
The functional results were assessed according to the MSTS eval-
uation system including the analysis of six factors. The patient’s
occupation and recreational abilities were particularly emphasized.
Simplified, a three-factor evaluation scale was also introduced and
compared with the MSTS system. Analysis of local recurrence as
the main drawback of limb sparing surgery was performed. At the
moment, 22 patients are alive free of disease. Out of nine patients
who died, four deceased with symptoms of local recurrence. In two
cases, local recurrence was accompanied or preceeded by systemic
dissemination. One patient is free of disease 84 months after reop-
eration of his recurrence. Together, local recurrence was observed
in five out 31 patients (18.5). No evident correlation between local
recurrence and the extent of the free margin was found. All failures
concerned advanced cases Ð  II B according to the TNM staging
system. 
Non-oncological complications were infrequent (6/31). None of
them resulted in permanent disability. Only one temporary palsy of
the radical nerve was observed. 
The  mean  functional  score  in  accordance  with  MSTS  rating
system was 72.6% (range, 50± 90%). This outcome corresponds to
the data published by the others. The lack of prosthetic reconstruc-
tion resulted in inferior hand positioning, but due to the applica-
tion  of  external  devices,  does  not  seem  to  effect  significantly
patients’ ability.
102 Lymphopenia (Lyp) As An Independent Prognostic 
Factor For Survival In Advanced Soft Tissue Sarcomas As 
Well As In Lymphomas, And Metastatic Breast And Renal 
Carcinoma
Blgy J, Ray-Coquard I, van Glabbeke M, Nù grier S, Saghatchian 
M, Verweij J, Sebban C, Escudler B, Guastalla J-P, Judson I, 
Nielsen OS, Biron P, Le Cesne A, Centre L. Bù rard, H.Ed. 
Herriot, Lyon, I.G. Roussy, Villejulf, France, and EORTC 
STSSG
Bruxelles, Belgium
Lyp is frequently observed in patients (pts) with advanced cancers
and is a powerful predictor of the toxicity of chemotherapy (J Clin
Oncol 14:636; J Clin Oncol 17:2W; Blood 92:405), Here, we ana-
lysed the prognostic value of lyp on survival after chemotherapy
or immunotherapy in four distinct tumor types. The prognostic
value of lyp was tested in databases of previously reported multi-
centric prospective studies of systemic therapies in untreated pts:
(1) of CYVADIC in advanced soft tissue sarcomas (ASTS) (n =
191) (Cancer 1984; 53:1825); (2) of CEF chemotherapy in met-
astatic breast  carcinoma (MBC) (n = 280) (Bull  Cancer 1990;
77:941); (3) of IL-2 ± IFNa  in metastatic renal cell carcinoma
(MPCC) (n = 481) (N Engl J Med 1998; 338:1272); and in a pro-
spective monocentric serie of agressive nonHodgkin’s lymphomas
(NHL)  treated  in  consecutive  phase  III  studies  in  the  CLB
between 1987 and 1993 (n = 322). The incidence of lyp < 1000/
m l was remarkably constant among these four series, i.e. 240/a,
24%, 20% and 27%, respectively. Lymphopenia was significantly
more frequent (p < 0.05) in pts with performance status (PS) > l
in ASTS, MBC, and MRCC series, and in pts aged > 60 (p <
0.05) with NHL. Lyp < 1000/m l was not significantly correlated
to response to chemotherapy of inummotherapy in multivariateCTOS  abstracts 79
analysis using logistic regression in any series tested. In contrast,
lyp < 1000/m l significantly correlated to overall survival in univar-
iate analysis (median survival (MS)): in ASTS, 6 months versus
12  months  (p  <  0.001);  in  MBC,  MS  10  months  versus  14
months (p < 0.01); in NHL, MS 11 months versus 94 months (p
< 0.001)’ and in MPCC (lyp < 1500/m l), MS 11 months versus
18 months (p = 0.01). In multivariate analysis using Cox model,
lyp was found to be an independent prognostic factor for overall
survival in ASTS (RR, 1.46; 95% CI, 1.001± 2.142) along with
liver metastases (mets) and PS; in MBC (RR, 1.75; 95% CI, 1.3±
2.4) along with mets and PS; in MPCC (RR, 1.2; 95% CI, 0.97±
1.51) along with met free interval, number of met sites, loss >
10% of body weight and PS > O; and in NHL (RR, 1.47; 95%
CI, 1.02± 2-1, along with prognostic factors of the International
Prognostic Index). We conclude that lymphopenia is a general
and yet unrecognised prognostic factor for overall survival in wide
variety of frequent cancers including advanced soft tissue sarco-
mas.